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ABSTRACT 
Malaria is a major cause of morbidity and mortality globally, resulting in over 200 million 
cases and 650, 000 deaths in 2010 according to the 2012 WHO Malaria Report. 
Furthermore, malaria endemicity is associated with poor economic growth. One of the 
greatest challenges facing malaria chemotherapy is the emergence of Plasmodium 
strains resistant to all known clinically used antimalarials. This underscores the need for 
the development of new drugs that retain efficacy against the resistant parasites. 
In this study, analogue-based drug design was employed as a form of drug ‘rescue’ in 
the development of novel potential antimalarials. The main aim was to design and 
synthesize analogues of the 4-aminoquinoline drug amodiaquine with potentially 
improved safety and efficacy profiles using prior knowledge of the drug metabolism and 
pharmacokinetics (DMPK), toxicity and efficacy profile of the drug. 
A representative set of compounds in four different series was synthesized in which the 
4-aminoquinoline ring was coupled with benzothiazole, benzimidazole, benzoxazole and 
pyridyl rings bearing different aliphatic amines and diamines. The chemistry involved 
aromatic nucleophilic substitution reactions and hydrogenation of nitro aromatic 
compounds. Benzothiazole and benzoxazole analogues with a tertiary protonatable 
nitrogen were found to possess potent antiplasmodial activity against the drug resistant 
W2 and K1 Plasmodium falciparum strains. Among the most active compounds were 
benzothiazole analogues 3.2c (W2 IC50 12 nM, K1 IC50 14 nM) and 3.2d (W2 IC50 13 
nM, K1 IC50 7 nM) and benzoxazole analogue 3.9b (W2 IC50 8 nM, K1 IC50 22 nM). 
Using electrochemistry online with electrospray ionization mass spectrometry, 
benzothiazole analogues were found to form glutathione adducts most readily, followed 
 vi 
 
by benzimidazole and pyridyl analogues. Benzoxazole analogues 3.9a and 3.9b did not 
form glutathione adducts. In trapping experiments with methoxylamine and KCN, all 
compounds with protonatable tertiary nitrogen atoms formed adducts. All the four series 
of compounds were potent but reversible CYP3A4 inhibitors and moderate CYP2D6 
inhibitors. The benzoxazole series were selected for an expanded structure-activity 
relationship study based on the glutathione trapping results. 
A library of benzoxazole analogues was synthesized in the last phase of the project. 
Consistent with our earlier findings, tertiary protonatable nitrogen containing compounds 
had potent antiplasmodial activity against the chloroquine sensitive NF54 strain and the 
drug resistant K1 strain. Compounds in which the tertiary amine was attached to the 
benzoxazole ring via an ethyl linker such as 3.9c (NF54 IC50 10 nM, K1 IC50 24 nM), 
3.9e (NF54 IC50 11 nM, K1 IC50 42 nM) and 3.9f (NF54 IC50 12 nM, K1 IC50 42 nM) were 
the most potent. A weak correlation between antiplasmodial activity and β-hematin 
formation inhibition was observed particularly for dialkylamino analogues. Although 
compounds with potent antiplasmodial activity displayed cytotoxicity against Chinese 
Hamster Ovary cells in the low micromolar range, they had high selectivity indexes. In 
general the compounds were more metabolically stable than amodiaquine in human 
and rat liver microsomes, the most stable compound being 3.9f (>99% remaining after 
incubation for 30 minutes). In P. berghei infected mice, analogues 3.9b, 3.9c and 3.9j 
suppressed parasitemia by >99% at oral doses of 4 x 50 mg/kg. Analogue 3.9b cured 
all three treated mice (30 mean survival days) while analogues 3.9c and 3.9j cured 1/3 
(27 mean survival days) and 2/3 (30 mean survival days) of treated mice, respectively. 
In conclusion, the benzoxazole analogues are a new class of leads for further 
exploration as antimalarial compounds. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1 
 
Chapter 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1 CHAPTER OVERVIEW 
This Chapter starts with a review of aspects of the etiology, epidemiology, 
pathophysiology and chemotherapy of malaria. Adverse drug reactions are 
subsequently discussed under the topics of the significance and classification of ADRs. 
The role of drug metabolism in the bioactivation of xenobiotics and the various methods 
used to assess bioactivation potential are highlighted thereafter. Literature on 
amodiaquine pharmacokinetics and bioactivation is reviewed followed by medicinal 
chemistry efforts aimed at preventing this bioactivation. Justification, the research 
question and specific objectives are given at the end of the chapter. 
 
1.2 ETIOLOGY OF MALARIA 
The protozoal disease malaria arises from infection by apicomplexan parasites of the 
genus Plasmodium. As of 2008, approximately 200 Plasmodium species from different 
mammalian, avian and reptile intermediate hosts had been described 1. In humans, 
Plasmodium falciparum, P. vivax, P. ovale and P. malariae are the malaria parasites of 
clinical significance based on the severity of disease and prevalence of infection 2. 
However, P. knowlesi, originally considered a malaria parasite of macaque monkeys, 
has been identified in patients in parts of Southeast Asia and is currently regarded as 
the fifth malaria parasite 2,3. Based on findings from multilocus genetic analysis 
Surtherland and co-workers concluded that Plasmodium ovale actually consists of two 
non-recombining species, P. ovale curtisi and P. ovale wallikeri 4. 
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1.3 EPIDEMIOLOGY 
According to the 2012 World Malaria Report, there were an estimated 219 million cases 
of malaria in 101 malaria endemic countries in 2011, 80 % of which were reported in 
Africa. In the same year, 3.17 billion people globally were at risk of malaria 5. The 
number of malaria deaths was estimated to be 660,000 in 2010. Of these, 86 % were 
children under 5 years of age and again >90% of malaria deaths occurred in the WHO 
Africa region 6. The disproportionately high mortality and morbidity associated with 
malaria in Africa is attributed to the differential distribution of Plasmodium species as 
well as economic development. Plasmodium falciparum, the most virulent species, is 
preponderant in tropical Africa. Two countries, Nigeria and the Democratic Republic of 
Congo, account for 23 % of the global P. falciparum burden 7. In South America, P. 
vivax is the major species while in south-eastern Asia and Western Pacific, both P. 
falciparum and P. vivax are prevalent 8,9. However, P. vivax has been virtually non-
existent in West Africa where Duffy blood group negativity predominates 10. Perhaps as 
a stark reminder of the evolutionary ability of the malaria parasite and the imperative for 
continuing research into approaches of eradicating malaria, reports have emerged that 
Duffy negativity may no longer confer immunity against P. vivax 11,12. Figure 1 illustrates 
the global distribution of these two species. Although P. malariae is widely distributed 
around the world, its prevalence is generally low. In Africa, P. malariae infections are 
usually reported mixed with those of P. falciparum 13. Plasmodium ovale is principally 
distributed, albeit at a low prevalence, in tropical Africa but has been reported in the 
Middle East, India and other parts of the world 14 while P. knowlesi is localized to South-
East Asia 3.  
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Malaria primarily affects poor populations in tropical and subtropical regions 15. The 
Nobel laureate T.H. Weller noted that “a malarious community is an impoverished 
community” 16.  Indeed, malaria was once widespread in temperate areas including 
Western Europe and the United States. Economic development and public health 
interventions such as the WHO sponsored Global Malaria Eradication Program (GMEP) 
of the 1950s have virtually eliminated the disease in these areas 15. Unfortunately, the 
GMEP, which relied on chloroquine chemotherapy and vector control using DDT, did 
not attempt to eradicate malaria in Africa, the worst affected continent 15. More recently, 
however, major advances in malaria research and public health practices, coupled with  
 
Figure 1.1: Global distribution of (a) Plasmodium falciparum and (b) Plasmodium 
vivax9. 
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careful epidemiologic and economic analyses of malaria burden and cost effective ways 
to lessen it have renewed optimism for malaria control, particularly in Africa 17. Once 
more, malaria control is on the political agenda of the world’s leading economies with 
impressive funding being provided to fight the disease via the Global Fund to Fight 
AIDS, Tuberculosis and Malaria, The US President’s Malaria Initiative, the World Bank 
and bilateral donors. The coordination of these global efforts is the function of the Roll 
Back Malaria Partnership and involves the use of preventive measures such as 
promoting the use of insecticide treated nets (ITNs), proper diagnostics and Artemisinin 
Combination Therapies (ACTs) 18.  It is worth noting that between 2005 and 2010, 
malaria cases decreased from 244 to 216 million while there was a reduction in global 
malaria mortality rates by 26 % between 2000 and 2010  8. Despite this welcome trend, 
a lot still remains to be done in containing the burden of malaria. Reports of emerging 
Plasmodium resistance to artemisinin in parts of Asia 19 are a sobering reminder against 
complacence.  
With regard to the impact of malaria on economic development, Gallup and Sachs  
observed that countries that eliminated malaria experienced higher economic growth 
thereafter compared to their neighbors 16. Further, they report that countries with 
intensive malaria grew 1.3 % less per person while a 10 % reduction in malaria 
incidences resulted in 0.3 % higher growth.  
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1.4 LIFE CYCLE 
As illustrated in figure 1.2, the life cycle of malaria parasites involves two hosts: human 
beings and female Anopheles mosquitoes, which act as the definitive hosts and malaria 
vectors, respectively 20. The sexual phase (sporogony) takes place in the mosquito 
while the asexual stage (schizogony) occurs in the human host 2. During a blood meal, 
a mosquito will inject approximately 15-20 motile sporozoites into the subcutaneous 
tissue and sometimes directly into the bloodstream 21,22. The sporozoites are 
transported in blood to the liver where they invade hepatocytes thus concealing 
themselves from the host’s immune system. Sporozoite motility and hepatocyte invasion 
have been attributed to a protein referred to as thrombospondin related adhesive 
protein (TRAP). Within the hepatocytes, each sporozoite develops into a tissue schizont 
containing between 10,000 and 30,000 merozoites. The higher merozoite content is 
characteristic of Plasmodium falciparum infections. This liver stage of the disease, 
referred to as exoerythrocytic schizogony, lasts for between 6 days (P. falciparum) and 
14 days (P. malariae) and is asymptomatic. Subsequently, mature schizonts rupture 
and release merozoites into the bloodstream to start the erythrocytic schizogony. 2,20–22 
P. vivax and P. ovale can persist in the liver as hypnozoites for months to years and are 
responsible for relapse after successful treatment. This phenomenon represents a 
formidable barrier to malaria eradication 23. 
In the erythrocytic schizogony, each merozoite invades a red blood cell (RBC) heralding 
the beginning of symptomatic malaria. The selective invasion of RBCs is mediated by 
interaction between merozoite ligands and RBC receptors. Invasion is both rapid and 
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efficient which is necessary for merozoite survival considering that the antigens on the 
merozoite surface are highly vulnerable to immune attack 24. 
 
Figure 1.2: Life cycle of Plasmodium parasites 15. 
Furthermore, some of the ligands involved in invasion are stored in micronemes and 
rhoptries and only secreted during invasion 21. Once the merozoite gets in contact with 
the RBC, it reorients itself and a tight junction is formed between the parasite and host 
membrane. This tight junction then moves from the apical to the posterior end of the 
merozoite and eventually envelops it. In the process, the merozoite sheds its own 
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coating and enters the RBC wrapped in a parasitophorous vacuole that is hospitable for 
development 24,25. 
Within the RBCs merozoites develop asexually from a ring stage via a trophozoite stage 
into a blood schizont containing 16-32 merozoites 26. Upon maturation, the swollen 
infected erythrocyte explodes to releases fresh merozoites which will further re-infect 
other RBCs in repeated erythrocytic cycles greatly multiplying the number of parasites 
in the host 27,28. The cycle time is 48 h for P. falciparum, P. vivax and P. ovale and 72 h 
for P. malariae. Some merozoites differentiate into male and female gametocytes which 
enter the sporogonic cycle when ingested by the Anopheles mosquito during a blood 
meal and develop into infective sporozoites 22. 
 
1.5 PATHOPHYSIOLOGY AND CLINICAL PRESENTATION 
The WHO classifies malaria as uncomplicated or severe. Uncomplicated malaria is 
defined as asymptomatic malaria without signs of severity or evidence of vital organ 
damage. It presents as a nonspecific febrile illness which may be accompanied by chills 
and sweats, headache, vomiting, watery diarrhea, anemia, jaundice, and splenomegally 
29. Malaria fever presents as a classical cyclical paroxysm that coincides with the 
rupture of blood schizonts during a synchronous asexual erythrocytic schizogony. The 
fever lasts for only a few hours, occurring every 48 hours (tertian) for P. falciparum, P. 
vivax, and P. ovale, and every 72 hours (quartan) for P. malariae 30. Malaria fever starts 
at a pyrogenic threshold. Plasmodium vivax has a lower pyrogenic threshold and elicits 
a greater inflammatory response than P. falciparum infections of similar or greater 
parasite biomass. This may be attributed to higher cytokine production in vivax malaria 
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31. Two malaria toxins, heme and malaria glycosylphosphatidylinositol (GPI) are among 
the products released during rupture of the schizont and their interaction with host toll-
like receptors (TLRs) results in stimulation of a pro-inflammatory response 30,32. If 
untreated or not contained by the host immune response, uncomplicated malaria 
progresses to severe malaria. 
Severe malaria is characterized by the presence of P. falciparum asexual parasitemia 
and the presence of one or more of the following symptoms with no other obvious 
cause: impaired consciousness or unrousable coma, prostration, failure to feed, multiple 
convulsions, deep breathing, respiratory distress (acidotic breathing), circulatory 
collapse or shock, systolic blood pressure <70 mm Hg in adults and <50 mm Hg in 
children, clinical jaundice plus evidence of other vital organ dysfunction, 
hemoglobinuria, abnormal spontaneous bleeding and pulmonary edema 33,34. Malaria 
deaths are a result of any combination of these complications. The main manifestations 
of severe malaria are highlighted in the following paragraphs. 
Key differences among Plasmodium species in the erythrocytic schizogony explain the 
difference in severity of malaria. Plasmodium falciparum infects RBCs of all ages while 
P. vivax only infects reticulocytes. Thus P. falciparum infection results in higher 
parasitemia 21 while vivax malaria parasitemias rarely exceed 2 % of circulating RBCs 
31. Significant mortality is observed when parasitemia exceeds 5 % even with 
appropriate parenteral antimalarial therapy. Exchange transfusion may rapidly reduce 
parasitemia in such cases 33. Additionally, unlike other malaria parasites P. falciparum 
modifies the surface of infected RBCs so that gametocytes and asexual parasites can 
adhere to the microvascular endothelium and asexual parasites to the placenta 21 
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resulting in parasite sequestration in deep tissue and microvascular obstruction. 
Sequestration of asexual parasites in the brain is responsible for cerebral malaria. The 
pathology underlying cerebral malaria may involve the initiation of an inflammatory 
process, endothelial activation, release of endothelial microparticles and apoptosis 
around the region of cytoadherence and sequestration. Cerebral malaria is a leading 
cause of malaria deaths in children in sub-Saharan Africa 35. Parasite adherence to the 
placenta is responsible for premature deliveries, low birth weight, increased infant 
mortality and maternal anemia 21.  
Severe anemia is common in P. falciparum and P. vivax infections and is a major 
hazard to pregnant women in malaria endemic areas and a leading factor in child 
deaths resulting from malaria. The three mechanisms postulated to explain anemia in 
malaria are direct destruction of RBCs as schizonts rupture, suppressed erythropoiesis 
which implies that not all destroyed cells are replaced and increased destruction of 
uninfected cells 36. Anemia resultant from P. vivax infection does not correlate with the 
observed low parasite biomass. Studies have shown that in vivax malaria, for every 
infected erythrocyte destroyed, 32 uninfected erythrocytes are removed from circulation 
31. This is in contrast to the destruction of only 8 uninfected RBCs for every infected 
erythrocyte in falciparum malaria 37. 
It has been observed that in falciparum malaria, deformability of infected and non-
infected RBCs under shear stresses in arterioles and capillaries with reduced flow is 
reduced. This phenomenon is a predictor of mortality in severe malaria. It leads to 
reduced microcirculatory flow and reduced oxygen delivery to tissues and eventually to 
anerobic glycolysis which correlates with elevated lactate levels 38. 
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Respiratory distress is a common feature in severe falciparum malaria occurring in up to 
25 % of adults and 40 % of children infected with the disease. Causes include severe 
anemia, metabolic acidosis, noncardiogenic pulmonary edema, concomitant pneumonia 
and fluid overload.  Acute lung injury (ALI) and Acute Respiratory Distress Syndrome 
(ARDS) may develop in patients with severe falciparum, vivax, and knowlesi malaria, 
often several days after antimalarial drug treatment. The pathophysiology of ARDS 
centers on inflammatory-mediated increased capillary permeability or endothelial 
damage leading to diffuse alveolar damage 39.  
Malaria and HIV/AIDS are the leading infectious diseases in Africa. Not only is there 
enormous geographic overlap between the two diseases but there is growing evidence 
of interactive pathology. HIV increases the risk of malaria infection and the development 
of clinical malaria 40. A study in Malawi reported increased prevalence of malaria and 
higher parasitemia in HIV infected pregnant patients compared to uninfected patients. 
41. Grimwade et al. demonstrated a strong association between HIV infection and poor 
outcome in adults with P. falciparum malaria 42. Clearly, the emergence of HIV has 
serious implications on any programs targeting the treatment and prevention of malaria. 
 
1.6 MALARIA CHEMOTHERAPY 
1.6.1 Targets for antimalarial chemotherapy 
Antimalarial drugs target different stages of the malaria parasite life cycle. The main 
pathways traditionally targeted are nucleic acid and heme metabolism as well as the 
redox system. Increased understanding of Plasmodium biology as well as the 
development of sophisticated methods of molecular analysis including genome 
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sequence analysis have facilitated the discovery of numerous novel targets 43,44. For 
example, elucidation of the genome sequence of Chromosome 2 of P. falciparum 
enabled researchers to identify several lipid biosynthesis genes in the parasite targeted 
to the apicoplast. These genes play a critical role in parasite viability and are attractive 
drug targets 45. The identification and exploitation of such new targets is of particular 
importance in the search for molecules that circumvent existing and emerging 
resistance against antimalarial drugs 46. Table 1.1 summarizes main targets for malaria 
chemotherapy. 
 
Table 1.1: New and old targets for malaria chemotherapy 43,47–49  
Pathway Target Notes 
Nucleic acid 
metabolism 
Dihydropteroate 
synthetase (DHPS)  
inhibition 
Reduced folate co-factors are 
essential for many reactions 
involving one-carbon unit transfer 
such as DNA and protein 
synthesis. Plasmodium possesses 
a de novo folate biosynthesis 
pathway unlike the host making it 
an excellent antimalarial target 
50,51. 
Dihydrofolate reductase 
(DHFR) inhibition 
Dihydroorotate 
dehydrogenase (DHODH) 
inhibition 
DHODH catalyzes the rate limiting 
step in pyrimidine biosynthesis. 
Malaria parasites only rely on de 
novo pyrimidine biosynthesis 
making this an attractive target 52.  
Purine nucleoside 
phosphorylase inhibition 
Malaria parasites are unable to 
synthesize purines de novo but 
rely on an elaborate salvage 
pathway which can be targeted by 
drugs 53. 
Adenosine deaminase 
inhibition 
Hypoxanthine-guanine-
xanthine 
phosphoribosyltransferase 
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inhibition 
Heme 
detoxification 
Hemozoin formation 
inhibition 
 
Hemoglobin 
proteolysis 
Falcipain and plasmepsin 
inhibitors 
Cysteine proteases (falcipains 1, 
2, 2’ and 3) and aspartic 
proteases (plasmepsins I, II, and 
IV) are necessary for the cleavage 
of host proteins to provide the 
parasite with amino acids 54.  
Redox system Generation of free 
radicals which alkylate or 
hydroxylate some 
unidentified targets. 
An efficient antioxidant system is 
required in intra-erythrocytic 
malaria parasites to counter the 
oxidant effects of hemoglobin 
digestion. The parasites lack 
catalase and glutathione 
peroxidase making them even 
more susceptible to oxidative 
stress. 55 
Apicoplast 
function 
Protein, DNA and fatty 
acid biosynthesis 
disruption 
The absence of apicoplasts in the 
human host underlies the 
selectivity of compounds targeting 
this organelle 56. 
DNA replication Histone deacetylase 
(HDAC) inhibition 
HDAC regulates gene 
transcription and is very important 
for parasite survival. These 
enzymes are also found in 
humans and inhibition selectivity 
is a primary concern 57. 
Signal 
transduction 
Kinase inhibitors The Plasmodium kinome, 
comprising several families of 
kinases that are clearly distinct 
from human kinases, provides a 
potential target for malaria 
chemotherapy 58,59. 
Parasite 
membrane 
transport 
New permeability pathway 
(NPP) inhibitors 
NPPs are induced in infected 
RBCs partly to provide entry for 
essential nutrients 60. 
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1.6.2 Hemoglobin metabolism in Plasmodium 
The metabolism of hemoglobin is necessary for the survival of the malaria parasite and 
is, consequently, an important antimalarial target 61. Chloroquine, arguably the most 
important antimalarial drug historically, together with related quinoline antimalarial 
drugs, targets this important pathway. Although chloroquine resistance is now 
widespread, the attractiveness of hemoglobin metabolism as a drug target has in no 
way diminished. Indeed, it is worth noting that chloroquine resistance does not actually 
result from modification of this target but from alteration of a transmembrane protein on 
the parasite 62.  
In the blood stages, the malaria parasite resides in a parasitophorous vacuole within the 
RBC 63. Hemoglobin comprises 95% of the RBC cytosolic protein and is a major nutrient 
source for the maturing trophozoites 64,65. Plasmodium degrades up to 80% of host cell 
hemoglobin 65,66.  
Hemoglobin degradation occurs in the food vacuole, a sophisticated, acidic (pH≈5) 
organelle optimized for its function 67. Host cell cytosol is taken up through a cytosome 
formed by invagination of the parasitophorous vacuolar membrane and parasite plasma 
membrane. Transport vesicles then bud off from the cytosome, migrate toward and fuse 
with the food vacuole. Once in the vacuole they are lysed to release the contents 64,68.  
In the initial catabolism of hemoglobin, three cysteine proteases (FP-2, FP-2’, FP-3) and 
four aspartic proteases (PM I, PM II, HAP, and PM IV) are involved. Studies have 
demonstrated that plasmepsins are activated by falcipains but that there exists a level of 
redundancy in the activity of these proteases such that autoprocessing of plasmepsins 
can occur if falcipain activity were blocked 54. The products of hemoglobin metabolism 
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are ferrous heme and amino acids. The parasite has a limited capacity for de novo 
amino acid synthesis. Studies have confirmed that hemoglobin metabolism is sufficient 
to supply most of the parasite’s amino acid requirements for protein synthesis and 
energy production 69. However, hemoglobin is a poor source of methionine, cysteine, 
glutamine, and glutamate and contains no isoleucine at all. This implies that the parasite 
must additionally rely on an exogenous source of amino acids 65. 
 
1.6.2.1 The fate of heme in the parasite 
Ferrous heme (FeII-protoporphyrin IX) is a water-soluble substance which 
autocatalytically oxidizes to ferric heme (FeIII-protoporphyrin IX) upon release from 
hemoglobin 70. The presence of iron, the high oxygen content and the acidic pH of the 
food vacuole are conducive for oxygen radical formation via the Fenton and Haber-
Weiss reactions. The reactive oxygen species (ROS) formed include superoxide anions 
(O2-), hydroxyl radicals and hydrogen peroxide. These are a major source of oxidative 
stress to the parasite and may cause protein and DNA denaturation as well as 
membrane disruption resulting in cell lysis and death 22,65,66. Plasmodium employs 
various mechanisms to counter oxidative stress. Superoxide dismutase (SOD) converts 
superoxide radicals to hydrogen peroxide. Catalase, most likely obtained from the host 
in ingested cytosol, catalyzes the conversion of hydrogen peroxide to water and oxygen 
65. The parasite also employs thioredoxin and glutathione redox cycles 55. Thus, not 
surprisingly, free heme at elevated concentrations is toxic to the parasite and must be 
efficiently detoxified. 
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Plasmodium lacks heme oxygenase which in humans detoxifies free heme into 
biliverdin 71.  Instead, the parasite primarily detoxifies heme via dimerization to an inert 
crystalline substance called hemozoin 62,72.  
Synthetic β-hematin (FeIII-protoporphyrin IX)2 is chemically, spectroscopically and 
crystallographically identical to hemozoin 73. The structure of FeIII-protoporphyrin IX 
used in the structure solution of β-hematin is shown in figure 1.3 below. Dimerization 
occurs through Fe1-O41 links whereas the dimers are cross-linked by the formation of 
hydrogen bonds through O36 and O37 73 as illustrated in figure 1.4. 
 
 
Figure 1.3: The structure of FeIII-protoporphyrin IX with arrows indicating torsional 
degrees of freedom for the vinyl and propionic acid groups 73. 
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Figure 1.4: Three β-hematin dimers linked by hydrogen bonds between propionic acid 
groups 62. 
 
In a recent review, Egan highlights the lack of consensus on the mechanism of 
hemozoin formation 74. One of the earliest theories was the involvement of an enzyme, 
heme polymerase 66, but this was disputed. A second hypothesis was that hemozoin 
promotes β-hematin formation while yet a third school of thought was that lipids are 
responsible, two theories that have been experimentally demonstrated. Egan notes that 
although an enzymatic process may not be feasible given the almost macroscopic size 
of the product, a protein may act as a nucleation site for crystal growth as happens in 
other biomineralization processes 74.  The conclusion reached is that hemozoin 
formation may involve an autocatalytic process after initiation by lipids and proteins 
including the histidine rich protein 74. Notwithstanding this lack of consensus, the fact 
that hemozoin and hematin are fixed chemical entities not susceptible to mutation and 
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that they are handled by a unique biochemical pathway in the malaria parasite, makes 
them attractive for antimalarial drug development 62. 
 
1.6.3 Classes of drugs used in malaria chemotherapy 
The eradication of malaria requires long-term efforts focused on decreasing malaria-
associated fatalities through integrated, creative trans-disciplinary approach that spans 
basic biomedical research, public health efforts and policy implementation. It relies on 
both vector and parasite control strategies. Among the vector control strategies 
deployed widely are insecticide-treated nets and indoor residual spraying. Parasite 
control depends on the judicious use of available antimalarial drugs for prophylaxis as 
well as treatment 75. Apart from primaquine, which acts on the pre-erythrocytic stage of 
malaria, all antimalarial drugs are primarily blood schizonticides. The main classes of 
antimalarial drugs that have been or are currently being used clinically are quinoline 
containing drugs, folate antagonists and artemisinin derivatives 48. 
1.6.3.1 Quinoline antimalarials 
Quinoline antimalarials have played an important role in the treatment of malaria. 
Quinine (1), the oldest universally known antimalarial agent, was first isolated from the 
bark of the cinchona tree in 1820. It continues to play an important role in the treatment 
of severe and complicated malaria 76. A synthetic quinoline drug, chloroquine (2), was 
perhaps the most successful antimalarial drug known and at one time gave rise to the 
hope of eradicating malaria globally in the 1950s and 1960s 77.  
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a. The 8-aminoquinolines 
The observation that methylene blue exhibited some antimalarial activity spurred the 
synthesis of the 8-aminoquinolines. The first synthetic antimalarial, pamaquine (3), 
synthesized in the 1920s, belongs to this class 78. However, pamaquine was found to 
precipitate severe methemoglobinemia in patients with glucose 6-phosphate 
dehydrogenase (G6PD) deficiency 79,80 and this drove the search for safer analogues 81. 
Primaquine (4), the less toxic primary amine analogue of pamaquine, is currently 
considered the drug of choice for the radical cure of malaria 82. Apart from their activity 
against Plasmodium vivax and P. ovale hypnozoites, 8-aminoquinolines display rapid 
gametocytocidal activity 83.  
 
b. The 4-aminoquinolines 
Modifications of the ring system of pamaquine led to the development of mepacrine and 
the eventual synthesis of chloroquine in 1934 by scientists at Bayer laboratories 77,84. 
Chloroquine became the most widely used antimalarial drug by the 1940s. The 
popularity of chloroquine was as a result of its efficacy and low risk of side effects when 
used at prescribed doses 77. Resistance to chloroquine developed slowly but once 
established rapidly spread around the world limiting the use of this drug 85. Several 
chloroquine analogues have been synthesized to address the problem of resistance. 
Amodiaquine (5) was once used for malaria prophylaxis but due to toxicity is currently 
used with artesunate in ACT for acute malaria treatment 86. To address the 
shortcomings of the older 4-aminoquinolines, compounds such as ferroquine (6) 87, tert-
butyl isoquine (7) 88 and AQ-13 (8) 89 have been synthesized and progressed to clinical 
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trials. Ferroquine is in the most advanced stage of clinical development, having recently 
completed phase II clinical trials. While tert-butyl isoquine development has been 
terminated, AQ-13 will be entering phase II clinical trials in Mali to study its efficacy in 
uncomplicated P. falciparum malaria 
(http://clinicaltrials.gov/ct2/show/NCT01614964?term=aq13). 
 
c. Quinoline methanols and the related phenanthrene methanols. 
Synthetic quinoline methanols such as mefloquine (9) are structural analogues of 
quinine which possessed excellent activity against multidrug resistant malaria parasites. 
Severe adverse neurological effects have eroded the clinical use of mefloquine 90. 
Nonetheless, mefloquine still enjoys widespread use for malaria chemoprophylaxis 
among travelers and as a curative agent in the treatment of malaria infections 91. 
Studies have demonstrated that the (+)-erythro-enantiomer may have an improved 
safety profile over the marketed racemic mixture 92. The 9-phenanthrene methanols 
such as halofantrine (10) were developed by replacing the quinoline ring of the quinoline 
methanols with various aromatic substituents. Halofantrine use is, however, restricted 
due to severe cardiotoxicity. This serious side effect has not been reported with the use 
of the structurally related lumefantrine (11) 93. Indeed, lumefantrine is combined with 
artemether in the first ACT recommended and prequalified by the WHO for the 
treatment of uncomplicated malaria 94,95. The artemether/ lumefantrine combination, 
marketed as Coartem®, accounts for 75% of ACT treatments 96. Representative 
chemical structures of quinoline antimalarials and phenanthrene methanols are shown 
in figure 1.5. 
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Figure 1.5: Chemical structures of quinoline antimalarials and related phenanthrene 
methanols 
d. Mode of action of quinoline antimalarials 
Quinoline antimalarials in general and the 4-aminoquinolines in particular, are believed 
to exert their antimalarial activity primarily by decreasing the rate of hemozoin formation 
97. This results in high concentrations of heme in the food vacuole that are ultimately 
fatal to the parasite. Chloroquine has been extensively studied in an attempt to 
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understand the mode of action of quinoline antimalarials. In the acidic food vacuole, 
chloroquine is 99.99 % protonated making it membrane impermeable. It, therefore, 
accumulates in the vacuole to very high concentrations. Chloroquine enters the food 
vacuole both by passive diffusion and active transportation. Studies have implicated a 
plasmodial Na+/H+ exchanger in the active importation of chloroquine into the food 
vacuole 77. Chloroquine caps hemozoin molecules by π-stacking of the quinoline ring to 
the porphyrin of heme 92. This prevents further heme biocrystallization resulting in its 
buildup to toxic concentrations. Furthermore, chloroquine forms a ferriprotoporphyrin-
chloroquine complex that is highly toxic to the parasite and disrupts membrane function. 
The end result is cell lysis and auto-digestion of the parasite 98.  The quinoline 
methanols tend to associate only weakly with heme and may exert their effects by 
interfering with other steps in hemoglobin metabolism. The 8-aminoquinolines act by 
interfering with mitochondrial function. This action may be related to that of the 
naphthoquinones which inhibit the cytochrome bc1 complex of the mitochondrial 
respiratory chain and collapse the mitochondrial membrane potential 77,99. 
 
e. Resistance to quinoline antimalarials 
Resistance to quinoline antimalarials is, again, best explained using the well studied 
example of chloroquine. Chloroquine-resistant parasites accumulate chloroquine less 
efficiently in their food vacuoles than sensitive strains. Thus resistance is primarily a 
result of exclusion of the drug from the site of action rather than an alteration of the 
target 62,77. Mutations on the pfcrt (Plasmodium falciparum chloroquine resistance 
transporter) gene residing on chromosome 7 have been identified in the chloroquine 
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resistance phenotype of various strains and are now recognized as the primary cause of 
chloroquine resistance 44,100.  Although the gene displays considerable polymorphism, 
only one amino acid change, K76T, located in the first transmemberane domain, is 
found consistently in all chloroquine-resistance parasites. However, it has been 
observed that K76T never occurs alone but with at least three other changes. In K76T, 
the positively charged lysine is substituted with an uncharged threonine residue. It is 
postulated that the positively charged K76 prevents or limits the efflux of chloroquine 
from the food vacuole and its substitution with an unprotonated amino acid may allow 
efflux to occur. Moreover, it appears that the mutant PfCRT becomes a gated channel 
through which charged chloroquine escapes from the food vacuole 44.  
Similarities between the multidrug-resistant phenotype of tumor cells including partial 
resistance reversal by calcium channel antagonists led scientists to hypothesize that 
resistance to quinoline antimalarials may be mediated by accelerated drug efflux 48,101. 
Such efflux would result from increased expression of P-glycoprotein on the food 
vacuole membrane. Pfmdr1 and 2 (Plasmodium falciparum multidrug resistance) genes 
have been identified in Plasmodium species. Pfmdr1 is located on chromosome 5 and 
codes for P-glycoprotein homologue-1 (Pgh-1). Several polymorphisms of this gene 
such as A86T have been associated with chloroquine resistance 85.  
 
1.6.3.2 Folate antagonists 
Folate antagonists used as antimalarials belong to two classes: DHPS inhibitors or 
class I antifolates and DHFR inhibitors also known as class II antifolates. The two 
classes act synergistically and are, therefore, used in combination 51.  
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a. DHFR inhibitors 
Proguanil (12), chlorproguanil (13) and the 2,4-diaminopyrimidine pyrimethamine (14) 
are among the DHFR inhibitors that have been used as antimalarial agents.  
Themselves virtually inactive antimalarial prodrugs, proguanil and chlorproguanil are 
metabolized in vivo to the highly active cycloguanil (15) and chlorcycloguanil (16) (see 
figure 1.6). 
b. DHPS inhibitors 
DHPS inhibitors are sulfone or sulfonamide containing drugs. Dapsone (17), the oldest 
and most potent DHPS inhibitor, sulfadoxine (18), sulfaphenazole (19) and 
sulfamethoxypyrazine (20) (figure 1.6) have been used in various combinations with 
DHFR inhibitors. Combinations that have been marketed for malaria chemotherapy 
include sulfadoxine/pyrimethamine, sulfamethoxypyrazine/pyrimethamine and 
dapsone/chlorproguanil 50,51. 
   
12 13 14 
   
15 16 17 
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Figure 1.6: Chemical structures of folate antagonists 
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c. Mode of action 
Folate antagonists sequentially inhibit two key enzymes involved in the de novo 
synthesis of folic acid in the malaria parasite.  In so doing, they deprive the parasite of 
reduced folate co-factors essential for many reactions involving one-carbon unit transfer 
such as DNA and amino acid synthesis. This is not only an effective way of killing the 
parasites but it also blocks the ability of the parasite to multiply 50. DHPS inhibitors 
mimic para aminobenzoic acid (PABA) and competitively inhibit the enzyme. In addition, 
these drugs condense with 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine 
pyrophosphate to form sulfa-dihydropteroate (sulfa-DHP) which may disrupt folate 
metabolism by other mechanisms 102.  
 
d. Resistance to folate antagonists 
Resistance to folate antagonists developed rapidly upon introduction of these drugs and 
is associated with point mutations on DHFR and DHPS. The mutant enzymes have 
altered properties and interact sub-optimally with the antagonists making them less 
susceptible to inhibition. Gregson and Plowe have extensively reviewed the various 
point mutations involved in conferring resistance to folate antagonists 103. Specificity has 
been observed in resistance of various DHFR mutants to different DHFR inhibitors. It 
has further been suggested that parasites have a limitation in mutation possibilities. 
Such observations have served as an impetus for the development of new folate 
antagonists. Additional molecular targets in the folate biosynthesis pathway are also 
being exploited to develop new antimalarials 50. 
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1.6.3.3 Artemisinin derivatives 
Artemisinin (21) was isolated from Artemisia annua, long used in Chinese herbal 
medicine for the treatment of fever, in 1972. This followed the demonstration of potent 
antimalarial activity of A. annua extracts in 1967 by Chinese scientists 104. Following 
widespread resistance to chloroquine and folate antagonists, ACT is now the first-line 
treatment for uncomplicated malaria 105. Artemisinin derivatives have a rapid onset of 
action and rapidly clear parasitemia leading to quick resolution of symptoms. 
Additionally, these compounds are rapidly eliminated and are thus recommended to 
delay resistance mechanisms 106.  
 
a. First generation artemisinins 
Artemisinin is only marginally soluble in water or oil thus making it difficult to formulate 
and limiting its bioavailability. Its short in vivo half life (about 2 h) necessitates a 
weeklong treatment regimen. The first generation of semisynthetic derivatives 
developed to address this shortcoming include dihydroartemisinin (22) (which is also a 
metabolite of artemisinin), a compound that is twice as potent as artemisinin but that is 
thermally less stable and possibly neurotoxic 107. The water-soluble artesunate (23) and 
artelinate (24) are administered intravenously in the treatment of severe malaria. 
Artemether (25) and arteether (26) are β-alkyl ethers of dihydroartemisinin with 
increased lipid solubility and improved pharmacokinetic and antimalarial efficacy 108. 
Combinations of artemisinin derivatives in use include artesunate-amodiaquine, 
artesunate-mefloquine, dihydroartemisinin-piperaquine and artemether-lumefantrine 105.   
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b. Second generation artemisinins 
Thousands of second generation artemisinin derivatives have been synthesized that 
preserve the trioxane’s powerful antimalarial activity against both drug sensitive and 
resistant malaria strains while improving the pharmacokinetic and solubility 
characteristics and lowering the potential for neurotoxicity. These include various 
semisynthetic monomeric, dimeric, trimeric and tetrameric analogues of artemisinin and 
dihydroartemisinin, synthetic endoperoxides and hybrids of both classes peroxide 
antimalarials 107. Owing to the structural complexity of artemisinin, commercial 
production relies on extraction and purification from Artemisia annua 109. With increasing 
demand for artemisinin-based therapies, especially fueled by the provision of subsidized 
medicines to fight malaria, plant extraction may no longer remain a sustainable source 
110. Inspired by the excellent activity of the artemisinins and the need to find viable 
alternatives to plant extraction, chemists have developed novel purely synthetic 
endoperoxides that are synthetically tractable and can be produced at low cost 111. 
Several trioxanes, trioxolanes and tetraoxanes have been synthesized to this end. Two 
ozonides from these campaigns, OZ277 (27) and OZ439 (28), are currently undergoing 
clinical trials as candidate drugs for malaria treatment. OZ439 has greater stability in 
blood and improved oral bioavailability relative to OZ277 which was found to have 
increased chemical instability in iron-rich infected blood 92,112. In 2012, OZ277 was 
approved for the Indian market as a combination product with piperaquine phosphate 
(Synriam) for the treatment of malaria 207. 
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Figure 1.7: Chemical structures of selected artemisinin derivatives ozonides 
 
c.  Mode of action of artemisinin derivatives 
The demonstration that the endoperoxide bridge was necessary for antimalarial activity 
suggested that reactive oxygen species and free radicals may be involved in 
artemisinin’s mechanism of action 113. The opening of the peroxide bridge to form free 
radicals may be activated by heme or free iron 114. It is generally believed that reductive 
scission of the peroxide bridge produces an O-centered radical which undergoes 
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rearrangement to generate a C-centered free radical 115. The C-centered radicals could 
be involved in the alkylation of several malarial proteins. Specifically, cysteine adducts 
of artemisinin have been reported, implicating alkylation of cysteine residues of various 
proteins as a possible mechanism by which this compound interferes with protein 
function. Indeed, artemisinin derivatives have been shown to inhibit falcipains, thus 
interfering with hemoglobin degradation 115. In addition, inhibition of PfATP6, the 
sarco/endoplasmic reticulum membrane calcium ATPase (SERCA) by artemisinin has 
been demonstrated. This inhibition leads to increased cytosolic free calcium 
concentrations resulting in parasite death 116. Parasite membrane damage by 
accumulation within neutral lipids appears to be yet another mechanism of action of the 
artemisinins. Thus artemisinin derivatives appear to exert their effects by acting at 
several targets which partly explains why they are active against multidrug resistant 
parasites 106. 
 
d. Mechanism of resistance to artemisinin derivatives 
The first cases of artemisinin resistance were reported in South-East Asia along the 
Thai-Cambodia border 19. Among the proteins implicated in modulating Plasmodium 
susceptibility to antimalarials are PfATP6, translationally controlled tumor protein 
(TCTP), PfCRT and PfMDR1 108. Point mutations of the genes encoding these proteins 
may be responsible for the development of resistance against artemisinin. O’Brien et al. 
have aptly concluded that with precious few drugs available to replace ARTs should 
they fail, the importance of countering resistance cannot be underestimated 117. This 
dire predicament is also a major rationale for the search for new antimalarial drugs 118. 
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1.7 ADVERSE DRUG REACTIONS/DRUG TOXICITY 
Edwards and Aronson comprehensively and unambiguously define adverse drug 
reactions (ADRs) as “an appreciably harmful or unpleasant reaction, resulting from an 
intervention related to the use of a medicinal product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the dosage 
regimen, or withdrawal of the product” 119. The impact of ADRs can be viewed from two 
perspectives: the pharmaceutical industry perspective and the clinical perspective. 
 
1.7.1: The economic and health significance of ADRs 
1.7.1.1 ADRs: The industry perspective 
As far as the pharmaceutical industry is concerned, nonclinical and clinical safety has 
remained a major cause of drug attrition and the attendant enormous financial and time 
ramifications. Attrition can occur during preclinical or clinical development and at the 
post-approval stage, resulting in withdrawal of marketed drugs accounting for 
approximately one-third of all drug discontinuation 120. Lasser et al. reported that out of 
the 548 new chemical entities approved for the US market between 1975 and 1999, 16 
were subsequently withdrawn from the market while 45 acquired at least one black box 
warning as a consequence of their toxicity 121. About 2.3 million case reports of adverse 
events for the cumulative number of approximately 6000 marketed drugs were entered 
in the US Adverse Event Reporting System database between 1969 and 2002. As a 
result, 75 drugs and drug products were withdrawn by the US Food and Drug 
Administration over this period 122. 
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1.7.1.2 ADRs: The patient’s perspective 
From the patient’s perspective, adverse reactions are a significant cause of patient 
morbidity and mortality besides prohibiting the use of effective treatment. ADRs are a 
major cause of hospital admission. Pirmohamed et al. reported that 6.4 % of hospital 
admissions in two large UK hospitals were related to ADRs with an overall fatality of 
0.15 % and a projected national annual cost to the NHS of USD 847 million 123. In a 
later study it was estimated that 1 out of every 7 in-patients experiences an ADR 
resulting in prolonged hospitalization 124. Elsewhere, a 2001 study in the Netherlands 
found that 1.83 % of all acute hospital admissions were ADR related. This was slightly 
below the 2.4 % to 6.4 % estimated from meta-analyses for Western countries 125. 
Fatalities directly attributable to adverse drug reactions are estimated to be the fourth to 
sixth leading cause of death in US hospitals, exceeding deaths caused by pneumonia 
and diabetes 126. Clearly, therefore, it is imperative to address the issue of drug safety 
as early as possible in drug development in order to save time, money and lives while at 
the same time contributing to safer treatment options. ADRs can be divided into five 
main classes 119,127.  
 
1.7.2 Types of ADRs 
1.7.2.1 Type A ADRs 
Type A (Augmented) reactions can be predicted from the known pharmacology of the 
drug, both on-target and off-target. They are the most frequent ADRs and generally 
arise from an exaggeration of pharmacological effect. The difference between type A 
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reactions and other ADRs is that in the case of type A reactions, the identity of the 
pharmacological target (whether the primary or the secondary one) is established 127,128. 
1.7.2.2 Type B ADRs 
Also referred to as idiosyncratic drug reactions (IDRs), type B (Bizarre) reactions do not 
exhibit the classic dose-response relationship, cannot be predicted from the known 
pharmacology of a drug, are host-dependent and are rare within the range of doses 
used clinically 129. These reactions generally require repeat administration of a drug to 
elicit a toxic response. Characteristics of type B reactions suggest the involvement of 
the immune system. The covalent binding of reactive metabolites (or of the parent drug 
in a few cases) to proteins or other macromolecules is considered the first pivotal event 
in type B toxicity 128. The ‘hapten hypothesis’ has been put forward to link the reactive 
metabolites with immune-mediated IDRs.  According to this hypothesis, modification of 
a protein may result in the immune system recognizing the protein as foreign and 
subsequently mounting an immune response 130. The liver, blood cells and skin are the 
three prime sites of type B toxicity. Consequently, these reactions manifest as 
hepatotoxicity, blood dyscrasias, such as agranulocytosis, and dermatitis. In almost all 
cases, type B reactions are delayed and occur a week or more after exposure 129. 
1.7.2.3 Type C ADRs 
Type C (chemical) reactions are caused by a chemical reaction between the drug or its 
metabolite and macromolecules resulting in a rapidly ensuing response 127. Similarly to 
type B reactions, bioactivation to reactive metabolites plays a role except for a few 
drugs such as alkylating antineoplastic drugs which directly form covalent bonds with 
proteins. Type C reactions in most cases show a dose-response relationship 128. These 
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reactions can be predicted or rationalized in terms of chemical structure 131. A well 
known example of a type C adverse drug reaction is the hepatotoxicity caused by high 
doses of acetaminophen (paracetamol). Acetaminophen is metabolized to the readily 
water soluble O-glucuronide or sulfate and excreted in urine. A small percentage of the 
dose undergoes bioactivation to N-acetyl-p-benzoquinoneimine (NAPQI) which, at 
therapeutic doses, is quenched with glutathione. Following an overdose, glutathione 
depletion occurs and NAPQI covalently reacts with liver proteins resulting in toxicity 132. 
N-acetyl cysteine, which acts by restoring GSH levels, has been widely used as an 
antidote to acetaminophen poisoning and the associated hepatotoxicity 208. 
 
Figure 1.8: Bioactivation of acetaminophen 
1.7.2.4 Type D ADRs 
Type D (Delayed) reactions, exemplified by teratology and carcinogenicity, occur 
months or even years after exposure to the drug 119. Carcinogenicity is associated with 
a dose-response relationship in which the duration of exposure is more important than 
the concentration or dose size. It can be caused by genotoxins, in most cases reactive 
metabolites, or by disruption of endocrinological processes. Thus, mechanisms for 
delayed toxicity tend to overlap with those of types A, B and C reactions 128.  
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1.7.2.5 Type E ADRs 
Type E (end of treatment) reactions occur when a drug is withdrawn such as the 
withdrawal syndrome observed with opioid analgesics 131. Another class of reactions 
that occurs commonly are type F (unexpected failure) reactions. These are dose related 
and are often caused by drug interactions for example with cytochrome P450 inducers 
which result in inadequate dosage of the coadministered drugs 119. The figure below 
illustrates the role of drug bioactivation in drug toxicity. 
 
Figure 1.9: Xenobiotic metabolism and toxicity 131 
1.7.3 Overview of drug metabolism 
In drug discovery and development, the optimization of pharmacokinetics properties is 
of paramount importance 133. These properties include absorption, distribution, 
metabolism and excretion (ADME). Toxicity is commonly considered with ADME 
properties (hence the acronym ADMET) because of its close association with 
pharmacokinetics 134. Prior to 1990, ADME properties were a leading cause of drug 
attrition. However, incorporating them early in drug discovery largely minimized their 
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contribution to attrition 135. As Kola and Landis reported in their landmark study, after the 
year 2000, clinical safety and toxicology are emerging as the leading causes of drug 
attrition 135. 
From the preceding discussion on ADRs, it is evident that drug metabolism plays a 
critical role in drug toxicity. However, bioactivation is a minor pathway in the overall drug 
metabolism. In a meta-analysis of 6767 drugs, Testa, Pedretti, and Vistoli found toxic 
and reactive metabolites to account for 7 % of total metabolites 136.  
The primary function of drug metabolism is to make a lipophilic molecule more 
hydrophilic so that it can be readily conjugated and/or excreted from the body 137. Drug 
metabolism has been, albeit inaccurately, traditionally divided into phase I and phase II 
metabolism 138.  
1.7.3.1 Phase I metabolism 
Phase I metabolism introduces or unmasks chemically reactive functional groups on 
which phase 2 reactions can occur 139. Apart from a few exceptions, phase I metabolism 
generally precedes phase II metabolism. Over 75% of phase I drug metabolism is 
carried out by cytochrome P450 monooxygenases 140 although a more recent analysis 
puts this figure at about 60% 136. Five of the 57 human P450s (1A2, 2C9, 2C19, 2D6, 
and 3A4) catalyze over 90% of P450 reactions. Overall, only about a quarter of the 
CYPs are involved in xenobiotic metabolism. Reactions catalyzed by CYP450 enzymes 
include epoxidation, hydroxylation, dealkylation (N-, S-, and O-), oxidation (N-, S- and 
P-), desulfuration, dehalogenation as well as nitro and azo reduction 141. CYP3A4 
accounts for approximately 50 % of the total metabolism by these 5 enzymes as 
illustrated in the figure below which also depicts the contribution of other enzymes to 
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phase I metabolism 140,142. Another enzyme involved in phase I metabolism, in particular 
the oxygenation of heteroatom-containing compounds, is the flavin-containing 
monooxygenase 143. 
 
Figure 1.10: Phase 1 drug metabolizing enzymes.  CYP: cytochrome P450, NQ01: 
NADPH:quinone oxidoreductase; DPD: dihydropyrimidine dehydrogenase; ADH: 
alcohol dehydrogenase; ALDH: aldehyde dehydrogenase 144. 
 
The CYP450 catalytic cycle 
The main function of CYP450 enzymes is the activation of molecular oxygen to a 
reactive species that can attack relatively inert chemical sites such as hydrocarbon 
chains and aromatic rings 145,146. This involves the split of molecular oxygen into two 
atoms, one of which gets incorporated into the substrate and the other released as part 
of a water molecule 146. The typical oxidation reaction (with the substrate represented by 
R-H) requires NADH or NADPH as a cofactor as shown below 147. 
NAD(P)H + O2 + R-H + H+ → NAD(P)+ + R-O-H + H2O. 
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The CYP450 catalytic cycle (figure 1.11) is represented as a series of distinct steps: 
substrate binding, reduction of ferric P450 to ferrous P450, reaction with oxygen to form 
a ferrous-O2 adduct, reduction of the adduct, release of one oxygen atom as part of a 
water molecule, the actual oxidation of the substrate and its final release 145,148. 
 
Figure 1.11: CYP450 catalytic cycle 148. 
 
1.7.3.2 Phase II metabolism 
Phase II metabolism generally involves conjugation of nucleophilic groups present in a 
molecule or introduced in phase I metabolism with small molecular weight organic donor 
molecules 149. These conjugation reactions enhance the water solubility and hence the 
excretion of the resulting metabolites. Furthermore, they play a fundamental role in 
metabolic inactivation and detoxification though in a few cases they are involved in 
bioactivation 150. The main enzymes involved include UDP-glucuronosyltransferases, 
sulfotransferases, N-acetyltransferases, glutathione-S-transferases and 
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methyltransferases such as thiopurine-S-methyl transferase and catechol-O-methyl 
transferase 151. 
 
1.7.4 Bioactivation 
Bioactivation is the process whereby an innocuous molecule is metabolically converted 
to a reactive metabolite, potentially deleterious to the cell 152. The reactive chemical 
species are either electrophiles or free radicals and exert their effects by subsequently 
covalently reacting with tissue nucleophiles resulting in their modification or 
denaturation 142. The CYP450 enzymes are the major enzymes involved in drug 
bioactivation. Other reactions such as glucuronidation and sulfation are, however, also 
involved in bioactivation as exemplified by the bioactivation of nonsteroidal anti-
inflammatory drugs to acyl glucuronides 131. Moreover, bioactivation by oxidative 
chemicals, particularly hypochlorous acid, released by activated neutrophils has been 
implicated in the development of blood dyscrasias such as amodiaquine-induced 
agranulocytosis 131. 
The potential for reactive metabolite formation is routinely examined as part of lead 
optimization efforts in drug discovery 153.  
 
1.7.4.1 The concept of structural alerts 
Several substructures, referred to as structural alerts, that form chemically reactive 
metabolites have been identified 154. Stepan et al. analyzed the top 200 drugs marketed 
in the USA in 2009 and found that 78-86 % of the drugs associated with toxicity 
contained at least one structural alert 153.  This confirms the assertion that most drugs 
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that elicit ADRs possess structural alerts and undergo bioactivation culminating in 
toxicity 155,156. Several examples exist where the substitution of structural alerts with 
metabolically (more) benign groups in drugs exhibiting toxicity has improved the safety 
profile of the resulting molecules. The procainamide (29a)/flecainide (29b), metiamide 
(30a)/cimetidine (30b), suprofen (31a)/ketoprofen (31b) drug pairs (figure 1.12) are but 
a few examples 157,158.  
 
 
 
29a 30a 31a 
   
29b 30b 31b 
Figure 1.12: Drug pairs where substitution of the structural alert (dotted box) has 
resulted in safer molecules 
 
The avoidance of structural alerts is, therefore, almost a norm in drug design. However, 
the challenge facing medicinal chemists is the fact that not all molecules that possess 
structural alerts cause ADRs and there are a number of safe drugs in the market to 
illustrate this point 153. It is now recognized that factors such as dose, duration of usage, 
detoxification efficiency and the presence of multiple metabolism and/or elimination 
pathways play a role in determining whether a molecule with a structural alert will elicit 
toxicity 155,156,158. A list of functional groups recognized as structural alerts and their 
reactive metabolites is given in Table 1.2. 
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Table 1.2: Common structural alerts, their reactive metabolites and associated toxicities 
155,158 
Functional group Reactive metabolite Examples 
Aromatic amines 
(anilines, anilides, p- 
aminophenols) 
Quinone imine or nitroso Acetaminophen (hepatotoxicity) 
Procainamide (lupus 
erythematosus) 
Hydrazine, hydrazide Diazene or diazonium 
ion 
Isoniazid (hepatotoxicity) 
Nitroarenes Nitroso Tolcapome (hepatotoxicity) 
Fused azaheterocycles Nitrenium ion Clozapime (agranulocytosis) 
Sulfonylureas Isocyanate Tolbutamide (teratogenicity) 
Furans α,β-unsaturated 
dicarbonyl 
Furosemide (nephrotoxicity) 
Thiophenes α,β-unsaturated 
dicarbonyl 
Ticlopidine (agranulocytosis) 
Thiazoles Thioamide, glyoxal Sudoxicam (hepatotoxicity) 
Thiazolidinediones S-oxide, isocyanate Troglitazone (hepatotoxicity) 
α,β-unsaturated 
carbonyls 
Intrinsic electrophilicity Cyclophosphamide (hemorrhagic 
cystitis) 
Aliphatic amines Iminium ion 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (neurotoxicity) 
 
1.7.4.2 Reactivity of reactive metabolites 
Most reactive metabolites are short-lived and unstable thus making their detection in 
circulating blood or plasma impossible 159,160. This can be attributed to rapid conjugation 
with the endogenous anti-oxidant, glutathione (GSH), elimination via some other 
detoxification process such as hydrolysis or reaction with cell macromolecules resulting 
in toxicity 153,156,161. As a result, the formation of reactive metabolites is often inferred 
from the detection of stable glutathione conjugates156.  
Electrophilic reactive metabolites are generally classified as soft or hard electrophiles 
158. A majority of reactive metabolites are soft electrophiles and include quinones, 
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quinone imines, quinone methides, epoxides, arene oxides and nitrenium ions 162. Hard 
reactive metabolites include aldehydes and iminium ions. Generally hard electrophiles 
react with hard nucleophiles which are mostly nitrogen containing compounds while soft 
electrophiles react with soft nucleophiles, usually sulfur containing compounds 163. 
Reactive metabolite formation can be assessed using three main techniques: trapping 
reactions, covalent protein binding and mechanism-based CYP inhibition 161,163. 
 
1.7.4.3 Assessment of bioactivation 
1.7.4.3.1 Trapping reactions 
The chemical reaction of reactive metabolites with trapping agents to form stable 
adducts which are then characterized by liquid chromatography coupled with tandem 
mass spectroscopy (LC-MS/MS) and/or nuclear magnetic resonance (NMR) 
spectroscopy is a widely used technique for assessing reactive metabolite formation. 
Such trapping experiments are carried out using liver microsomes in the presence of 
NADPH or other co-factors to generate reactive metabolites and an appropriate trapping 
agent that immediately reacts with the metabolites 163.  
For soft electrophiles, GSH is the trapping agent most commonly used, although other 
thiol containing compounds such as N-acetylcysteine can be used 164.  Potassium 
cyanide, methoxylamine, semicarbazide, γ-glutamylcysteinyl lysine are some of the 
compounds that have been employed to trap hard electrophiles 165,166. It has been 
demonstrated that γ-glutamylcysteinyl lysine can simultaneously trap both soft and hard 
electrophiles thus increasing the sensitivity and reliability of reactive metabolite 
screening 162. To improve on the sensitivity and specificity of trapping reactions, the 
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radiolabeling of GSH, semicarbazide and potassium cyanide has been successfully 
employed 167,168.  
The use of microsomes and NADPH is predicated on the fact that bioactivation is mainly 
a function of phase I metabolism. It is, therefore, important to consider other 
bioactivation pathways for example by the addition of different co-factors and the use of 
different in vitro systems such as hepatocytes or neutrophils 164. The use of 
electrochemical oxidation to mimic phase I metabolism will be discussed later on. Free 
radicals may be trapped using spin-trapping reagents. These include 5,5-
dimethylpyrroline-N-oxide, tert-nitrosobutane, phenyl-tert-butylnitrone and α-(4-pyridyl-
N-oxide)-N-tert-butylnitrone 163.  
 
1.7.4.3.2 Covalent binding 
The formation and irreversible binding of reactive metabolites to macromolecules can 
be detected and quantified using 14C- and/or 3H-labeled compounds 163. The 
radiolabeled compounds are usually incubated with liver microsomes in the presence of 
appropriate co-factors. Freshly isolated hepatocytes may be used to assess 
bioactivation processesses that depend on a full complement of cellular enzymes 166. 
The amount of unextractable radioactivity remaining in the protein pellet is an indication 
of the extent of covalent binding and is expressed in pmol /mg of protein 163. A value of 
>50 pmol /mg of proteins is generally considered, but not absolutely fixed, to imply 
potential toxicity 159.  
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1.7.4.3.3 Mechanism-based CYP inhibition 
In some cases, the metabolite formed by an enzyme is so reactive that it reacts directly 
with the enzyme active site resulting in inactivation of the enzyme 169. Such mechanism-
based inhibition is NADPH-, time- and concentration-dependent 170 and is also referred 
to as time-dependent inhibition (TDI). The TDI assay involves an inactivation assay 
where the enzyme is incubated with the inhibitor followed by an activity assay where a 
substrate is added to assess remaining enzyme activity using MS or fluorescence 
techniques 171. Since a positive TDI hit indicates the formation of reactive metabolites, 
TDI is employed as an in vitro screening method for  these metabolites 163.  
 
1.7.4.4 Animal models for bioactivation and the use of integrated systems 
It is virtually impossible to reproduce certain adverse drug reactions that occur in 
humans in in vitro systems 153. The use of animal models is, therefore, an important tool 
for mechanistic studies especially of type B reactions. However, challenges of 
extrapolation to humans and the paucity of practical and valid animal models still remain 
129.  Consequently, in the case of drug-induced hypersensitivity, the use of lymphocytes 
from hypersensitive patients in ex vivo studies represents the only relevant system to 
study cellular, molecular and chemical mechanisms 158. In the pharmaceutical industry, 
an integrated system of risk assessment and mitigation strategies for reactive 
metabolites in drug development such as that described by Thompson and co-workers 
would be useful in decision making. This system quantifies CYP450 dependent and 
CYP450 independent cell toxicity, mitochondrial impairment, inhibition of the Bile Salt 
Export Pump as well as covalent binding of radiolabeled drug to human hepatocyte 
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proteins 172. Such comprehensive testing is likely to minimize chances of false positives 
or false negatives usually associated with the use of a single test. 
1.7.4.5 Electrochemical oxidation online with electrospray ionization mass 
spectrometry (EC-ESI/MS) 
When using conventional in vivo and in vitro techniques, detection of reactive 
metabolites is hampered because the reactive species formed are immediately 
covalently bound to cellular macromolecules 160.  To overcome this challenge, the use 
of electrochemical oxidation, electrochemically assisted Fenton chemistry and synthetic 
metalloporphines to mimic CYP450 catalyzed oxidations has been extensively 
investigated 173. Electrochemical oxidation has been found to successfully mimic 
benzylic hydroxylation, hydroxylation of aromatic rings containing electron-donating 
groups, N-dealkylation, S-oxidation, dehydrogenation and, less efficiently, N-oxidation 
and O-dealkylation 173. Johansson and co-workers have demonstrated the utility of 
electrochemical oxidation to mimic CYP450 and liver microsome catalyzed oxidation of 
amodiaquine and desethylamodiaquine 174. This finding corroborates observations by 
other researchers on the usefulness of electrochemistry in mimicking phase I oxidation 
of paracetamol, clozapine, and trimethoprim 175 and diclofenac 176. The coupling of EC 
with MS means that MS/MS can be used to provide important structural information 
about the reactive metabolites formed. An important advantage of using electrochemical 
oxidation, however, is that it can be employed at a semi-preparative to preparative scale 
to generate reactive metabolite adducts which can be characterized by NMR thus 
facilitating unambiguous structural identification 177. 
 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
44 
 
1.8 AMODIAQUINE  
1.8.1 Pharmacokinetics 
Amodiaquine is rapidly absorbed and extensively metabolized after oral administration 
in humans, which leads to a low plasma exposure of the parent drug 178. 
Desethylamodiaquine is the main metabolite of amodiaquine. Other reported 
metabolites are bisdesethylamodiaquine and 2-hydroxydesethylamodiaquine 179,180. The 
elimination of desethylamodiaquine is very slow unlike that of amodiaquine; giving this 
metabolite a long terminal half-life 181,182. Both parent and metabolite have antimalarial 
activity, making amodiaquine act as a prodrug of desethylamodiaquine 179. The main 
enzyme responsible for amodiaquine deethylation was shown to be CYP2C8 183,184. 
Asymmetrical permeability properties of amodiaquine in the Caco-2 absorption model 
system have been observed, which alludes to the possible role of active transport of the 
drug 185,186. Both amodiaquine and desethylamodiaquine have been shown to be potent 
inhibitors of the important drug metabolising enzyme, CYP2D6 187. 
 
1.8.2 Toxicity 
In spite of its excellent antimalarial activity, it was observed, through pharmacovigilance 
programs, that prophylactic use of amodiaquine caused severe side effects including 
hepatitis, aplastic anemia and agranulocytosis 155,188,189. Among patients undergoing 
treatment with amodiaquine, the risk of each of these adverse effects is estimated to be 
1 in 15,500 for hepatotoxicity, 1 in 2,100 for agranulocytosis and 1 in 30,000 for aplastic 
anemia 190. Its use is, consequently, restricted to the treatment of the acute phase of 
malaria, during which no serious cases of toxicity have been reported 182. In acute 
malaria treatment, amodiaquine is administered in combination with other antimalarial 
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agents such as artesunate in the artemisinin-based combination therapy currently 
recommended by the World Health Organization 191. 
The 4-aminophenol moiety of amodiaquine has been identified as a ‘structural alert’ for 
toxicity. Bioactivation of this moiety to a reactive quinone imine metabolite has been 
identified as the likely cause of amodiaquine toxicity 155. This reactive metabolite acts by 
covalently binding to cellular macromolecules causing drug-induced toxicity and cell 
damage directly or via immunological mechanisms. The detoxification of the quinone 
imine and other reactive intermediates involves rapid binding to a trapping agent, 
usually reduced glutathione (GSH) 159. Indeed, studies in rats indicate that amodiaquine 
is excreted exclusively as the thioether conjugates of glutathione and cysteine 192. High 
doses of the drug overwhelm the detoxification mechanisms and the depletion of GSH 
is recognized as one of the risk factors for amodiaquine-induced hepatotoxicity 193. 
Naisbitt and co-workers showed that this protein-reactive quinone imine metabolite 
depleted intracellular glutathione levels when incubated with neutrophils in an activating 
medium 194. Incubation of amodiaquine with stimulated polymorphonuclear leukocytes 
(PMN) produced the quinone imine metabolite 195. These and several other studies 
point to the possible role of bioactivation in drug-induced agranulocytosis. Immune-
mediated hypersensitivity reactions have also been suggested as an attendant 
mechanism of quinone imine toxicity 196,197. This mechanism has been corroborated by 
the detection of antidrug IgG antibodies in some patients receiving amodiaquine 198.  
The aldehyde metabolite has been postulated as another possible explanation for 
amodiaquine toxicity. Using a panel of 13 human recombinantly expressed cytochromes 
P450 (rP450s), CYP1A1 and CYP1B1 were shown to mediate the formation of an 
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unidentified metabolite, M2 183. These two enzymes are found in extrahepatic tissues 
including leukocytes. Another group of researchers found that electrochemical oxidation 
of amodiaquine using EC-ESI/MS generated, besides the quinone imine species, 
another oxidation product with the same molecular mass as M2, for which they 
proposed an aldehyde structure 177. Using in vitro systems (CYP1A1 and CYP1B1) and 
electrochemical oxidation, Masimirembwa and coworkers confirmed (using retention 
times, accurate mass, and product ion spectra) that the second major oxidation product 
from the electrochemical system was identical with the major metabolite formed by 
CYP1A1 and CYP1B1. This metabolite, with a pseudomolecular ion at m/z 299, was the 
same as the unidentified metabolite M2 and was not observed in incubations with 
human liver microsomes 174. Since these enzymes are involved in the bioactivation of 
many procarcinogens 199,200, it was of interest to establish the structure of M2 and 
assess its potential reactivity. The electrochemical generation of the aldehyde 
metabolite was repeated on a preparative scale, and NMR spectroscopy confirmed the 
structure of M2 as the aldehyde metabolite of amodiaquine 174. The same study 
demonstrated using trapping experiments with N-acetylcysteine that the aldehyde 
metabolite undergoes further oxidation to an aldehyde quinone imine species 174. The 
distinct distribution of ADQ metabolising enzymes may be construed to imply that the 
quinone imine is responsible for hepatotoxicity while the aldehyde and/or the aldehyde 
quinone imine may be responsible for the blood dyscrasias.. 
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Figure 1.13: Metabolic routes of amodiaquine and desethylamodiaquine observed in rat 
and human liver microsomes and recombinant CYP1A1 and CYP1B1. MA is 
methoxamine, NAC is N-acetylcysteine. 
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1.8.3 Amodiaquine analogues synthesized to circumvent toxicity 
The implication of the quinone imine metabolite of amodiaquine (5) in its toxicity has 
spurred the synthesis of many analogues to prevent its formation, with little attention 
paid to the aldehyde metabolite. Park et al. have demonstrated that the 4′-hydroxyl 
group of amodiaquine (5) could be replaced with a 4′-fluorine atom to produce analogue 
32 with antimalarial activity in the low nanomolar range. Though less active than 
amodiaquine (5), compounds with this substitution pattern do not form the reactive 
quinone imine metabolite 195,201.  
Interchange of the 4′-hydroxyl and the 3′ Mannich side chain function of amodiaquine 
(5) has been carried out to provide the isoquine series of analogues. These do not form 
the toxic quinone imine metabolite and isoquine (33) was shown to possess excellent 
antimalarial activity against both the chloroquine sensitive HB3 and chloroquine 
resistant K1 strains of Plasmodium falciparum 202. A drawback with isoquine is the low 
oral bioavailability in animal models due to extensive metabolism of the N-diethylamino 
Mannich side chain as well as a narrow therapeutic index and the associated off-target 
pharmacology of the isoquine series. Further studies in this area have revealed that N-
tert-butyl isoquine (7) has superior pharmacokinetic and pharmacodynamic profiles 
compared to isoquine. This compound completed preclinical evaluation with Glaxo-
SmithKline pharmaceuticals and entered phase I clinical trial in April 2008 88. N-tert-
butyl fluoroamodiaquine (34) which has moderate  to excellent oral bioavailability 
compared to isoquine was identified as ‘back-up’ compound for N-tert-butyl isoquine 203. 
The clinical development of N-tert-butyl isoquine has since been discontinued due to 
exposures insufficient to demonstrate drug safety superior to chloroquine 204. 
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Elsewhere, Miroshnikova and coworkers synthesized various isotebuquine analogs 
(35). Although the antimalarial activity of the analogs was comparable to that of 
tebuquine, with no formation of the quinone imine, the compounds were not orally 
bioavailable 205.  
  
32 33 
  
34 35 
Figure 1.14: Examples of analogues synthesized to prevent bioactivation to the 
quinone imine 
 
1.9 JUSTIFICATION 
The 4-aminoquinoline drug amodiaquine has many favorable aspects including a high 
degree of efficacy against most of the highly chloroquine-resistant strains, a reasonable 
costing, relatively easy synthesis, and few compliance issues since it is only 
administered over three days 206. These factors make amodiaquine a good lead 
compound for the exploration of newer antimalarials. In addition and as already 
mentioned, it is known that 4-aminoquinoline resistance is not related to the target but is 
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due to mutations affecting a membrane transporter on the food vacuole. Thus it is 
possible, using available knowledge on the resistance mechanism, to produce 
efficacious drugs that inhibit hemozoin formation. The well established role of 
bioactivation in amodiaquine toxicity also implies that it is possible to rationally design 
compounds with a potentially improved safety profile. Previous research efforts have 
only focused on avoiding quinone imine formation but have not resulted in compounds 
with an acceptable safety profile. 
 
1.10 RESEARCH QUESTION AND SPECIFIC OBJECTIVES 
1.10.1 Hypothesis 
The research question is whether it will be possible to discover analogues of the 4-
aminoquinoline drug amodiaquine with potentially improved safety and efficacy profiles 
using the present and available knowledge of the drug metabolism and 
pharmacokinetics (DMPK), toxicity and efficacy profile of the drug. 
1.10.2 Specific aims 
 To synthesize analogues of amodiaquine which potentially prevent bioactivation 
to the quinone imine and aldehyde metabolites which could be associated with 
hepatotoxicity and agranulocytosis. 
 To use EC-ESI/MS and CYP inhibition studies to assess the bioactivation 
potential of the amodiaquine analogues synthesized. 
 To use bioactivation and antiplasmodial data to select the series with the best 
efficacy/safety profile for further SAR expansion. 
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 To conduct in vitro metabolic stability and solubility assays on synthesized 
analogues. 
 To conduct mechanistic studies on the synthesized analogues. 
 To conduct in vivo efficacy studies on compounds with the most potent 
antiplasmodial activity and good metabolic stability. 
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Chapter 2 
DESIGN AND SYNTHESIS OF BENZOHETEROCYCLIC AND PYRIDYL 
AMODIAQUINE ANALOGUES 
2.1 DESIGN 
As mentioned in Chapter 1, the 4-aminophenol moiety of amodiaquine is essential for 
the quinone imine reactive metabolite formation while the presence of the Mannich side 
chain is a prerequisite for the formation of the aldehyde reactive metabolite. We 
postulated that incorporating the Mannich side chain and the hydroxyl group of 
amodiaquine into a second benzoheterocyclic ring system would potentially block the 
formation of the two reactive metabolites. The aromatic ring, which is known to impart 
activity against chloroquine resistant strains, would thus still be retained in the resulting 
molecules 1. A second approach was to replace the aromatic aminophenol ring with an 
aminopyridyl ring thus designing out the toxicophore from the resulting molecules. In 
both cases, a good leaving group, such as a halogen, on the azole benzoheterocyclic 
(benzazole) or pyridyl ring would serve as a handle for the introduction of diversity in the 
target molecules (Figure 2.1).  
The choice of the benzoheterocyclic ring system was informed by commercial 
availability and chemical tractability. Consequently, the readily available and tractable 
benzoheterocyles became the ring systems of interest. Molecules with the 
benzothiazole scaffold are known to possess diverse pharmacological activity which 
includes antimalarial, antitubercular, antifungal, anthelmintic, antitumoral, antibacterial, 
antifungal and analgesic activities 2–5. Benzoxazole analogues possess, among other 
reported activities, antifungal 6, antibacterial 7–10, antitumor 11, antiviral, antitubercular 
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and anthelmintic activity 12. The pharmacological activities of benzimidazole containing 
molecules have been comprehensively reviewed and include antiviral, antibacterial, 
antitumoral, anthelmintic, antihypertensive, antiallergic, gastric proton pump inhibition 
and analgesic 13. The extensive biological profile and synthetic accessibility of 
benzothiazole, as well as the benzoxazole and benzimidazole compounds make these 
scaffolds attractive in the design of potential chemotherapeutics 14. 
 
Figure 2.1: General chemical structures of the four series of amodiaquine analogues 
 
The second aspect of the design was the choice of groups to introduce diversity in the 
molecules. The primary consideration was the fact that these compounds, being 
amodiaquine analogues, should have a protonatable tertiary nitrogen attached to the 
benzoheterocyclic or pyridyl rings. This would enhance accumulation in the parasitic 
food vacuole, assuming the mode of action of these compounds to primarily involve 
disruption of heme detoxification 15. Different diamines were selected in which the 
tertiary nitrogen was part of an aliphatic or cyclic system. The second amine was a 
primary amine (or secondary amine in some compounds) that would take part in a 
substitution reaction with the leaving group on the tractable intermediates. The length of 
the linker between the two nitrogen atoms was varied and, in some molecules, a 
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piperazinyl linker was chosen instead of an alkyl linker. To more fully explore the groups 
tolerated on the side chain, different aromatic and simple alkyl amines were also 
incorporated in the side chain. The different amines selected are shown in Figure 2.2. 
    
    
   
 
    
Figure 2.2: Amines employed in substitution reactions: n=1, 2, X= H, Cl, CF3. 
 
2.2  SYNTHESIS 
After the introduction of the leaving group on the different ring systems, the synthesis of 
the four series of amodiaquine analogues proceeded through a common pathway: a 
substitution reaction on the leaving group to introduce the amino side chain, reduction of 
the aromatic nitro group to an aromatic amine and a second substitution reaction 
between the amine thus obtained and 4,7-dichloroquinoline to give the target molecules. 
The retrosynthetic analysis of the four series will be illustrated using the benzothiazole 
series (Scheme 2.1). The target molecule was envisaged to be obtained by 
disconnection of the 4-aminoquinoline bond. Commercially available 4,7-
dichloroquinoline  could then serve as the synthetic equivalent of the electrophilic 
synthon with the aromatic amine serving as the nucleophile. A functional group 
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interconversion (FGI) of the aromatic nitro compound by a variety of reduction 
techniques could readily furnish the aromatic amine. A second disconnection at the 2-
amino position of the nitro intermediate revealed the starting molecules to be a 
substituted amine and a nitrobenzoheterocycle (or nitropyridine for the pyridyl series) 
with an appropriate leaving group. 
 
Scheme 2.1: Retrosynthetic scheme for the benzothiazole series 
 
2.2.1   Towards chemically tractable intermediates 
2.2.1.1  Bromo intermediates 
The commercially available 6-nitrobenzothiazol-2-amine (2.1) was  readily converted to 
2-bromo-6-nitrobenzothiazole (2.2) at room temperature using the Sandmeyer reaction 
16. The mechanism for this reaction is well known, involving diazotization, loss of 
nitrogen gas and probably reaction of the resulting radical C-center on benzene with a 
bromide radical supplied by copper bromide to give the bromo substituted intermediate 
17. The same approach was applied to the conversion of 2-amino-5-nitropyridine (2.3) to 
2-bromo-5-nitropyridine (2.4). However, this conversion did not go to completion and 
silica gel chromatography was required to separate the product from the starting 
material. The downfield shift of the proton attached to C3 to 7.7 ppm (it usually 
CHAPTER 2: DESIGN AND SYNTHESIS 
84 
 
resonates at <7.0 ppm in 2-aminopyridine) confirmed successful substitution.  
Bromination of the commercially available 5-nitrobenzimidazole-2-thiol (2.5) using 
bromine and HBr in acetic acid, as reported in literature, afforded 2-bromo-5-
nitrobenzimidazole (2.6) 18. The reaction conditions are illustrated in Scheme 2.2. 
 
2.1 2.2 
 
2.3 2.4 
 
2.5 2.6 
Scheme 2.2: Reagents and conditions: (i) 48% HBr, NaNO2, CuBr, H2O, 4h, r.t. (ii) Br2, 
48 % HBr, AcOH, 5°C-r.t., 4.5h, r.t.-0°C, H2O, NaOH, pH 4. 
 
2.2.1.2  2-(Methylthio)-5-nitrobenzoxazole 
Cyclization of the readily available 2-amino-4-nitrophenol (2.7) using potassium ethyl 
xanthate in ethanol was carried out under reflux to give 5-nitrobenzoxazole-2-thione 
(2.8) 19. Pyridine has also been used as a solvent for this reaction but its use 
necessitates prolonged drying of the product at elevated temperatures under vacuum 4. 
Both solvents give excellent yields and thus ethanol was preferred. After completion of 
the reaction, which was monitored by TLC, the reaction mixture was cooled, diluted with 
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water and acidified to precipitate the product as a yellow solid. The benzoxazole-2- 
thione can also be obtained by reacting 2-aminophenol with carbon disulfide usually in 
the presence of base with ethanol or methanol as solvent 20,21. In the second step, thiol 
(2.8) was converted to 2-(methylthio)-5-nitrobenzoxazole (2.9) by reaction with 
iodomethane in acetonitrile in the presence of a base at room temperature as shown in 
Scheme 2.3 22. The product was obtained after aqueous work-up and used without 
further purification after drying. The methylthio was envisaged to act as a better leaving 
group compared to the thione 23. The structure of the target intermediate was confirmed 
by the presence of a characteristic deshielded methyl singlet at 2.8 ppm in the 1H NMR 
spectrum.  
 
2.7 2.8 2.9 
Scheme 2.3: Reagents and conditions: (i) Potassium ethyl xanthate, EtOH, reflux, 4.5 
h, AcOH, pH 5 (ii) MeI, ACN, 25 °C, 4 h. 
2.2.2   First nucelophilic substitution step 
With the appropriately substituted intermediates in hand, the next step involved a 
nucleophilic substitution reaction with different amines to introduce diversity. For the 
simple alkyl amines (tert-butylamine and ethylamine), the reaction with 2-bromo-6-
nitrobenzothiazole (2.2) took place at room temperature in THF. On the other hand, only 
ethylamine reacted with 2-(methylthio)-5-nitrobenzoxazole (2.9) in DMF at 80 °C to give 
the desired product. Attempts to react 2-bromo-5-nitrobenzimidazole (2.6) with 
ethylamine proved unsuccessful. Furthermore, reactions between 2-bromo-6-
nitrobenzothiazole (2.2) and bulkier amines were found to be extremely slow and low 
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yielding while these amines did not react at all with 2-(methylthio)-5-nitrobenzoxazole 
(2.9).  In a search for alternative synthetic schemes, it was noted that microwave 
assisted synthesis and the use of sealed tubes under thermal conditions have been 
reported in many amination reactions 24. The microwave approach was adopted 
because of the associated short reaction times. After successfully applying microwave 
synthesis to obtain N-ethyl-5-nitro-benzimidazol-2-amine in only 20 minutes at 120 °C, 
we were encouraged to employ these conditions for all the other amination reactions. 
Except for aryl-substituted amines, the products were obtained after aqueous work-up 
and silica gel column chromatography. The aryl-substituted amines were observed to 
crystallize out of the reaction mixture after standing overnight and were obtained by 
filtration. In all these reactions, the starting heterocyclic intermediates had three well 
resolved aromatic proton signals in their 1H NMR spectra. In the benzoxazole, 
benzimidazole and benzothiazole series, proton A was the most deshielded and 
appeared as a doublet with a small coupling constant (J≈2.2 Hz due to meta coupling 
with proton B), followed by protons B and C in that order (Figure 2.3). Proton B 
appeared as a doublet of doublets due to meta coupling with A (J≈2.2 Hz) and ortho 
coupling with C (J≈8.7 Hz). Generally, the nature of heteroatom X was seen to influence 
deshielding in the order S>O>NH. 
  
X=S (2.2a-f) 2.4a-b 
X=O (2.9a-v) 
X=NH (2.6a-d) 
 
Figure 2.3: General structures of amine intermediates 
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In the pyridyl series (Figure 2.3), the presence of the electron withdrawing nitro group 
and the pyridyl nitrogen combined to make proton D the most deshielded (a doublet with 
a small coupling constant due to meta coupling at >9.1 ppm). Proton F was the most 
shielded due to its proximity to the amino group and appeared as a doublet with a large 
coupling constant (J≈9.0 Hz) due to ortho coupling with E. Proton E, as expected, 
appeared as a doublet of doublets due to coupling with D (J≈2.7 Hz) and F (J≈9.0 Hz).  
Successful amination was easily confirmed by the appearance of additional aliphatic or 
aromatic signals at the expected chemical shifts as illustrated using the spectrum of 
2.2d in Figure 2.4. In this case, the ethylene protons 4 and 5 couple with each other and 
appear as triplets (J=6.7 Hz) at 3.57 and 2.61, respectively. These two pairs of protons 
appear more downfield compared to normal ethylene protons owing to the deshielding 
effect of the benzothiazolamine NH and piperidine nitrogen atom. The localization of the 
NH electrons into the benzothiazole ring results in proton pair D being the more 
deshielded. The multiplets for the piperidinyl protons 6, 7 and 8 appear progressively 
upfield as the deshielding effect of the piperidine nitrogen decreases. The diastereotopic 
nature of the axial and equatorial protons on the piperidine ring splits the signals of both 
geminal and vicinal protons thus explaining the appearance of proton groups 6, 7 and 8 
as multiplets. Mass spectroscopy and 13C NMR were utilized to more fully characterize 
novel intermediates.  
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Figure 2.4: The 1H NMR spectrum of 2.2d showing an expansion of the aromatic 
region. 
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The isolated yields of the nitro intermediates are reported in Tables 2.1 through 2.4. In 
general, only the benzoxazole intermediates bearing aliphatic and alicyclic side chains 
were subjected to silica gel column chromatography. 
Table 2.1: Yields of benzothiazole analogues 
 
2.2 2.2a-f 
Reagents and conditions: (i) RNH2, THF, r.t., 15h or RNH2, 
acetonitrile, MW, 120 °C, 20 min 
Compound -R Yield % 
2.2a (DS1B)  78 
2.2b (DS1C)  93 
2.2c (DS11) 
 
87 
2.2d (DS12) 
 
90 
2.2e (DS13) 
 
81 
2.2f (DS18) 
 
76 
 
Table 2.2: Yields of benzimidazole analogues 
 
2.6 2.6a-d 
Reagents and conditions: (i) RNH2, acetonitrile, MW, 120 °C, 
20 min 
Compound -R Yield % 
2.6a (DS5C)  92 
2.6b (DS21) 
 
86 
2.6c (DS22) 
 
84 
2.6d (DS24) 
 
83 
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Table 2.3: Yields of pyridyl analogues 
 
2.4 2.4a-b 
Reagents and conditions: (i) RNH2, acetonitrile, MW, 120 °C, 
20 min 
Compound -R Yield % 
2.4a (DS26) 
 
65 
2.4b (DS27) 
 
77 
 
Table 2.4: Yields of benzoxazole analogues 
 
2.9 2.9a-r 
Reagents and conditions: (i) RNH2, acetonitrile, MW, 120 °C, 
20 min 
Compound -R Yield % 
2.9a (DS4C)  87 
2.9b (DS23) 
 
80 
2.9c (DS46) 
 
62 
2.9d (DS31) 
 
62 
2.9e (DS33) 
 
65 
2.9f (DS50) 
 
52 
2.9g (DS34) 
 
41 
2.9h (DS36) 
 
68 
2.9i (DS37)  61 
2.9j (DS48) 
 
69 
2.9k (DS56) 
 
53 
2.9l (DS41)  76 
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2.9m (DS42) 
 
59 
2.9n (DS54) 
 
84 
2.9o (DS32) 
 
52 
2.9p (DS35) 
 
81 
2.9q (DS47) 
 
38 
2.9r (DS49) 
 
60 
 
2.9 2.9s-v 
Reagents and conditions: (i) R2NH, acetonitrile, MW, 120 °C, 
20 min 
Compound -NR2 Yield % 
2.9s (DS39) 
 
56 
2.9t (DS51) 
 
70 
2.9u (DS52) 
 
77 
2.9v (DS53) 
 
72 
 
2.2.3   Reduction of the nitro group 
Aromatic nitro groups can be reduced by a variety of methods. The use of combinations 
of metal and acid is a common approach. Zn/HCl and Sn/HCl require basic work-up and 
generate large amounts of residue thus making their use environmentally unfriendly 
when used in large scale synthesis or in routine syntheses. The combination of iron and 
HCl or acetic acid offers two advantages: it requires only catalytic amounts of acid and 
the iron (III) oxide by-product formed precipitates out of solution making product 
purification easy. In catalytic hydrogenation, the nitro compound is dissolved in an 
alcohol in which finely divided metal catalyst is suspended and maintained under an 
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atmosphere of hydrogen gas, usually under pressure. The catalysts used include 
palladium or platinum on carbon or alumina and the Raney catalysts comprising nickel, 
cobalt or copper. A hydrogen donor, such as hydrazine can be used instead of 
hydrogen gas. At the end of reaction, the hydrogenation vessel is vented and the 
catalyst simply filtered off leaving the product in solution 25. Several other nitro reduction 
methods are available, including selective methods that can be employed when the nitro 
compound also contains other reducible groups 26,27. We opted to use catalytic 
hydrogenation because the method consistently gave quantitative yields and did not 
require further work-up after filtration. The typical reaction time was between 8 and 10 
hours. To monitor completion of the reaction, TLC was employed. Upon completion of 
the reduction, the reaction mixture was filtered through Celite® and the solvent 
evaporated in vacuo to obtain the aromatic amines. Selected amines were subjected to 
1H NMR spectroscopy to confirm the reduction of the nitro group. The typical difference 
in the spectra was the expected shielding of all aromatic protons, with a dramatic effect 
being observed on protons A and B that are adjacent to the amino group, as illustrated 
by the NMR spectra of 2.2d before and after the hydrogenation reaction in Figure 2.5. 
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Figure 2.5: The aromatic region of the 1H NMR spectra of 2.2d and its reduced 
intermediate 
 
2.2.4   Second substitution reaction (coupling with 4,7-dichloroquinoline) 
The aromatic amines obtained in the previous step were coupled to position 4 of 4,7-
dichloroquinoline by a nucleophilic aromatic substitution reaction to give the target 
molecules. The obvious starting point was to use the conditions employed in the 
synthesis of amodiaquine, namely reflux in ethanol 28. However, these conditions gave 
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poor yields. In their synthesis of amodiaquine and amopyroquine analogues, Paunescu 
and coworkers reported good yields when they refluxed the reactants in acidified 
acetonitrile 29. We adopted this method and reacted a slight excess of 4,7-
dichloroquinoline with the amine to obtain the product, as the hydrochloride salt, in 
moderate yields. Typically, the reaction mixture was refluxed for 15 to 24 hours and 
then cooled to room temperature. The product was isolated after work-up involving 
basification with saturated sodium bicarbonate and silica gel column chromatography. 
Characterization of the target molecules was carried out using 1H NMR, 13C NMR and 
mass spectroscopy. Purity was assayed using HPLC. 
 
Scheme 2.4: Reagents and conditions: (i) Acetonitrile, HCl, reflux, 24 h. 
 
2.3 CHARACTERIZATION OF TARGET MOLECULES 
The aromatic region in the NMR spectra of all target molecules except those with 
additional aromatic rings attached to the benzoheterocylic or pyridine ring were similar. 
The spectrum of 3.9k (Figure 2.6) will be used to discuss the characterization of target 
molecules with an aliphatic (or cyclic aliphatic) side chain. The quinolinyl protons were 
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generally more deshielded compared to the protons on the other aromatic rings. The 
proton attached to the α carbon of the quinoline ring (proton A) was the most 
deshielded, typically appearing at 8.3-8.4 ppm. This is explained by the fact that the 
quinolinyl nitrogen acts as an electron sink and leaves a partial positive charge on the α 
carbon. Conversely, the proton on the β carbon (proton H) was the most shielded of all 
the aromatic protons and appeared at ≈ 6.7 ppm, mainly due to the ortho directing effect 
of the 4-amino group which increases the electron density around carbon H. The two 
protons appeared as doublets with a coupling constant of approximately 5.6 Hz. Proton 
B was the second most deshielded and appeared as a doublet with a large coupling 
constant of 9.0 Hz due to ortho coupling. Proton C could only experience meta coupling 
with proton D and accordingly had a small coupling constant of ≈2.2 Hz. Finally proton 
D coupled with both proton B (ortho coupling, J = 9.0 Hz) and proton C (meta coupling, 
J =2.2 Hz) and appeared as a doublet of doublets. The aromatic region of the 1H NMR 
spectrum of 3.9k below illustrates these facts. The coupling of protons E, F and G has 
been discussed previously. The aliphatic region of the spectrum, in this case a 
propylmorpholino chain, has a multiplet for the deshielded morpholino protons I 
adjacent to the electronegative O, two triplets for the methylene protons J and K, which 
only couple with protons M, a second multiplet for the less deshielded morpholino 
protons L and an upfield multiplet signal for protons M due to coupling with both protons 
J and K. 
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Figure 2.6: The 1H NMR spectrum of 3.9k in CD3OD: a=aromatic, b=aliphatic 
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The 13C spectrum of 3.9k (Figure 2.7) has 16 aromatic carbon signals, 8 low intensity 
signals for the quaternary carbon atoms and 8 high intensity signals for the proton-
bearing carbon atoms. In the aliphatic region, two intense signals due to the equivalent 
pairs of morpholino carbon atoms are clearly visible at 54.88 and 67.85 ppm, along with 
three low intensity signals for the propyl chain. 
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Figure 2.7: The 13C spectrum of 3.9k in CD3OD. 
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The 1H NMR spectrum of pyridyl analogue 3.9r (Figure 2.8) was expected to have 12 
aromatic protons: 5 from the quinolinyl ring, 3 from the benzoxazolyl ring and 4 from the 
pyridyl ring. However, the DMSO-d6 spectrum shows 14 protons in the aromatic region, 
the extra two protons coming from the two NH protons in the molecule. The NH proton 
at position 4 of the quinoline ring is the most deshielded and appears as singlet O at 
9.01 ppm. After assigning all the aromatic protons, we were left with triplet D at 8.06 
ppm. In the aliphatic region, two triplets were expected due to interaction between the 
two sets of ethylene protons.  However, the more deshielded pair of ethylene protons 
(L) appear as a multiplet. This was attributed to coupling with both D and M. Such 
interaction would be expected to split the NH proton into a triplet and thus triplet D at 
8.06 ppm was accordingly assigned. 
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Figure 2.8: The aromatic region of the 1H NMR spectrum of 3.9r. 
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The 13C spectrum of 3.9r (Figure 2.9) has the expected 21 aromatic carbon signals, 
including a cluster of 3 signals at 149.58, 149.82 and 149.92 ppm. Of these, there are 
12 high intensity signals for the CH carbon atoms. Seven low intensity signals are 
visible in the spectrum. These, together with the signals at 149.82 and 149.92 ppm 
which are seen on expanding the spectrum correspond to the nine quaternary carbon 
atoms. Finally, there are two signals for the ethylene carbon atoms in the aliphatic 
region at 37.56 and 42.53 ppm. 
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Figure 2.9: The 13C spectrum of 3.9r 
 
 
CHAPTER 2: DESIGN AND SYNTHESIS 
100 
 
The isolated yields of the target molecules are given in the tables 2.5 to 2.8 below. The 
greatest contributor to low yield was the difficulty encountered in purifying tertiary amine 
containing products which tended to co-elute with the aromatic amine reactant during 
column chromatography. 
Table 2.5: Isolated yields of benzothiazole target molecules 
 
3.2a-f 
Compound -R Yield % 
3.2a (DS1F)  58 
3.2b (DS1G)  42 
3.2c (DS11B) 
 
47 
3.2d (DS12B) 
 
53 
3.2e (DS13B) 
 
45 
3.2f (DS18B) 
 
49 
 
Table 2.6: Isolated yields of benzimidazole targets 
 
3.6a-d 
Compound -R Yield % 
3.6a (DS5G)  60 
3.6b (DS21B) 
 
50 
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3.6c (DS22B) 
 
71 
3.6d (DS24B) 
 
65 
 
 
Table 2.7: Isolated yields of pyridyl targets 
 
3.4a-b 
Compound -R Yield % 
3.4a (DS26B) 
 
58 
3.4b (DS27B) 
 
61 
 
Table 2.8: Isolated yields of benzoxazole targets 
General structure Compound -R or -NR2 Yield % 
 
3.9a (DS4F)  51 
3.9b (DS23B) 
 
61 
3.9c (DS46B) 
 
60 
3.9d (DS31B) 
 
57 
3.9e (DS33B) 
 
55 
3.9f (DS50B) 
 
44 
3.9g (DS34B) 
 
65 
3.9h (DS36B) 
 
46 
3.9i (DS37B)  52 
3.9j (DS48B) 
 
58 
3.9k (DS56B) 
 
53 
3.9a-r 
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3.9l (DS41B) 
 
55 
3.9m (DS42B) 
 
52 
3.9n (DS54B) 
 
46 
3.9o (DS32B) 
 
61 
3.9p (DS35B) 
 
58 
3.9q (DS47B) 
 
23 
3.9r (DS49B) 
 
67 
 
3.9s (DS39B) 
 
58 
3.9t (DS51B) 
 
47 
3.9u (DS52B) 
 
74 
3.9v (DS53B) 
 
40 
 
2.4 CONCLUSION 
This chapter described the rational design and synthesis of the four series of 
amodiaquine analogues that formed the basis of this project. The synthesis was carried 
out in two phases. A limited number of representative compounds were synthesized 
from each of the four series and assayed for their bioactivation potential as reported in 
Chapter 3. Results from this assay led to the selection of the benzoxazole series for 
expanded antiplasmodial SAR studies. In vitro antiplasmodial and metabolic stability as 
well as in vivo antimalarial data are presented in Chapter 4. 
 
 
 
3.9s-v 
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Chapter 3 
REACTIVE METABOLITE STUDIES 
3.1 INTRODUCTION 
In this chapter, the bioactivation potential of the four series of amodiaquine analogues 
previously described is assessed using representative compounds. Two methods are 
employed: trapping reactions using glutathione, potassium cyanide and methoxylamine 
as well as time-dependent CYP inhibition. Based on findings from this evaluation, the 
best series is selected for further exploration. 
As mentioned in Chapter 1, reactive metabolites readily form covalent bonds with 
nucleophiles, a phenomenon that underlies both their detoxification and toxicity 1. This 
reactivity is taken advantage of in trapping reactions where the test compound is 
exposed to conditions conducive for bioactivation in the presence of selected 
nucleophiles 2,3. The formation of adducts with the nucleophiles is then detected using 
mass spectroscopic techniques and is a measure of the bioactivation potential of the 
test compound 4. In our project, we were privileged to have a working collaboration with 
Dr Jurva Ulrik at AstraZeneca, Sweden, who gladly offered to carry out on-line 
Electrochemistry /Electrospray Ionization Mass Spectrometry (EC/ESI-MS) on the first 
batch of compounds.  
Time-dependent CYP inhibition can be used as an indicator of the ability of a compound 
to form reactive metabolites as discussed in Chapter 1. In such cases, the metabolite is 
so reactive that it reacts directly with enzyme when it is formed resulting in inactivation 
of the enzyme 5. To assess this type of inhibition, it was first necessary to determine 
whether the test compounds inhibited any of the five major CYP isoforms involved in 
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xenobiotic metabolism namely CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 6. 
These studies were conducted at the African Institute of Biomedical Science and 
Technology (AiBST) in Harare, Zimbabwe. 
3.1.1 The EC/ESI-MS procedure 
This method involved infusion of the substrate solution through the electrochemical cell 
via a syringe pump (Figure 3.1). A pH adjusted make-up flow was added before the cell. 
The electrochemical cell was controlled using a potentiostat, at a fixed or varying 
potential of between 0 and 1500 V. The sample was collected in glass vials containing 
glutathione, methoxylamine or potassium cyanide as the trapping agents for subsequent 
analysis by LC/MS 7. 
 
Figure 3.1: Schematic overview of the electrochemical system 7. 
3.1.2 The CYP inhibition assay procedure 
This assay was carried out according to the method by Crespi and Stresser in 96-well 
microtiter plates at high (20μM) and low (3μM) concentrations 8. Enzyme substrates that 
are metabolized to fluorescent compounds were employed. After incubation for 15 
minutes at 37 °C, the reaction was quenched using 1 mM Tris solution in 80% 
acetonitrile and the formation of fluorescent metabolites was measured. Ketoconazole, 
thioridazine, sulfaphenazole and α-naphthoflavone are known inhibitors of CYP3A4, 
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CYP2D6, CYP1A2 and CYP2C9, respectively, and were used as positive controls for 
these enzymes 9. 
In the time-dependent CYP inhibition assay, a two-step incubation scheme consisting of 
an inactivation assay and an activity assay was used according to the method by 
Thelingwani et al. 10. In the inactivation assay, the test compounds (at concentrations of 
2 and 10 μM) were incubated with recombinant enzyme. The assay was performed both 
in the presence and absence of NADPH for 15 min at 37°C. An aliquot was then 
transferred to the activity assay plate consisting of buffer, NADPH and a substrate that 
is metabolized to a fluorescent compound. The mixture was incubated for a further 15 
min at 37°C and the reaction was terminated by addition of an ice-cold 20% Tris 
base/80% acetonitrile solution. Enzyme activity was measured as described for the one 
step CYP inhibition assay. Troleandomycin, a known mechanism-based inhibitor of 
CYP3A4, was used as the positive control in this assay 11. 
3.1.3 Treatment of results 
In the glutathione trapping experiments, the mass spectrometer was set to detect 
glutathione adducts of the test compounds (305.32 mass units above the molecular 
weight of the test compound). Clozapine was used as the positive control compound. 
Clozapine is a neuroleptic drug that readily forms glutathione adducts following its 
bioactivation to a reactive nitrenium metabolite (figure) 12. 
 
Figure 3.2: Bioactivation of clozapine and detoxification by glutathione. 
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The results of the trapping experiment were semi-quantitatively expressed using as a 
ratio of the peak areas of test compound and clozapine adducts as shown in equation 1 
below. 
 
Equation 1 
Methoxylamine and potassium cyanide trapping was assessed by directly scanning for 
the masses of methoxylamine and cyanide adduct formation and were qualitatively 
expressed as yes (adduct detected) or no (adduct not detected) observations. 
In the CYP inhibition assays, enzyme activity was estimated by comparing the level of 
fluorescence in wells containing test compounds with that in wells containing no 
inhibitor. Results were presented as % of remaining enzyme activity. Finally, 
mechanism-based inhibition (MBI) results were presented as a normalized ratio 
(Equation 2) as previously described 10. 
 
Equation 2 
where R+I+NADPH and R+I-NADPH refer the rates of reaction when incubation is performed 
in the presence of the inhibitor with and without NADPH, respectively, while R-I+NADPH 
and R-I-NADPH refer to the rate when incubation is performed in the absence of inhibitor 
with and without NADPH, respectively. 
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3.2 RESULTS AND DISCUSSION 
3.2.1 Glutathione trapping 
Table 3.1: Glutathione trapping results 
General structure Compound R 
GSH 
ratio 
 
3.2a (DS1F)  0.74 
3.2c (DS11B) 
 
0.39 
3.2d (DS12B) 
 
0.88 
3.2e (DS13B) 
 
1.13 
3.2f (DS18B) 
 
0.54 
 
3.6a (DS5G)  0.54 
3.6b (DS21B) 
 
0.19 
3.6c (DS22B) 
 
0.24 
3.6d (DS24B) 
 
0.17 
 
3.9a (DS4F)  0.07 
3.9b (DS23B) 
 
0.00 
 
3.4a (DS26B) 
 
0.10 
3.4b (DS27B) 
 
0.33 
Amodiaquine 0.22 
 
The results of the GSH trapping results showed the benzothiazole compounds to have 
the highest bioactivation potential. The highest GSH ratio, 1.13, was seen for the 
morpholine compound 3.2e, indicating that this compound could be more reactive than 
clozapine itself. The second and third highest ratios were seen for 3.2d and 3.2a, 
respectively. In this series of compounds, 3.2c had the lowest bioactivation potential 
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(GSH ratio 0.39). Thus all the compounds had a GSH ratio greater than that of 
amodiaquine, with the least reactive compound having a GSH ratio 1.8 times that of the 
amodiaquine. Among the remaining three series of compounds, 3.6a and 3.4b had GSH 
ratios 2.5 and 1.5 times that of amodiaquine, respectively. The rest of the compounds 
had GSH ratios equal to or less than amodiaquine. The least reactive compounds were 
the benzoxazole analogues of which 3.9a had a low ratio of 0.07 while no adducts were 
detected for 3.9b. 
The HSAB (Hard Soft Acid Base) theory states that a hard electrophile will have 
increased reactivity towards hard nucleophiles and decreased reactivity towards soft 
nucleophiles and, conversely, a soft electrophile will have increased reactivity towards 
soft nucleophiles and decreased reactivity towards hard nucleophiles 13. Glutathione 
contains a free sulfhydryl group that is classified as a soft nucleophile because the large 
atomic radius of the sulfur atom results in highly polarized valence electrons 14. As such, 
glutathione will preferentially react with soft electrophiles including quinones, quinone 
imines, iminoquinone methides, epoxides, arene oxides and nitrenium ions 15. 
Considering the chemical structures of the four series of compounds, the most probable 
reactive species that would trap glutathione are imine or quinone-like metabolites as 
illustrated in Figure 3.3.  
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Figure 3.3: Proposed bioactivation of the pyridyl and benzazole analogues to soft 
electrophiles and their conjugation with GSH. 
We postulate that, in the case of the benzothiazole compounds, the nucleophilic sulfur 
atom donates electrons into the ring efficiently to form a quinone-like positively charged 
reactive intermediate on account of the 1,4-relationship with the 4-amino group on the 
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quinoline ring. The benzimidazole and pyridyl compounds have two para nitrogen atoms 
which form the reactive quinone diimine metabolite. Evidence of this reactive metabolite 
is available in the literature 16. The main biliary metabolite of the antileukemic drug 
amsacrine in rats was found to be the glutathione conjugate which was postulated to 
arise from reaction with amsacrine quinone diimine (Figure 3.4) 16. Subsequent 
synthesis of the quinone diimine, which could not be detected in cellular matrix, 
demonstrated the high reactivity of this metabolite towards nucleophiles and thus 
confirmed the initial hypothesis 17. Mitoxantrone, a drug used in the management of 
advanced breast cancer and acute leukemia, has also been shown to form glutathione 
conjugates following its metabolism to a metabolite containing a quinone dimine (Figure 
3.5), whose structure has been confirmed using microsomal and electrochemical 
oxidation methods 18,19. 
 
Figure 3.4: Bioactivation of amsacrine 
 
Figure 3.5: Bioactivation of mitoxantrone 
It appears that in the benzoxazole series, despite the para position of the oxygen atom 
relative to the 4-aminoquinoline nitrogen, the high electronegativity, and hence reduced 
nuceophilicity, of oxygen makes the formation of a quinone imine reactive species less 
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likely. As expected, amodiaquine was confirmed to form glutathione conjugates in this 
study. The variations in the glutathione ratios appear significant, especially among the 
benzothiazole analogues as well as between the ethyl and the other analogues in the 
benzimidazole series. This may imply that the side chains have a role to play in 
influencing the overall reactivity of the benzazole nucleus. 
 
3.2.2 Trapping with cyanide and methoxylamine 
Table 3.2: Potassium cyanide and methoxyalmine trapping experiment results 
General structure CODE R 
KCN 
adduct? 
Methoxylamine 
adduct? 
 
3.2a (DS1F)  No No 
3.2c (DS11B) 
 
Yes Yes 
3.2d (DS12B) 
 
Yes Yes 
3.2e (DS13B) 
 
Yes Yes 
3.2f (DS18B) 
 
Yes Yes 
 
3.6a (DS5G)  No No 
3.6b (DS21B) 
 
No Yes 
3.6c (DS22B) 
 
Yes Yes 
3.6d (DS24B) 
 
Yes Yes 
 
3.9a (DS4F)  No No 
3.9b (DS23B) 
 
Yes Yes 
 
3.4a (DS26B) 
 
Yes Yes 
3.4b (DS27B) 
 
Yes Yes 
Amodiaquine No Yes 
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The most obvious observation in the results from the cyanide and methoxylamine 
trapping experiments was the fact that analogues bearing ethyl (3.9a and 3.6a) or tert-
butyl (3.2a) did not form adducts with the two trapping agents. The rest of the molecules 
formed adducts with both trapping agents except for benzimidazole analogue 3.6b and 
amodiaquine which did not form adducts with potassium cyanide, or whose adducts 
were not detected under the experimental conditions. The two observations were 
consistent regardless of the nature of the aromatic ring system. It follows, therefore, that 
the observed trapping was purely dependent on the nature of the side chain, and that 
only molecules with a tertiary protonatable amine on the side chain could form reactive 
species capable of reacting with potassium cyanide and methoxylamine. 
Trapping with methoxylamine and potassium cyanide is commonly used in the detection 
of hard nucelophiles, specifically the highly reactive iminium and aldehyde metabolites 
20,21. The bioactivation of cyclic and aliphatic tertiary amines to iminium and aldehyde 
metabolites is a well established metabolic pathway 22. Figure 3.6, using piperidine as 
an example, illustrates the formation and trapping of the iminium and aldehyde 
metabolites. It can, therefore, be concluded that the bioactivation of compounds bearing 
a tertiary amine is an unavoidable outcome. As mentioned in earlier chapters, the 
presence of a tertiary amine in the side chain of aminoquinoline antimalarials enhances 
vacuolar trapping in the parasite and is essential for enhanced potency. There is thus 
an overlap between the pharmacophore and toxicophore. This makes it difficult to 
design out this part of the molecule without affecting activity, as the antiplasmodial 
results will later confirm.  
CHAPTER 3: REACTIVE METABOLITE STUDIES 
117 
 
 
Figure 3.6: Bioactivation of piperidinyl compounds 
3.2.3 CYP inhibition assays 
The CYP inhibition assay results for four CYP isoforms are graphically presented in 
figures 3.7 to 3.10. The CYP2C19 assay did not give conclusive results even after 
repeated testing, probably due to background fluorescence interference. 
3.2.3.1 CYP3A4 inhibition 
 
Figure 3.7: Results for the CYP3A4 inhibition assay. [Low] = 3 μM and [High] =20 μM. 
Ketocon= ketoconazole, ADQ = Amodiaquine, DADQ = Desethylamodiaquine. 
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Potent CYP3A4 inhibition was observed for all the compounds tested (Figure 3.7). In 
general, the analogues inhibited CYP3A4 more potently than amodiaquine and 
desethylamodiaquine (except for 3.6d, a benzimidazole analogue, and 3.4a, a pyridyl 
analogue). At 20 μM, 3.6d, 3.4a and 3.4b inhibited the enzyme to the same extent as 
amodiaquine. At both concentrations, the benzothiazole analogues with a tertiary amine 
side chain (3.2c, 3.2d, 3.2e and 3.2f) were the most potent inhibitors of the enzyme. 
3.2d, the piperidine benzothiazole analogue, was the most potent CYP3A4 inhibitor of 
all the compounds tested with only 14.1 % and 4.9 % remaining enzymatic activity at 3 
μM and 20 μM, respectively. In the benzimidazole class, 3.6a with a simple ethyl side 
chain was comparable to the benzimidazole morpholino analogue 3.6c in its inhibition of 
the enzyme at 20 μM. Interestingly, the other two benzimidazole analogues 3.6b and 
3.6d had virtually the same level of % remaining enzymatic activity at 20 μM as well. 
The pyridine analogs 3.4a and 3.4b were among the weakest inhibitors of all the 
compounds tested, along with 3.6d, at both concentrations. The benzoxazole analogue 
3.9b, with 21.4% remaining enzyme activity, was one of only five compounds that had 
>20% remaining enzyme activity at 20 μM. 
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3.2.3.2 CYP2D6 inhibition 
 
Figure 3.8: Results for the CYP2D6 inhibition assay. [Low] = 3 μM and [High] =20 μM. Thiorid = 
Thioridazine, ADQ = Amodiaquine, DADQ = Desethylamodiaquine. 
All analogues were less potent than amodiaquine as CYP2D6 inhibitors (Figure 3.8). 
The benzothiazole analogues 3.2a and 3.2e were very weak CYP2D6 inhibitors with 
>80 % remaining enzyme activity at both concentrations. Less than 40 % remaining 
enzyme activity was seen for 3.2c (benzothiazole analogue), 3.6c, 3.6d (benzimidazole 
analogues) and 3.9b (benzoxazole analogue) at 20 μM. However, all the compounds 
had a level of enzyme activity at this concentration greater than the 33.5 % seen with 
amodiaquine. Desethylamodiaquine was found to be a more potent inhibitor of CYP2D6 
than amodiaquine, in agreement with the literature 23. 
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3.2.3.3 CYP2C9 inhibition 
 
Figure 3.9: Results for the CYP2C9 inhibition assay. [Low] = 3 μM and [High] =20 μM. 
Sulfaphen = Sulfaphenazole, ADQ = Amodiaquine, DADQ = Desethylamodiaquine. 
From Figure 3.9, it can be seen that 3.2a, 3.2c, 3.2e (benzothiazole analogues) and 
3.4b (a pyridine analogue) inhibited CYP2C9 marginally more potently than 
amodiaquine at 20 μM. Only 3.2a, 3.2d and 3.2e (benzothiazole analogues) and 3.6a (a 
benzimidazole analogue) resulted in >20% inhibition of the enzyme at 3 μM. However, 
the inhibition remained less than 50 % at both 3 and 20 μM. Thus all the compounds 
tested were considered weak inhibitors of CYP2C9, especially when compared to the 
positive control inhibitor sulfaphenazole. 
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3.2.3.4 CYP1A2 inhibition 
 
Figure 3.10: Results for the CYP1A2 inhibition assay. [Low] = 3 μM and [High] =20 μM. Naphth 
= α-naphthoflavone, ADQ = Amodiaquine, DADQ = Desethylamodiaquine. 
None of the compounds tested inhibited CYP1A2 by >15% even at 20 μM, except 
amodiaquine which had 74.8% remaining activity at that concentration. This led to the 
conclusion that all the analogues tested were not CYP1A2 inhibitors. 
3.2.4 Time-dependent inhibition results 
From the foregoing results, the analogues tested were potent inhibitors of CYP3A4 and 
the time-dependent inhibition TDI) assay was thus carried out using this enzyme. The 
results obtained are graphically presented in Figure 3.11. In interpreting these results, 
we used the criteria set by Thelingwani et al. 10 whereby a normalized ratio <0.7 was 
taken to indicate  MBI, a ratio between 0.7 and 0.9 was considered to be indeterminate 
while a ratio >0.9 implied lack of MBI. 
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Figure 3.11: Results for the CYP3A4 time dependent inhibition assay. [Low] = 2 μM and [High] 
=10 μM. Ktz ketoconazole, TAO = troleandomycin. 
The results showed that none of the analogues tested were mechanism-based inhibitors 
of CYP3A4. There is a clear distinction between the ratios seen for the positive control 
troleandomycin and those seen for the test compounds at both the high and low 
concentrations. Although the normalized ratio for 3.6d at 2 μM fell below 0.7, the 
concentration-dependent nature of MBI was absent since at the high concentration, the 
ratio is greater than 0.9. At 10 μM, the normalized ratios for 3.2c, 3.2d, 3.2e, 3.4a, 3.4b, 
3.6c and 3.9b representing compounds from all the four series lay in the indeterminate 
region. Again, the concentration dependency requirement for MBI was lacking with 
compound 3.9b. 
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3.3 DISCUSSION 
Metabolism is one of the most important determinants of the pharmacokinetic 
disposition of a drug 24. The liver is the primary site of drug metabolism, with 
cytochrome P450 enzymes being responsible for over 90 % of drug metabolism 25. 
Identification of enzymes responsible for the metabolism of a test compound is, 
therefore, important in understanding the compounds’ clearance mechanisms. Drug-
drug interactions at metabolic level, particularly those involving CYP inhibition, have 
also been shown to result in undesirable adverse drug reactions 26–28. Competitive and 
non-competitive inhibition have been shown to be the most common mechanisms of 
CYP inhibition 29. There are also a significant number of compounds that have been 
shown to cause time-dependent inhibition which usually involves the generation of a 
reactive metabolite which reacts covalently with the enzyme, thus irreversibly 
inactivating it (mechanism based inhibition – MBI) or binding strongly to the heme in a 
quasi-irreversible manner (metabolite intermediate complex – MIC) 30,31. Metabolism, 
inhibition and enzyme crystal structure studies have resulted in extensive knowledge of 
the active sites of major drug metabolizing enzymes 25,32. 
The CYP1A2 active site has been modeled as an approximately rectangular slot 
composed of several aromatic side chains, including the coplanar rings of Phe181 and 
Tyr437, which restrict the size and shape of the cavity such that only planar structures 
(approximately 6 Å in width) are able to occupy the binding site 33. CYP1A2 substrates 
/inhibitors are, therefore, generally lipophilic planar polyaromatic/heteroaromatic 
molecules defined by a small depth and a large area-to-depth ratio 33. A 3D presentation 
of the simplest target molecule tested (3.6a, Figure 3.12) reveals a lack of planarity due 
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to the trigonal pyramidal arrangement at the quinolinyl 4-amino group. The resulting 
increased depth of the molecule may partly explain the lack of CYP1A2 inhibition 
observed among all the compounds tested. 
 
 
Figure 3.12: 3D view (Marvin Sketch®) of 3.6a with the benzimidazole ring out of plane with the 
quinoline ring 
 
A majority of CYP2C9 substrates are acidic and ionized at physiological pH or have a 
region that can act as a hydrogen bond donor 34. The weak to moderate inhibition 
observed with CYP2C9 may be attributed to the lack of these properties in the 
compounds screened against this enzyme. Our findings that amodiaquine weakly 
inhibits CYP2C9 are in agreement with those by Wennerholm and coworkers who 
reported inhibition of CYP2C9-mediated metabolism of losartan by amodiaquine and 
desethylamodiaquine 35. The binding and subsequent inhibition of CYP2C9 observed 
may involve interaction with water molecules at the active site. Such interactions have 
been reported for compounds like sulfaphenazole and warfarin 33,36.  
Typical CYP2D6 substrates are lipophilic bases with a planar hydrophobic aromatic 
ring, a nitrogen atom which can be protonated at physiological pH and a negative 
molecular electrostatic potential above the planar part of the molecule 37,38. It is not 
surprising then that a number of quinoline compounds such as chloroquine, 
amodiaquine and its major metabolite, desethylamodiaquine, are known inhibitors of 
CHAPTER 3: REACTIVE METABOLITE STUDIES 
125 
 
CYP2D6 23,39. This finding was confirmed in our study. The compounds screened were 
generally found to moderately inhibit CYP2D6, which was expected considering their 
structural similarity with amodiaquine. Potent CYP2D6 inhibition (up to 77 %) has been 
reported for chloroquine analogues with an aromatic substituent as one of the groups on 
the tertiary amine 40. The researchers found secondary amines to be less potent 
CYP2D6 inhibitors than secondary amines. In our study, the two secondary amines 
screened, 3.2a and 3.6a, were the weakest inhibitors in their series, namely the 
benzothiazole and benzimidazole analogues, respectively. Indeed 3.2a showed virtually 
no inhibition of the enzyme at both 3 and 20 μM. It can, consequently, be concluded that 
none of the series of compounds tested were potent CYP2D6 inhibitors to the extent 
exhibited by amodiaquine and desethylamodiaquine. Amodiaquine has a short half life 
(5.7-7.9 hours) and acts as a prodrug for desethylamodiaquine which has a much 
longer half life (7-9 days) 41. After a single 600 mg dose of amodiaquine, its main 
metabolite desethylamodiaquine attains high circulating concentrations in blood 
(maximum concentration 660 mmol/l compared to 47 mmol/l for amodiaquine) 35. In 
addition to the high circulating concentrations and long half life, desethylamodiaquine 
inhibits CYP2D6 by up to 99% and can change an individual’s metabolism status from 
extensive to poor metabolizer status 23. In the clinical setting, this can lead to high 
circulating concentrations of CYP2D6 substrate drugs and could result in adverse 
effects 42,43. 
Potent inhibition of CYP3A4 was observed among all the compounds tested, including 
the antimalarial drug amodiaquine. It is worth noting that the four series of compounds 
screened meet the requirements for typical CYP3A4 substrates: lipophilic neutral or 
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basic molecules whose metabolism will primarily involve N-dealkylation 34. As 
mentioned earlier in the section on trapping reactions, this metabolic pathway proceeds 
via reactive intermediates, namely aldehydes and iminium ions. A number of secondary 
and tertiary amine containing compounds such as diltiazem, N-desmethyl-diltiazem, 
fluoxetine, nortriptyline, phencyclidine and verapamil are known to be mechanism-
based inhibitors of CYP3A4 5. Our results, however, showed that the analogues tested 
did not result in CYP3A4 MBI although the formation of reactive aldehyde and iminium 
metabolite formation was observed under electrochemical oxidation conditions. Thus 
there appears to be a difference in outcome between the electrochemical and the 
biological system. In the latter, the protein matrix and enzyme affinity, among other 
factors, influence the fate of a substrate. The lack of MBI observed may be attributed to 
efficient conversion of the reactive metabolic intermediates to less reactive species such 
as the carboxylic acid or, in the case of the cyclic tertiary amines, some degree of 
metabolic stability such that dealkylation occurs very slowly. CYP3A4 catalyzes the 
metabolism of a wide range of drugs 44,45. Its inhibition is likely to result in elevated 
blood levels of co-administered drugs that are substrates of the isozyme, leading to 
toxicity and drug-drug interactions 46,47. Further thorough investigation of these findings 
will therefore be necessary for any lead compound arising from this project. 
In interpreting these results, it is important to note that CYP3A4 inhibition is substrate 
dependent, a factor that is attributed to the possible existence of more than one 
substrate binding pocket or the ability of the enzyme to exist in multiple conformations 
48. To get a more conclusive picture, the need to carry out the assay using multiple 
substrates has been recommended 8,48. Furthermore, the fluorescence-based CYP 
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inhibition assay relies on substrates that are not exactly drug-like. Consequently, the 
pharmaceutical industry is switching to assays that employ drug substrates such as 
midazolam and testosterone which tend to be more specific for CYP3A4, as well as 
LC/MS analysis 49. For rapid screening in early drug development, however, 
fluorescence-based assays are an affordable and readily accessible tool for the 
medicinal chemist 50. 
3.4 CONCLUSION 
The methoxylamine and cyanide trapping experiments revealed the potential for 
formation of reactive aldehyde and iminium intermediates by all tertiary nitrogen 
containing compounds, regardless of their series. The overall conclusion of the CYP 
inhibition assays was that benzothiazole analogues had the greatest inhibition potential 
of all the four series. Thus these two assays could not be used to select the safest 
series but gave useful information on which series to drop. Glutathione trapping results 
clearly revealed that the benzoxazole series has the least potential for formation of soft 
electrophilic metabolites. In light of these findings, the benzoxazole series was selected 
for further SAR expansion. 
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Chapter 4 
EVALUATION OF PHYSICOCHEMICAL PROPERTIES, METABOLIC 
STABILITY AND ANTIPLASMODIAL ACTIVITY OF AMODIAQUINE 
ANALOGUES 
4.1 CHAPTER OVERVIEW 
This Chapter starts with an evaluation of the physicochemical properties of all the 
analogues synthesized in the project for their ‘drug-likeness’, specifically those 
properties that are predictive of good oral bioavailability. Results for antiplasmodial and 
cytotoxicity studies are then presented and discussed. Subsequently, mechanistic 
investigation of the benzoxazole analogues, based on the known mode of action of 
amodiaquine, is discussed. This is followed by in vitro metabolic stability evaluation of 
selected analogues and in vivo efficacy studies in Plasmodium berghei infected mice. 
 
4.2 PHYSICOCHEMICAL PROPERTIES 
4.2.1 Introduction and rationale 
One of the underlying objectives of medicinal chemistry research is to discover new 
chemical entities which have similarities with existing drugs with respect to key 
physicochemical and biological properties (drug-like properties) with the understanding 
that such properties may help achieve good pharmacokinetic and pharmacodynamic 
properties 1. Several computational approaches exist that enable the prediction of 
various physicochemical properties of complex organic molecules from their molecular 
structures without the need of any experimentally derived parameters 2. Lipinski and co-
workers were the first researchers to identify and then to list, in a formalized and 
simplified form, the molecular properties that contribute most to drug-likeness, based on 
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disposition criteria 3,4. Since molecular properties can be estimated from computational 
molecular descriptors, Lipinski et al. postulated that computational methods in the early 
discovery setting could deal with large numbers of compounds and serve as filters to 
direct chemistry SAR towards compounds with greater probability of oral activity 4. 
Currently, the chemical space can be navigated using a large number of 
physicochemical descriptors, with Volsurf+® for example using as many as 56 
descriptors 5. However, Lipinski’s ‘rule of 5’ remains a useful guide in the design of 
molecules intended for oral administration 4. The ‘rule of 5’ states that for good oral 
absorption and permeation (for compound classes that are not substrates for biological 
transporters) a compound should not have >5 H-bond donors (expressed as the sum of 
OHs and NHs), molecular weight >500, ClogP >5 (or MLogP >4.15) and >10 H-bond 
acceptors (expressed as the sum of Ns and Os) 4. Veber and coworkers found the use 
of the rotatable bond count in conjunction with the polar surface area to give an effective 
rule for prediction of oral bioavailability 6. According to the researchers, molecules with > 
10 rotatable bonds generally had poor oral bioavailability 6. Furthermore, the 
researchers observed that reduced polar surface area (PSA) correlated better with 
increased permeation rate than did lipophilicity (cLogP) 6. Elsewhere, Palm and 
coworkers noted that the molecular descriptor PSA, which is related to the hydrogen-
bonding capacity, was a good predictor of intestinal epithelial permeability 7.  
Assessment of drug-likeness, therefore, includes the ‘rule of 5’ properties as well as 
rotatable bond count and PSA, among other properties 8. In general, compounds that 
violate no more than one of Lipinski’s guidelines, have less than 10 rotatable bonds and 
a PSA < 160 Å2 are more likely to be orally bioavailable 9. It is worth mentioning that 
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more and more drugs approved since 2002 are moving away from the traditional drug 
space making the application of semi-empirical rules derived from knowledge 
accumulated from historic, older molecules not necessarily valid 5.  
The target molecules included in this project were assessed for drug-likeness using the 
‘rule of 5’ properties as well as rotatable bond count and PSA in the design stages. In 
addition, the pKa was also predicted. This was done with a view to explaining any 
variations observed in antiplasmodial activity since a number of target molecules were 
envisaged to have the same mode of action as other 4-aminoquinoline antimalarials that 
rely on basicity for accumulation at the site of action. Prediction of cLogP was done 
using ChemDraw while MarvinSketch was employed for all the other predictions. 
Lipophilicity and solubility are the two most important physicochemical factors affecting 
both the extent and rate of drug absorption 10. Increasing lipophilicity generally 
enhances membrane permeability. However, a drug that is highly lipophilic is also likely 
to undergo rapid metabolic clearance, hence the need for a balance between 
permeability and clearance. Orally administered drugs need to dissolve in the aqueous 
environment before they can be absorbed 10.  
To complement the results obtained from the prediction of drug-like properties, the 
turbidimetric solubility of the target molecules was assessed in 96-well microtiter plates 
as previously described 11,12. Briefly, the turbidmetric solubility assay involved diluting 
the test compounds from 10 mM stock solutions in DMSO in phosphate buffered saline 
(PBS) at pH 7.4 as well as in DMSO to obtain final concentrations of between 0 and 200 
μM. After incubation at room temperature for two hours, absorbance was read at 620 
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nm. Since most organic compounds are not freely soluble in aqueous media, as the 
concentration of compound in PBS increased, precipitation would occur resulting in 
increased absorbance in the PBS wells relative to the DMSO containing wells. The 
absorbance readings were plotted against concentration and the point at which 
absorbance started rising was taken as the higher bound of solubility. 
4.2.2 Results of physicochemical evaluation 
The results of the predicted physicochemical properties and experimentally determined 
solubility are given in Tables 4.1 to 4.4. The average molecular weight was 408.98. The 
mean number of hydrogen bond donors, hydrogen bond acceptors and rotatable bonds 
was 1.94, 5.06 and 5.71, respectively. The PSA ranged between 49.84 Å2 (3.2a) and 
83.29 Å2 (3.9g). The mean cLogP was 6.10 (range 4.44-7.70). Only analogues 3.4b, 
3.9w, 3.9x and 3.9t had cLogP values less than 5. The high cLogP values observed for 
the rest of the molecules are attributable to the presence of the largely nonpolar 
quinoline and benzoheterocyclic rings.  
Thus the analogues evaluated generally had only one ‘rule of 5’ violation. This was 
interpreted to imply that the compounds would most likely be orally bioavailable. With 
regard to the turbidmetric solubility results, compounds with a protonatable tertiary 
nitrogen tended to have excellent solubility compared to the rest of the analogues. Poor 
solubility was generally associated with compounds possessing additional aromatic 
rings. 
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Table 4.1: Physicochemical properties of benzothiazole, benzimidazole and pyridine analogues 
General structure Code -R MW HBD HBA cLogP RB 
PSA 
(Å2) 
pKa 
Soly* 
(μM) 
 
3.2a (DS1F)  382.91 2 4 7.22 4 49.84 - 10 
3.2c (DS11B) 
 
423.96 2 5 6.86 6 53.08 8.67 >100 
3.2d (DS12B) 
 
437.99 2 5 7.42 6 53.08 8.55 >100 
3.2e (DS13B) 
 
438.96 2 6 6.20 6 62.31 6.11 80 
3.2f (DS18B) 
 
425.98 2 5 7.25 8 53.08 9.17 >100 
 
3.6a (DS5G)  337.81 3 4 5.92 4 65.63 - 40 
3.6b (DS21B) 
 
420.94 3 5 6.82 6 68.87 8.98 >100 
3.6c (DS22B) 
 
422.91 3 6 5.60 6 78.10 6.84 >100 
3.6d (DS24B) 
 
408.93 3 5 6.65 8 68.87 9.44 >100 
 
3.4a (DS26B) 
 
367.88 2 5 5.42 6 53.08 8.90 >100 
3.4b (DS27B) 
 
383.87 2 6 4.77 6 62.31 6.85 >100 
MW = Molecular weight; HBD = hydrogen bond donor; HBA = hydrogen bond acceptor; cLogP = calculated log of partition coefficient; RB 
=rotatable bonds; PSA = polar surface area; Soly* = Experimental solubility 
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Table 4.2: Physicochemical properties of dialkylamino and cycloalkylamino benzoxazole analogues 
General structure Code -R MW HBD HBA cLogP RB 
PSA 
(Å2) 
pKa 
Soly* 
(μM) 
 
3.9a (DS4F)  338.79 2 4 5.77 4 62.98 - 40 
3.9b (DS23B) 
 
407.90 2 5 6.11 6 66.22 8.69 200 
3.9c (DS46B) 
 
421.92 2 5 6.67 6 66.22 8.56 200 
3.9d (DS31B) 
 
423.90 2 7 5.45 6 75.45 6.11 160 
3.9e (DS33B) 
 
409.91 2 5 6.50 8 66.22 9.08 160 
3.9f (DS50B) 
 
381.86 2 5 5.46 6 66.22 8.54 160 
3.9g (DS34B) 
 
435.91 2 6 5.26 7 83.29 - 160 
3.9h (DS36B) 
 
423.94 2 5 6.83 9 66.22 9.94 >200 
3.9i (DS37B)  395.89 2 5 5.77 7 66.22 9.40 >200 
3.9j (DS48B) 
 
435.95 2 5 6.94 7 66.22 8.92 >200 
3.9k (DS56B) 
 
437.92 2 7 5.72 7 75.45 6.91 200 
 
3.9w (DS30B)  352.82 1 4 4.60 4 54.19 7.75 >200 
3.9x (DS58B)  353.80 1 5 4.44 5 60.18 - 80 
Amodiaquine   355.86 2 4 5.46 6 48.39 10.23 - 
MW = Molecular weight; HBD = hydrogen bond donor; HBA = hydrogen bond acceptor; cLogP = calculated log of partition coefficient; RB 
=rotatable bonds; PSA = polar surface area; Soly = Experimental solubility 
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Table 4.3: Physicochemical properties of benzylamino and alkylpyridyl benzoxazole analogues 
General structure Code -R MW HBD HBA cLogP RB 
PSA 
(Å2) 
Soly* 
(μM) 
 
3.9m (DS42B) 
 
435.31 2 4 7.40 5 62.98 40 
3.9n (DS54B) 
 
468.86 2 4 7.57 6 62.98 20 
3.9o (DS32B) 
 
401.85 2 5 5.19 5 75.87 80 
3.9p (DS35B) 
 
401.85 2 5 5.19 5 75.87 40 
3.9q (DS47B) 
 
401.85 2 5 5.19 5 75.87 80 
3.9r (DS49B) 
 
415.87 2 5 5.84 6 75.87 10 
MW = Molecular weight; HBD = hydrogen bond donor; HBA = hydrogen bond acceptor; cLogP = calculated log of partition coefficient; RB 
=rotatable bonds; PSA = polar surface area; Soly = Experimental solubility 
 
Table 4.4: Physicochemical properties of piperazinyl and dialkyl benzoxazole analogues 
General structure Code -NR2 MW HBD HBA cLogP RB 
PSA 
(Å2) 
pKa 
Soly* 
(μM) 
 
3.9s (DS39B) 
 
366.84 1 4 6.54 5 54.19 - 80 
3.9l (DS41B) 
 
408.88 2 6 5.74 4 69.46 5.64 200 
3.9t (DS51B) 
 
393.87 1 5 4.70 3 57.43 7.44 160 
3.9u (DS52B) 
 
455.94 1 5 6.82 4 57.43 3.00 40 
3.9v (DS53B) 
 
490.38 1 5 7.70 4 57.43 0.98 40 
MW = Molecular weight; HBD = hydrogen bond donor; HBA = hydrogen bond acceptor; cLogP = calculated og of partition coefficient; RB 
=rotatable bonds; PSA = polar surface area; Soly = Experimental solubility 
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4.3 ANTIPLASMODIAL ACTIVITY 
4.3.1 Introduction and rationale 
In the medicinal chemistry rescue of drugs with unfavorable toxicity profiles by analogue 
design, improvement of the safety profile must not adversely affect the pharmacological 
efficacy of the resulting molecules. For amodiaquine analogues, therefore, the objective 
was to retain antimalarial activity, not just against chloroquine sensitive strains, but also 
against multi-drug resistant strains.   The target compounds and selected intermediates 
were evaluated for activity against three Plasmodium falciparum strains: the drug 
sensitive NF54 strain and the drug resistant W2 and K1 strains. Testing was conducted 
at the University of California, San Francisco (W2) and the Swiss Tropical and Public 
Health Institute (NF54 and K1). Cytotoxicity assays were conducted against the L6 rat 
myoblasts (Swiss Tropical and Public Health Institute) and Chinese Hamster Ovarian 
(CHO) cells (University of Cape Town, Division of Pharmacology) to give an indication 
of the selectivity of the compounds for parasite cells. 
4.3.2  Antiplasmodial activity results 
4.3.2.1 Antiplasmodial activity of the initial library of benzoheterocyclic and 
pyridine analogues 
The library of representative compounds synthesized for reactive metabolite studies 
was screened for antiplasmodial activity against the W2 and K1 Plasmodium falciparum 
strains. The results are shown in Table 4.5. The analogues could be divided into two 
main classes: those with a simple alkyl side chain (3.2a, 3.9a and 3.6a) and those with 
dialkylamino or cycloalkylamino moieties attached to the heterocyclic ring. The simple 
alkyl side chain analogues exhibited moderate antiplasmodial activity in the low 
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micromolar (3.2a) and submicromolar (3.9a and 3.6a) ranges.  In general, these 
analogs did not retain activity against the two chloroquine resistant Plasmodium 
falciparum strains. However, benzimidazole analogue 3.6a (IC50 0.249 μM) was 
marginally more active than chloroquine against the K1 strain but was 31 times less 
active than amodiaquine against the same strain. Compounds with the dialkylamino and 
cycloalkylamino substituents displayed activity in the low nanomolar ranges except for 
the benzimidazole analogs which had activity in the low submicromolar to low 
micromolar range (0.189 μM-4.580 μM). The introduction of the tertiary amine was 
apparently responsible for a dramatic improvement in the potency of the benzothiazole 
and benzoxazole analogues but not the benzimidazole analogues. The benzoxazole 
analog 3.9b (IC50 8 nM) was the most potent analogue against the W2 strain, a 61-fold 
improvement over the activity observed for 3.9a. 
On the other hand, 3.2d (IC50 7 nM) was the most active compound against the K1 
strain, representing a 131-fold increase in activity relative to 3.2a. The two pyridyl 
analogues 3.4a and 3.4b exhibited modest activity against the W2 strain (IC50s 21 and 
41 nM, respectively). The morpholino pyridyl compound 3.4b was only marginally more 
active than chloroquine (IC50 49 nM) against the W2 strain. Interestingly, the morpholino 
benzothiazole analogue 3.2e showed similar activity with 3.4b against the W2 strain and 
was the least active tertiary amine containing benzothiazole analogue against both the 
W2 and K1 strains. 
A chloroquine-like resistance pattern was observed from the resistance index (RI) data 
(calculated as K1 IC50/W2 IC50 since the W2 strain used was more chloroquine sensitive 
compared to the K1 strain) among most compounds. However, for compounds with low 
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nanomolar activity, the benzothiazole analogues displayed the lowest RIs. The most 
active analogue, 3.2d, was almost twice as active against the more resistant K1 strain 
as it was against the W2 strain (RI 0.54).  
 
Table 4.5: Antiplasmodial activity of the initial library of benzoheterocyclic and pyridine 
analogues 
General structure Code R 
Antiplasmodial 
activity: IC50 (μM) 
Resistance 
index 
W2 K1 
 
3.2a (DS1F)  1.158 0.917 0.79 
3.2c (DS11B) 
 
0.012 0.014 1.17 
3.2d (DS12B) 
 
0.013 0.007 0.54 
3.2e (DS13B) 
 
0.040 0.025 0.63 
3.2f (DS18B) 
 
0.011 nt - 
 
3.6a (DS5G)  0.501 0.249 0.50 
3.6b (DS21B) 
 
4.580 0.09 0.02 
3.6c (DS22B) 
 
0.189 0.742 3.93 
3.6d (DS24B) 
 
0.200 0.827 4.14 
 
3.9a (DS4F)  0.491 0.921 1.88 
3.9b (DS23B) 
 
0.008 0.022 2.75 
 
3.4a (DS26B) 
 
0.021 0.092 4.38 
3.4b (DS27B) 
 
0.041 0.073 1.78 
Amodiaquine 0.005 0.008 1.60 
Chloroquine 0.049 0.344 7.02 
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4.3.2.2 Cytotoxicity and selectivity indexes of the initial library of 
benzoheterocyclic and pyridine analogues 
Results of the cytotoxic activity against the L6 rat myoblast cell line, expressed as IC50, 
are shown in Table 4.6. The selectivity index (SI) was calculated as the quotient of the 
cytotoxic IC50 divided by the antiplasmodial IC50.  
Table 4.6: Cytotoxicity and selectivity indexes of the initial library of benzoheterocyclic 
and pyridine analogues 
General structure Code R 
W2 IC50 
(μM) 
Cytotoxicity 
L6 IC50 (μM) 
SI 
 
3.2a DS1F  1.158 4.126 3.56 
3.2c DS11B 
 
0.012 5.118 426.50 
3.2d (DS12B) 
 
0.013 3.539 272.23 
3.2e (DS13B) 
 
0.040 4.67 116.75 
3.2f (DS18B) 
 
0.011 nt - 
 
3.6a (DS5G)  0.501 5.713 11.40 
3.6b (DS21B) 
 
4.580 5.25 1.15 
3.6c (DS22B) 
 
0.189 10.191 53.92 
3.6d (DS24B) 
 
0.200 15.284 76.42 
 
3.9a (DS4F)  0.491 16.352 33.30 
3.9b (DS23B) 
 
0.008 8.703 1087.88 
 
3.4a (DS26B) 
 
0.021 18.593 885.38 
3.4b (DS27B) 
 
0.041 47.412 1156.39 
Podophyllotoxin - 0.021  
Amodiaquine 0.005 - - 
Chloroquine 0.049 - - 
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An SI value of >1 is an indication that the compound is more cytotoxic to the parasite 
than the normal cells while a value of <1 implies that the compound will preferentially be 
lethal against the normal cells. In general, cytotoxicity was observed to decrease in the 
order pyridyl < benzoxazole < benzimidazole < benzothiazole. Pyridyl analogue 3.4b 
had the highest SI (1156.39) followed by benzoxazole analogue 3.9b (1087.88). 
The potent benzothiazole compounds had better selectivity indexes (116.75-426.50) 
than the benzimidazole compounds. This was a clear indication that the superior 
antiplasmodial potency of the benzothiazole analogues outweighed their cytotoxicity. In 
spite of the encouraging SI observed for pyridyl analogue 3.4b, this compound did not 
retain significant activity against the chloroquine resistant strains. Thus 3.9b was the 
compound with the best balance of potent activity and low cytotoxicity. 
 
As mentioned in Chapter 3, the benzoxazole analogues had the lowest bioactivation 
potential. The tertiary nitrogen containing compound 3.9b displayed potent activity 
against the drug resistant W2 and K1 Plasmodium falciparum strains. These findings 
formed the basis for an expanded SAR study of this benzoxazole series. The 
antiplasmodial data for the benzoxazole targets are shown in the following tables. 
 
4.3.2.3 Antiplasmodial activity of alkyl, amide, dialkylamino and 
cycloalkylamino analogues 
When tested against the NF54 strain, the most potent compounds (3.9b, 3.9c, 3.9e, 
3.9f, 3.9h and 3.9j) had IC50 values equal to or comparable to that of chloroquine (10 
nM) (Table 4.7). These potent compounds were all dialkylamino or cycloalkylamino 
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analogues with a protonatable tertiary nitrogen and could be classified as either ethyl 
(3.9b, 3.9c, 3.9d, 3.9e and 3.9f) or propyl (3.9h, 3.9i, 3.9j and 3.9k) linker analogues.  
Activity against the NF54 strain did not vary widely, ranging between 10 and 19 nM, 
except for the morpholino analogues. The ethylmorpholino analogue 3.9d was the least 
active compound against the NF54 strain within the protonatable tertiary nitrogen subset 
(IC50 0.108 μM), followed by the propylmorpholino analogue 3.9k (IC50 0.039 μM). 
 
Table 4.7: Antiplasmodial activity of alkyl, amide, dialkylamino and cycloalkylamino 
analogues 
General structure Code -R 
Activity , IC50 (μM) 
RI 
NF54 K1 
 
3.9a (DS4F)  0.466 1.003 2.15 
3.9b (DS23B) 
 
0.015 0.056 3.73 
3.9c (DS46B) 
 
0.010 0.024 2.40 
3.9d (DS31B) 
 
0.108 0.198 1.83 
3.9e (DS33B) 
 
0.011 0.042 3.82 
3.9f (DS50B) 
 
0.012 0.042 3.50 
3.9g (DS34B) 
 
1.876 0.773 0.41 
3.9h (DS36B) 
 
0.014 0.085 6.07 
3.9i (DS37B)  0.019 0.149 7.84 
3.9j (DS48B) 
 
0.010 0.039 3.90 
3.9k (DS56B) 
 
0.039 0.080 2.05 
Amodiaquine   0.004 0.010 2.50 
Chloroquine   0.010 0.275 27.50 
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Variations from which a tentative SAR could be derived were noticeable in K1 activity. 
Changing the dialkylamino group from diethyl to dimethyl did not have any effect on 
activity in ethyl linker analogues as both 3.9e and 3.9f had an IC50 of 42 nM. Changing 
to a propyl linker resulted in reduced activity. In addition, the diethyl analogue 3.9h (IC50 
85 nM) was more active than the dimethyl analogue 3.9i (IC50 149 nM). A similar trend 
was observed for the piperidine analogues where the ethylpiperidine compound 3.9c 
(24 nM) was more active than the propylpiperidine analogue 3.9j (39 nM). However, this 
trend was reversed among the morpholino analogues 3.9d and 3.9k mentioned earlier 
where the propyl linker analogue was more potent. Converting the tertiary amine to an 
amide, as in 3.9g, resulted in a drastic decline in activity against both strains, more so 
against the NF54 (IC50 1.876 μM) than the K1 (IC50 0.773 μM) strain. These results 
reinforced the importance of the protonatable nitrogen. Further exploratory studies 
involved the synthesis of analogues in which the side chain was attached to the 
benzoxazole group via a carbon instead of a nitrogen atom (Table 4.8). Although 
analogue 3.9w had a protonatable nitrogen, it showed remarkably reduced activity 
against both strains compared to the alkylamino or cycloalkylamino analogues. The 
reduction in activity could not simply be accounted for by the low predicted pKa (7.75) 
since the morpholino analogues with even lower pKas showed better activity. 
Attachment to the benzoxazole ring via a carbon atom was, therefore, considered to 
adversely affect antiplasmodial activity. Analogue 3.9x only exhibited micromolar 
activity, probably due to the lack of a protonatable nitrogen and the presence of a 
carbon linker.  
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Table 4.8: Antiplasmodial activity of carbon-linked analogues 
General structure Code R 
Activity, IC50 (μM) 
RI 
NF54 K1 
 
3.9w (DS30B)  0.213 0.411 1.93 
3.9x (DS58B)  1.094 2.111 1.93 
 
A chloroquine-like resistance pattern was generally observed among all the compounds. 
The exception was 3.9g which, unfortunately, was less active than chloroquine against 
both Plasmodium strains. Nonetheless, the RIs were much lower than the 27.50 
observed for chloroquine.  
4.3.2.4 Antiplasmodial activity of benzylamino and alkylpyridyl benzoxazole 
analogues 
When the alkylamino groups were replaced with substituted benzylamines (3.9m and 
3.9n) activity dropped to the low submicromolar range (Table 4.9). The benzylamine 
analogues were less active than chloroquine against the NF54 strain and virtually 
equipotent with the drug against the K1 strain. The methylpyridine analogues (3.9o, 
3.9p and 3.9q) had activity in the mid-submicromolar to low micromolar range with 
activity increasing in the order 4-methyl < 2-methyl < 3-methyl (Table 4.9). Increasing 
the length of the linker from a methyl to an ethyl (3.9r) did not affect activity when 
compared to the corresponding 2-methylpyridine analogue 3.9o. As with the rest of the 
analogues discussed above, these compounds were more active against the 
chloroquine sensitive strain as compared to the multi-drug resistant strain. 
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Table 4.9: Antiplasmodial activity of benzylamino and alkylpyridyl benzoxazole 
analogues 
General structure Code -R 
Activity , IC50 (μM) 
RI 
NF54 K1 
 
3.9m (DS42B) 
 
0.124 0.223 1.80 
3.9n (DS54B) 
 
0.107 0.282 2.64 
3.9o (DS32B) 
 
0.406 0.883 2.17 
3.9p (DS35B) 
 
0.309 0.704 2.28 
3.9q (DS47B) 
 
0.630 1.553 2.47 
3.9r (DS49B) 
 
0.402 0.851 2.12 
Amodiaquine   0.004 0.010 2.50 
Chloroquine   0.010 0.275 27.50 
 
4.3.2.5 Antiplasmoodial activity of piperazinyl and dialkyl benzoxazole 
analogues 
As shown in Table 4.10, the methylpiperazine analogue with the piperazine ring directly 
attached to the benzoxazole ring (3.9t) was more active than the corresponding 1-
amino-4-methylpiperazine analogue (3.9l)). Indeed 3.9t retained activity against the 
multi-drug resistant K1 strain. Attachment of aromatic groups to the piperazine linker 
(3.9u and 3.9v) resulted in further loss of activity against both the NF54 and K1 strains. 
The chloro substituted phenyl ring in 3.9v resulted in a two-fold improvement in activity 
against the K1 strain over analogue 3.9u with an unsubstituted phenyl ring. In all cases, 
the pattern of sensitivity observed with the other analogues was maintained. In terms of 
structure, analogue 3.9s was closely related to the diethylamino analogues 3.9e and 
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3.9h mentioned in Table 4.7 above and its reduced activity shows the importance of the 
alkyl linker in the antiplasmodial potency of these compounds. 
Table 4.10: Antiplasmoodial activity of piperazinyl and dialkyl benzoxazole analogues 
General structure Code -NR2 
Activity , IC50 
(μM) RI 
NF54 K1 
 
3.9s (DS39B) 
 
0.512 1.379 2.69 
3.9l (DS41B) 
 
0.144 0.240 1.67 
3.9t (DS51B) 
 
0.051 0.099 1.94 
3.9u (DS52B) 
 
0.274 0.875 3.19 
3.9v (DS53B) 
 
0.202 0.412 2.04 
Amodiaquine   0.004 0.010 2.50 
Chloroquine   0.010 0.275 27.50 
 
4.3.2.6 Antiplasmodial activity of selected intermediates 
A few nitrobenzoxazole intermediates were tested for activity against the NF54 and K1 
strains (Table 4.11). It was immediately clear that the quinoline coupled analogues had 
far superior activity compared to the intermediates. Whereas all the intermediates were 
considered inactive (IC50>20 μM), intermediate 2.9b with a protonatable tertiary nitrogen 
showed low micromolar activity against both plasmodial strains. The other tertiary 
nitrogen containing intermediate, 2.9i, displayed weak activity against the multi-drug 
resistant K1 strain but was inactive against the NF54 strain. These findings underscored 
the importance of the tertiary nitrogen in the activity of both the intermediates and the 
target molecules.  
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Table 4.11: Activity of selected benzoxazole intermediates 
Compound Structure 
Activity, IC50 (μM) 
NF54 K1 
2.9b (DS23) 
 
1.640 2.928 
2.9o (DS32) 
 
>20 >20 
2.9i (DS37) 
 
>20 10.992 
2.9s (DS39) 
 
>20 >20 
2.9r (DS49) 
 
>20 >20 
2.9t (DS51) 
 
>20 >20 
2.9u (DS52) 
 
>20 >20 
2.12b (DS62) 
 
>20 >20 
 
4.3.2.7 Cytotoxicity and selectivity indexes of benzoxazole analogues 
The benzoxazole analogues with potent antiplasmodial activity were also the 
compounds with the most potent cytotoxicity (Table 4.12). Except for 3.9d, all 
analogues with a protonatable tertiary nitrogen had cytotoxicity values less than 10 
μg/ml. The pyridyl analogues 3.9o, 3.9p, 3.9q and 3.9r were the subclass with the 
lowest cytotoxic activity. In this subclass 3.9p was the most cytotoxic (IC50 66.0 μg/ml) 
while the other three analogues had IC50 values >100 μg/ml. The piperazine linker 
analogues were generally only weakly cytotoxic except for analogue 3.9u (IC50 13.1 
μg/ml). It appears that the introduction of a chloro substituent as in 3.9v drastically 
decreases cytotoxic activity. Overall, analogue 3.9b had the highest cytotoxic activity at 
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2.0 μg/ml. However, all the active antiplasmodial compounds had high selectivity 
indexes ranging between 333 (3.9b) and 1175 (3.9e). These indexes were several 
magnitudes lower than that of amodiaquine in the CHO cell line but are not a cause for 
concern partly because there is still a sufficiently high enough in vitro safety window and 
partly because in vivo toxicity and in vitro cytoxicity on other mammalian cell lines are 
yet to be assessed. 
 
Table 4.12: Cytotoxicity against CHO cells and selectivity indexes 
General structure Compound -R or -NR2 
Activity, IC50 
(μg/ml) SI 
NF54 CHO 
 
3.9b (DS23B) 
 
0.006 2.0 333 
3.9c (DS46B) 
 
0.004 3.2 800 
3.9d (DS31B) 
 
0.046 52.6 1143 
3.9e (DS33B) 
 
0.004 4.7 1175 
3.9f (DS50B) 
 
0.004 2.9 725 
3.9g (DS34B) 
 
0.818 12.9 16 
3.9h (DS36B) 
 
0.006 2.7 450 
3.9i (DS37B)  0.008 5.0 625 
3.9j (DS48B) 
 
0.004 4.6 1150 
3.9k (DS56B) 
 
0.017 6.0 353 
3.9l (DS41B) 
 
0.059 50.0 847 
3.9m (DS42B) 
 
0.054 11.2 207 
3.9n (DS54B) 
 
0.050 8.8 176 
3.9o (DS32B) 
 
0.163 >100.0 - 
3.9p (DS35B) 
 
0.124 66.0 532 
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3.9q (DS47B) 
 
0.253 >100 - 
3.9r (DS49B) 
 
0.167 >100 - 
 
3.9s (DS39B) 
 
0.188 84.1 447 
3.9t (DS51B) 
 
0.020 >100 - 
3.9u (DS52B) 
 
0.125 13.1 105 
3.9v (DS53B) 
 
0.099 84.4 853 
Amodiaquine HCl   0.002 68.4 34,200 
Emetine   - 0.05  
 
4.3.2.8 Discussion of antiplasmodial activity data 
From the antiplasmodial data, a number of observations were made. The 4-
aminoquinoline ring was essential for activity. This pointed to a mode of action similar to 
that of other 4-aminoquinoline drugs, namely inhibition of heme detoxification by 
formation of the insoluble malaria pigment, hemozoin. Further support of this hypothesis 
was obtained from the observation that a tertiary nitrogen with a pKa greater than 8.00 
was a necessary feature for potent antiplasmodial activity. This tertiary nitrogen could 
be part of a cycloalkylamino ring or a dialkylamino moiety. Such a nitrogen could be 
protonated inside the parasite’s acidic food vacuole and result in increased 
accumulation of the compound. Among the most active compounds, there was no 
strong correlation between predicted pKa and antiplasmodial activity since compounds 
with a propyl linker had generally higher pKas but weaker antiplasmodial activity. This 
was a pointer to the involvement of other physicochemical and pharmacodynamic 
factors in the determination of antiplasmodial activity. However, in the overall picture, 
compounds without a protonatable tertiary nitrogen or those with a weakly basic tertiary 
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nitrogen, were found to have weak antiplasmodial activity. These observations informed 
the choice of β-hematin inhibition as the antiplasmodial mechanism to be studied. 
4.4 BETA HEMATIN FORMATION INHIBITION ACTIVITY 
4.4.1 Introduction 
Synthetic or in vitro generated hemozoin, referred to as β-hematin, is used to estimate 
the hemozoin formation inhibition potential of compounds, which can be correlated to 
their antiplasmodial activity  13,14. A number of in vitro assays using this approach have 
been described 15–17. Such assays can be carried out in tube or microplate format with 
the latter being amenable to high throughput screening. Following incubation of the test 
compound in a solution containing hemin, the amount of β-hematin formed or that of 
hematin (in monomeric or aggregate form) remaining is quantified to give a direct or 
inverse colorimetric, radiometric, fluorometric or HPLC readout of β-hematin formation. 
The differential solubility between β-hematin and hematin in alkaline bicarbonate 
solutions (the former is insoluble) has been utilized in some assays to wash off 
unreacted hematin after the reaction and quantify the amount of β-hematin formed 18. 
Alternatively, as in the assay described by Egan and Ncokazi, advantage is taken of the 
fact that free heme reacts with pyridine to form a pyridine–Fe(III)PPIX complex with a 
characteristic absorbance wavelength 15. Thus the amount of free heme remaining at 
the end of experiment can be quantified. The results from these assays are presented 
as lC50 values defined as the number of molar equivalents of the test compound relative 
to hematin required to inhibit its conversion to β-hematin by 50 %. 
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Table 4.13: β-hematin inhibition activity of benzoxazole analogues 
General structure Compound -R or -NR2 
Activity, IC50 (μM) 
NF54 BHIa 
 
3.9a (DS4F)  0.466 80.2 ± 2.90 
3.9b (DS23B) 
 
0.015 91.5 ± 1.69 
3.9c (DS46B) 
 
0.010 89 ± 0.48 
3.9d (DS31B) 
 
0.108 80.0 ± 2.36 
3.9e (DS33B) 
 
0.011 244.2 ± 7.26 
3.9f (DS50B) 
 
0.012 363.2 ± 17.6 
3.9g (DS34B) 
 
1.876 97.5 ± 3.43 
3.9h (DS36B) 
 
0.014 165.0 ± 9.10 
3.9i (DS37B)  0.019 173.7 ± 6.99 
3.9j (DS48B) 
 
0.010 105 ± 8.32 
3.9k (DS56B) 
 
0.039 80.1 ± 0.93 
3.9l (DS41B) 
 
0.144 73.3 ± 1.93 
3.9m (DS42B) 
 
0.124 27.1 ± 1.03 
3.9n (DS54B) 
 
0.107 22.4 ± 3.02 
3.9o (DS32B) 
 
0.406 106.3 ± 1.06 
3.9p (DS35B) 
 
0.309 100.1 ± 2.58 
3.9q (DS47B) 
 
0.630 93.0 ± 0.91 
3.9r (DS49B) 
 
0.402 63.0 ± 1.61 
 
3.9s (DS39B) 
 
0.512 50.7 ± 1.45 
3.9l (DS41B) 
 
0.051 71.7 ± 4.06 
3.9u (DS52B) 
 
0.274 29.6 ± 1.47 
3.9v (DS53B) 
 
0.202 24.7 ± 1.28 
Amodiaquine HCl   0.004 43.5 ± 5.32 
a
β-hematin inhibition 
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4.4.2 Results and discussion (β-hematin inhibition) 
The β-hematin inhibition activity was observed to group the compounds according to 
their chemical structures (Table 4.13). The cycloalkylamine compounds (3.9b, 3.9c, 
3.9d, 3.9j and 3.9k) had IC50 values lying between 80 and 105 μM. The dialkylamine 
analogues had higher IC50 values. Ethyldialkylamine analogues 3.9e and 3.9f (IC50s 
244.2 and 363.2 μM, respectively) had lower activity compared to the 
propyldialkylamine analogues 3.9h and 3.9i (IC50s 165.0 and 173.7 μM, respectively).  
Since these tertiary amine compounds did not show a wide variation in antiplasmodial 
activity, these results indicated a lack of correlation between β-hematin inhibition and 
antiplasmodial activities. It is worth mentioning that antiplasmodial activity against the 
chloroquine-sensitive NF54 strain was utilized in attempting to correlate observed β-
hematin inhibitory activity and antiplasmodial activity. This was done because in the 
resistant strain, the resistance mechanisms interfere with compound accumulation in 
the food vacuole. 
The morpholino analogues 3.9d and 3.9k were among the most potent inhibitors of β-
hematin formation (IC50 80 μM) in the tertiary amine group of compounds but had the 
lowest antiplasmodial activity (0.108 and 0.039 μM, respectively). The γ-lactam 
analogue 3.9g and the alkyl analogue 3.9a showed good β-hematin formation inhibition 
activity although they only had weak antiplasmodial activity. The methylpiperazine 
analogues 3.9l and 3.9t were marginally more potent inhibitors of β-hematin formation 
than the tertiary amine analogues. A large increase in β-hematin inhibition activity was 
seen with the introduction of an aromatic ring in the piperazine class with 3.9u and 3.9v 
being more potent inhibitors than amodiaquine. The benzylamine analogues 3.9m and 
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3.9n were equipotent with the arylpiperazine analogues, probably implying that the 
nature or length of linker was not as important a determinant of inhibition activity as was 
the presence of the aromatic ring. In the pyridine series, the methylpyridine analogues 
3.9o, 3.9p and 3.9q had activity about four-fold less than that observed among the 
benzylamines. The presence of the heteroatom, therefore appears to influence the 
efficiency of β-hematin inhibition. In this group, lengthening the linker by one carbon 
atom, as in 3.9r, resulted in improved β-hematin inhibition. As seen in the previous 
section, compounds with an extra aromatic or heteroaromatic ring had weak 
antiplasmodial activity. Thus the excellent β-hematin inhibition observed in this subset of 
compounds did not translate to excellent antiplasmodial activity. Finally, the non-
quinoline benzoxazole intermediates did not show any inhibitory activity even at the 
highest concentration of 1000 μM (data not tabulated). Thus it can be concluded, as 
expected, that the quinoline ring is essential for the β-hematin inhibition observed in this 
series of compounds. 
Overall, it is apparent that the presence of an aromatic ring, in addition to the quinoline, 
imparts greater β-hematin inhibitory activity. This may be attributed to increased π-π 
stacking. However, since analogues with an extra aromatic ring did not have a 
protonatable tertiary amine, they could not accumulate in the food vacuole in the 
parasite where these compounds are believed to act.  
Ferriprotoporphyrin IX can interact with drug molecules via two carboxyl groups 
(hydrogen bonding and electrostatic interactions) and a flat planar porphyrin ring 
(hydrophobic interactions). Potent amodiaquine analogues undergo a two-point 
attachment involving the H- bonding of the secondary amino group at one of the 
CHAPTER 4: PHYSICOCHEMICAL PROPERTIES AND BIOLOGICAL ACTIVITY 
159 
 
carboxyl groups in such a way that the quinoline group is π-stacked on top of the FP 
ring 19. This strong interaction may explain the high potency observed for the 
dialkylamino and cycloalkylamino analogues in this study. A high field NMR study 
showed that the aliphatic chain plays a key role in stabilizing heme-drug complexes with 
chains longer than three carbon chains forcing the end of the aliphatic chain outside the 
porphyrin rim and shorter chains reducing the stabilizing van der Waals contribution 20. 
This may partly explain our observation that ethyl linker cycloalkylamino analogues 
were more potent β-hematin inhibitors than their corresponding propyl linker analogues. 
The inverse trend was, however, observed among the dialkylamino compounds. This 
may be explained by effective van der Waals interactions. It appears that the cycloalkyl 
rings have greater ability to interact with the porphyrin ring compared to the dialkyl 
groups. The interaction of the rings may play a more important role than the aliphatic 
linker chains. However, in the case of the dialkyl analogues, the aliphatic linkers more 
effectively interact with the porphyrin ring via van der Waals forces compared to the 
terminal alkyl groups and thus the propyl linker analogues have improved binding 
affinities over the ethyl linker analogues. Analogously, it can be argued that the 
introduction of the piperazine linker improves β-hematin inhibitory activity by increasing 
the van der Waals interaction of the linker with the porphyrin ring. 
The observed lack of correlation between antiplasmodial and β-hematin inhibitory 
activity confirms one of the shortcomings of target-based drug discovery. Apart from 
having an effect on their target, in whole cell or organism assays, drugs need to 
traverse various biological spaces and membranes to access the target. A prerequisite 
for this is that drugs should possess appropriate physicochemical and pharmacokinetic 
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properties. In the case of drugs that inhibit β-hematin formation, drug accumulation in 
the acidic food vacuole is essential and is only possible for drugs with a tertiary nitrogen 
that is protonatable in the acidic pH in the food vacuole. The high β-hematin inhibitory 
activity of morpholino analogues is probably due to a favorable hydrogen bonding 
interaction with heme hydrogen atoms. However, the oxygen atom reduces the basicity 
of the morpholine nitrogen and results in reduced accumulation and antiplasmodial 
activity. Our findings are in agreement with those of other researchers who have 
reported reduced antiplasmodial activity for morpholine compared to other 
cycloalkylamine quinoline analogues 21,22. 
4.5 MICROSOMAL STABILITY STUDIES 
4.5.1 Introduction and rationale 
It was mentioned in Chapter 3 that metabolism is one of the most important 
determinants of the pharmacokinetic disposition of a xenobiotic 23. Pharmacokinetics is 
a term that encompasses the processes of absorption, distribution, metabolism and 
excretion (ADME) and is currently commonly studied in conjunction with toxicity, hence 
the acronym ADMET 24. Prior to the year 2,000, poor pharmacokinetics was the major 
cause of attrition in drug development programs 25. To address this issue, the 
pharmaceutical industry started including ADME/PK studies early in drug development, 
rather than simply utilizing it as a preclinical safety support function 26. This approach is 
currently the accepted norm in rational drug design 27,28. ADMET studies can be 
conducted using any combination of available in silico, in vitro and in vivo methods, 
depending on the volume and value of the test compounds 24,29. 
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Metabolic bioactivation has already been addressed in Chapter 3. In this section, the 
focus will be on metabolic stability. Extensive or extremely rapid metabolism of a 
compound to less active or inactive metabolites is a liability as it results in reduced 
efficacy 30. In vitro metabolic stability can be assessed using individual recombinant 
CYP enzymes, microsomes, hepatocytes or liver slices 31,32. Microsomes are the most 
widely employed system for metabolic stability studies 33. This can be attributed to, 
among other factors, ease of preservation, amenability to high throughput screening 
and the fact that the enzymatic activity remains stable even after  prolonged storage 34.  
4.5.2 Procedure for microsomal stability studies 
The general procedure for microsomal stability studies has been captured by Li 24. For 
most of the compounds, the assay was carried out in 96-well plates at two time points, 0 
and 30 minutes. The wells were preloaded with test and control compounds in 
phosphate buffer pH 7.4. Human liver and mouse liver microsomes were added to the 
appropriate wells. The reaction was initiated by the addition of NADPH and incubation 
was carried out at 37 °C for 30 minutes. The reaction was stopped using an ice-cold 
stop solution of Tris in acetonitrile. For the time 0 plate, the stop solution was added at 
the start of the experiment, followed by NADPH. After centrifugation and membrane 
filtration into a second 96-well plate, the amount of compound remaining in the mixture 
was quantified using LC/MS. Results were presented as percentage of compound 
remaining after incubation.  
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4.5.3 Results and discussion of microsomal stability studies 
Table 4.14: Percentage of compound remaining after 30 min incubation with 
microsomes 
General structure Code R 
% remaining 
HLM MLM 
 
3.2a (DS1F)  >99 2 
3.2c (DS11B) 
 
>99 85 
3.2d (DS12B) 
 
52 46 
3.2e (DS13B) 
 
55 90 
3.2f (DS18B) 
 
79 47 
 
3.6a (DS5G)  >99 35 
3.6b (DS21B) 
 
87 72 
3.6c (DS22B) 
 
93 84 
 
3.9a (DS4F)  81 1 
3.9b (DS23B) 
 
62 81 
3.9e (DS33B) 
 
78 74 
3.9f (DS50B)  >99 >99 
3.9c (DS46B) 
 
71 41 
3.9i (DS37B)  78 44 
3.9h (DS36B) 
 
70 70 
3.9j (DS48B) 
 
70 49 
3.9k (DS56B) 
 
27 26 
3.9t (DS51B)  61 18 
3.9v (DS53B) 
 
36 >99 
3.9n (DS54B) 
 
>99 71 
Amodiaquine 60 22 
HLM = Human liver microsomes; MLM = mouse liver microsomes 
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As can be seen from Table 4.14, alkyl analogues 3.2a (benzothiazole) and 3.9a 
(benzoxazole) were extremely unstable in MLMs but very stable in HLMs, probably as a 
result of species specific rapid dealkylation. However, the benzimidazole alkyl analogue 
3.6a was slightly more stable in MLMs. These analogues did not exhibit potent 
antiplasmodial activity and were not accorded further attention. The most stable 
compound was the dimethylamino analogue 3.9f. This analogue was virtually not 
metabolized in the presence of MLMs and HLMs after 30 minutes of incubation. This 
was a surprising finding since N-demethylation would have been expected to occur with 
ease. Propylmorpholino benzoxazole analogue 3.9k was the least metabolically stable 
analogue with <30% remaining after 30 minutes of incubation with both MLMs and 
HLMs. This was in stark contrast to the much more stable ethylmorpholino 
benzothiazole and benzimidazole analogues 3.2e and 3.6c. Ethyldialkylamino 
analogues 3.9e and 3.9f were also observed to be more metabolically stable than the 
corresponding propyldialkylamino analogues 3.9h and 3.9i, respectively. This may be 
construed to imply that the propyl linker is the source of metabolic liability. The 
methylpiperazine analogue 3.9t was moderately stable in HLMs but unstable in MLMs, 
with only 18 % of the compound remaining after 30 minutes, possibly as a result of rapid 
N-demethylation. Except for 3.2e, 3.9b and 3.9v, the analogues were generally more 
stable in HLMs than in MLMs. Overall, benzoxazole analogues with potent 
antiplasmodial activity (3.9b, 3.9c, 3.9e, 3.9f and 3.9j) exhibited metabolic stability 
equal to or greater than amodiaquine in HLMs. In MLM incubations, the analogues were 
at least twice as stable as amodiaquine except for 3.9c which had only 41 % of the 
parent compound remaining after 30 minutes. It was apparent that in MLMs, the 
CHAPTER 4: PHYSICOCHEMICAL PROPERTIES AND BIOLOGICAL ACTIVITY 
164 
 
metabolic stability of the cycloalkylamino compounds decreased in the order morpholine 
> pyrollidine > piperidine. 
 
4.6 IN VIVO EFFICACY STUDIES 
4.6.1 Introduction 
It is an established fact that in vitro potency does not necessarily translate to in vivo 
efficacy. This inconsistency may arise as a result of several whole organism factors 
coming into play. For this reason, compounds with desirable in vitro potency and 
ADMET characteristics usually undergo in vivo efficacy tests before advancing any 
further in the drug development process. 
Plasmodium falciparum only infects human beings and a small number of primates 35. 
Since widespread use of primates in malaria research is impractical, the use of avian 
and rodent plasmodial species that are non-pathogenic to humans as surrogates of P. 
falciparum offers a valuable alternative 36. The rodent malaria parasites P. berghei, P. 
vinckei, P. yoelii and P. chabaudii readily infect laboratory mice and are, consequently, 
extensively used in early drug discovery and development 37. The use of rodent models 
is not without its own challenges. First, the parasite species used is different from the 
human malaria parasite and as such may present with a dissimilar sensitivity to the 
antimalarial compound. Secondly, biological differences between the rodent and man 
may make interpretation of results obtained tentative at best. As an attempt to address 
the first challenge, P. falciparum infected humanized mouse models, usually 
immunodeficient mice engrafted with hematopoietic cells or tissues, or mice that 
transgenically express human genes, have been developed 38. Nonetheless, ready 
availability and ease of handling make the traditional rodent models an attractive choice 
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in early drug development studies. The most widely used initial in vivo test is the Peters’ 
four-day suppressive test in which the efficacy of four daily doses of compounds is 
measured by comparison of blood parasitemia (on day four after infection) and mouse 
survival time in treated and untreated mice 36. 
In this project three compounds, 3.9b, 3.9c and 3.9j were selected for in vivo efficacy 
studies based on their potent antiplasmodial activity, high selectivity indexes and 
improved metabolic stability over amodiaquine. Testing was carried out at the Swiss 
Tropical and Public Health Institute. Compounds were administered in four daily oral 
doses of 50 mg/kg. 
4.6.2 Results and discussion 
Table 4.15 shows the suppression of parasitemia by the three analogues tested as a 
percentage of the untreated control while Table 4.16 presents results on the effects of 
the analogues on mouse survival. A compound was considered curative if the animal 
survived to day 30 after infection with no detectable parasites. 
Table 4.15: In vivo suppression of parasitemia by 3.9b, 3.9c and 3.9j. 
 
 
 
General structure 
 
 
Compound 
 Parasitized RBC over 100 % of 
control 
% 
Activity R M1 M2 M3 M4 M5 Avg 
3.9b 
(DS23B)  
0.10 0.20 0.10 - - 0.13 0.17 99.83 
3.9c 
(DS46B)  
0.10 0.10 0.10 - - 0.10 0.13 99.87 
3.9j 
(DS48B)  0.10 0.10 0.20 - - 0.13 0.17 99.83 
Control  84.70 84.30 75.50 71.30 80.50 79.26   
CQ41         99.9 
M1, M2...=Mouse 1, Mouse 2…; CQ=Chloroquine (Data from reference 41, dosed at 4 x 30 mg/kg) 
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Table 4.16: Effect of 3.9b, 3.9c and 3.9j on mouse survival. 
 
 
 
General structure 
 
Compound 
 Mouse survival days (MSDs) 
Cured 
R M1 M2 M3 M4 M5 Avg 
3.9b 
(DS23B)  
30 30 30 - - 30 3/3 
3.9c 
(DS46B)  
30a 30 21b - - 27 1/3 
3.9j 
(DS48B)  
30 30 30a - - 30 2/3 
Control  4 4 4 4 4 4 0 
CQ41       24  
M1, M2...=Mouse 1, Mouse 2…; aMouse euthanized at end of 30 days due to presence of parasitemia; 
bMouse found dead; CQ=Chloroquine (Data from reference 41, dosed at 4 x 30 mg/kg) 
 
The results show that the three analogues tested suppressed parasitemia by >99% on 
the third day post-infection compared to the control. All the three mice treated with 3.9b 
survived the entire 30-day duration of the experiment. On their part, 3.9c and 3.9j cured 
1/3 and 2/3 of treated mice, respectively. One of the mice treated with 3.9b died on day 
21 while the rest of the mice in the experiment survived for the entire 30 days. However, 
at the end of 30 days, one mouse each from the groups treated with 3.9c and 3.9j 
showed parasitemia when a drop of blood was examined under the microscope. 
The potent oral in vivo efficacy of the three analogues was encouraging both from the 
antimalarial and pharmacokinetic perspectives. It was an indication of good oral 
bioavailability possibly due to lack of the first pass effect whereby compounds are 
rapidly converted to less active metabolites after oral administration 39. It could also 
imply a reasonably low volume of distribution affording sufficient free unbound drug 
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concentration in circulating blood to achieve parasitemia reduction in parasitized RBCs. 
The reduced efficacy of 3.9c and 3.9j as characterized by reduced MSDs (3.9c) and 
proportion of cured mice (3.9j) suggests parasite recrudescence. This may result from 
high clearance leading to short elimination half-lives for these two analogues. This 
finding may be supported by the observation that these two compounds had lower 
metabolic stability compared to 3.9b. The ideal profile for new antimalarials comprises 
orally active compounds that can cure the disease with a 3-day regimen using once-a-
day dosing 40. These analogues, especially 3.9b, have demonstrated the potential to 
meet these requirements. Detailed in vivo pharmacokinetic studies are ongoing to 
provide more information on the fate of these compounds. In addition, these analogues 
have been earmarked for single and lower multiple dose studies in the in vivo murine 
model. These studies will also include compounds from the dialkylamino class which 
had good microsomal stability. 
4.7 CONCLUSION 
The four series of analogues synthesized and developed in this study generally 
possessed drug-like properties suitable for oral absorption. In all the series, potent 
antiplasmodial activity was observed in 4-aminoquinoline compounds with dialkylamino 
and cycloalkylamino moieties whose tertiary nitrogen could be protonated at neutral or 
acidic pH. Among the benzoxazole analogues, there was generally a weak correlation 
between β-hematin activity and antiplasmodial potency against the chloroquine-
sensitive NF54 strain even though most of the potent antiplasmodial compounds were 
also potent β-hematin formation inhibitors. The lack of correlation was especially evident 
among the dialkylamino analogues which showed potent antiplasmodial activity and 
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weak β-hematin activity. Compounds with potent antiplasmodial activity were also found 
to possess high cytotoxic activity against CHO cells. However, these compounds had 
high selectivity indexes. With regard to in vitro metabolic stability, moderate to excellent 
stability was observed in compounds with potent antiplasmodial activity. These data 
informed the selection of three analogues for in vivo efficacy studies in P. berghei 
infected mice. The three analogues proved to be very potent in suppressing parasitemia 
(>99%) and resulted in oral cures in treated mice. 
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Chapter 5 
SUMMARY, CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK 
5.1 SUMMARY AND CONCLUSIONS 
This project aimed to discover analogues of the 4-aminoquinoline drug amodiaquine 
with potentially improved safety and efficacy profiles using the present and available 
knowledge of the drug metabolism and pharmacokinetics (DMPK), toxicity and efficacy 
profile of the drug. 
The first objective was to design and synthesize analogues of amodiaquine which 
potentially prevent bioactivation to the quinone imine and aldehyde metabolites which 
could be associated with hepatotoxicity and agranulocytosis. The molecules designed 
would retain most of the features of amodiaquine necessary for retention of activity 
against chloroquine resistant Plasmodium falciparum strains. A representative set of 
compounds in four different series was synthesized in which the 4-aminoquinoline ring 
was coupled with benzothiazole, benzimidazole, benzoxazole and pyridyl rings bearing 
different aliphatic amines and diamines. The chemistry mainly involved aromatic 
nucleophilic substitution reactions and reductive hydrogenation of nitro aromatic 
compounds which could be carried out with relative facility and using affordable starting 
materials. 
The second objective was to use EC-ESI/MS and CYP inhibition studies to assess the 
bioactivation potential of the amodiaquine analogues synthesized. Potent non-time-
dependent CYP3A4 inhibition was observed amongst all analogues tested. The 
benzothiazole analogues were the most potent inhibitors. Additionally, most of the 
analogues were moderate inhibitors of CYP2D6, though to a lesser extent than 
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amodiaquine and desethylamodiaquine. In EC-ESI/MS trapping experiments using 
potassium cyanide and methoxylamine, all analogues with a protonatable tertiary 
nitrogen formed reactive metabolites that were subsequently trapped. This finding was 
expected as it occurs for tertiary amine containing compounds. In the glutathione 
trapping experiments, the benzoxazole analogues did not form reactive metabolites that 
could be trapped. The benzothiazole analogues showed the highest potential for 
bioactivation as evidenced by high glutathione trapping ratios when compared to 
clozapine, the positive control. The benzimidazole and pyridyl analogues showed 
successively lower potentials for bioactivation. From these results, it was concluded that 
the benzoxazole series had the lowest bioactivation risk.  
The third objective was to carry out antiplasmodial assays on the synthesized 
analogues. For the representative set of compounds, this was done in parallel with the 
bioactivation studies. The results showed that benzothiazole and benzoxazole 
analogues with protonatable tertiary nitrogens had potent antiplasmodial acitivity against 
two chloroquine resistant P. falciparum strains. Weaker but noteworthy activity was also 
observed in the benzimidazole and pyridyl series. Based on the antiplasmodial data and 
results from the bioactivation studies, the benzothiazole series was selected for 
expanded SAR studies. 
The second synthetic campaign involved the synthesis of 4-amino-7-chloroquinoline-
coupled benzoxazole analogues bearing diverse amino groups on the benzoxazole ring. 
These included simple alkyl, cycloalkylamino, dialkylamino, aminobenzyl, aminopyridyl, 
alkylpiperazine and arylpiperazine groups. 
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Antiplasmodial assays on the expanded benzoxazole series confirmed that the tertiary 
protonatable nitrogen was essential for potent antiplasmodial activity, as was the 4-
amino-7-chloroquinoline ring. Ethyldialkylamino and ethylcycloalkylamino analogues 
were generally more potent than their corresponding propyl linker analogues. 
Mechanistic evaluation was conducted using the β-hematin formation inhibition assay, 
premised on the fact that these compounds would act similarly to amodiauine. There 
was generally a weak correlation between β-hematin activity and antiplasmodial 
potency even though most of the potent antiplasmodial compounds were also potent β-
hematin formation inhibitors. Dialkylamino analogues with potent antiplasmodial activity 
exhibited weak β-hematin formation inhibition activity. 
In vitro metabolic stability studies revealed moderate to excellent stability in compounds 
with potent antiplasmodial activity. This informed the selection of analogues 3.9b, 3.9c 
and 3.9j for in vivo evaluation. 
As a final objective, in vivo efficacy studies were conducted on analogues 3.9b, 3.9c 
and 3.9j in P. berghei infected mice at four daily oral doses of 50 mg/kg. All the three 
compounds efficiently suppressed parasitemia by >99% relative to the control. 
Analogue 3.9b cured all three treated mice while analogues 3.9c and 3.9j cured 1/3 and 
2/3 of treated mice, respectively. Mice treated with 3.9b and 3.9j survived the entire 
thirty day duration of the experiment while one of the three mice treated with 3.9c died 
on day 21 resulting in an average of 27 mouse survival days for this compound. 
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5.2 RECOMMENDATIONS FOR FUTURE WORK 
The potent in vitro antiplasmodial and in vivo antimalarial activity of benzoxazole 
amodiaquine analogues demonstrated in this project necessitates further more detailed 
toxicity studies on these compounds. In particular, the use of MS methods and actual 
drug substrates for CYP3A4 inhibition studies will provide useful information to guide 
any further development of this class of compounds. At the same time, in vivo 
pharmacokinetic studies will be provide valuable insights into the performance of these 
compounds in animal models. 
Further structural modifications to incorporate secondary instead of tertiary amines are 
needed. Other modifications will include the lengthening of the carbon linker in analogue 
3.9w as this may result in improved activity due to an increase in the pKa of the tertiary 
nitrogen. The effect of replacing the 7-chloro group on the quinoline ring with various 
groups also needs to be investigated. 
Finally, only cycloalkylamino compounds were selected for in vivo efficacy studies in 
this project. However, the dialkylamino analogues 3.9e and 3.9f also showed high 
potency and, especially in the case of 3.9f which would have been expected to be 
demethylated with ease, surprisingly excellent metabolic stability. These analogues 
would be interesting candidates for future in vivo efficacy studies. 
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Chapter 6 
EXPERIMENTAL 
6.1 REAGENTS AND SOLVENTS 
2-((dimethylamino)methyl)benzoxazol-5-amine and 2-(2-methoxyethyl)benzoxazol-5-
amine were sourced from Ukrorgsyntez Ltd, Riga, Latvia.. The rest of the commercially 
available chemicals and reagents were purchased from Sigma Aldrich and were of 
analytical grade quality. Acetonitrile, tetrahydrofuran and DMF were purchased from 
Sigma-Aldrich. South Africa. Methanol, ethanol, ethyl acetate, dichloromethane and 
hexane were obtained from Kimix Chemicals or Protea Chemicals, South Africa. Bulk 
solvents were purchased either as Chemically Pure (CP) grade solvents and distilled 
prior to use or as Analytical Reagent (AR) grade solvents and used as such. 
 
6.2 CHROMATOGRAPHY 
Reactions were monitored by thin layer chromatography (TLC) using Fluka or Merck 
F254 aluminium-backed pre-coated silica gel plates and were visualized under ultraviolet 
light at 254 nm. Silica gel column chromatography was performed using Merck kieselgel 
60: 70-230 mesh by gravity column chromatography or flash column chromatography 
on a Biotage Isolera™ system (Biotage AB, Uppsala, Sweden). HPLC purity checks 
were performed as per the methods listed in Table 6.1. 
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Table 6.1: HPLC conditions 
Method 
Time 
(min) 
%  A % B 
Composition Reversed phase column 
parameters A B 
A 
0.0-14.5 75 25 10 mM 
NH4OAc in 
HPLC grade 
H2O 
10 mM 
NH4OAc in 90 
% HPLC grade 
CH3OH in H2O 
Kinetex™ 2.6 µ C18 100Å 
LC column, 150 x 2.1 mm 
(Phenomenex, Torrance, 
CA, USA) 
14.5-19.5 0 100 
19.5-20.0 0 100 
20.0-25.0 75 25 
B 
0.0-7.0 100 0 
5% CH3CN in 
H2O 
5% H2O in 
CH3CN 
Luna® 3μm C18 100Å LC 
column, 150 x 4.6 mm 
(Phenomenex, Torrance, 
CA, USA) 
7.0-10.0 0 100 
10.0-12.0 0 100 
12.0-15.0 100 0 
C 
0.0-0.5 90 10 10 mM 
NH4OAc in 
HPLC grade 
H2O 
10 mM 
NH4OAc in 90 
% HPLC grade 
CH3OH in H2O 
Zorbax SB-C18 2.7 μm, LC 
column, 50 x2.1 mm, 
(Agilent Technologies, 
Santa Clara, CA, USA) 
0.5-2.5 90 10 
2.5-6.0 10 90 
6.0-8.0 90 10 
D 
0.0-4.0 20 80 
01 % NH4OH in 
HPLC grade 
H2O 
0.1 % NH4OH 
in HPLC grade 
CH3OH 
Luna® 3μm C18 100Å LC 
column, 150 x 4.6 mm 
(Phenomenex, Torrance, 
CA, USA) 
4.0-7.0 5 95 
7.0-14.0 100 0 
14.0-15.0 20 80 
 
6.3 PHYSICAL AND SPECTROSCOPIC CHARACTERIZATION 
Melting points were determined using a Reichert-Jung Thermovar hot stage microscope 
and are uncorrected. 1H NMR spectra were recorded on a Varian Mercury (300MHz), a 
Varian Unity (400 MHz) or a Bruker Ultrashield-Plus (400MHz) spectrometer. NMR 
samples were dissolved in deuterated chloroform (CDCl3), dimethylsulfoxide (DMSO-
d6) or methanol (CD3OD) with tetramethylsilane as the internal standard. 13C NMR 
spectra were recorded on the same instruments at 75 or 100 MHz. Chemical shifts (δ) 
are reported in parts per million (ppm) to 2 decimal places downfield from the internal 
standard tetramethylsilane (TMS). Coupling constants (J) are reported in Hertz (Hz) to 
one decimal place. Abbreviations used in assigning lH-NMR signals are: d (doublet), dd 
(doublet of doublets), ddd (doublet of doublet of doublets), m (multiplet), q (quartet), s 
(singlet), t (triplet) or td (triplet of doublets). High resolution mass spectrometry (ESI) 
was performed using a Waters API Q-TOF Ultima instrument at Stellenbosch University, 
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Cape Town, while low resolution mass spectrometry (LRMS) (EI+) was performed on a 
JEOL GC Mate III instrument at the University of Cape Town.  
 
6.4 SYNTHESIS 
2-Bromo-5-nitrobenzothiazole, 2.2 
CuBr (64.5 mg, 0.45 mmol, 1 eq) and 2-amino-6-nitrobenzothiazole (701.5 mg, 3.60 
mmol, 8 eq) were added to a solution of 3 ml of 48% HBr in 12 ml of water. The 
suspension was stirred at room temperature for 10 minutes. Sodium nitrate (2140.0 mg, 
31.00 mmol, 69 eq) was slowly added in small portions into the suspension, allowing for 
the evolution of nitrogen gas to stop before each addition, and the reaction mixture was 
stirred for a further 4 h. The mixture was filtered under suction and washed with water 
until the filtrate appeared colorless. The product was dried for 48 hour and used without 
further purification. 
As a brown solid (0.773 g, 83 %); m.p. 189-190 °C; Rf (EtOAc: 
Hexane, 7:3) 0.5; δH (300 MHz, DMSO-d6) 9.14 (1H, s, H1), 8.33 
(1H, d, J = 8.4 Hz, H2), 8.17 (1H, d, J = 8.4 Hz, H3). 
 
2-Bromo-5-nitropyridine, 2.4 (DS25) 
CuBr (362.2 mg, 2.52 mmol, 1 eq) and 2-amino-5-nitropyridine (2810.11 mg, 20.20 
mmol, 8 eq) were added to a solution of 18 ml of 48% HBr in 32 ml of water. The 
suspension was stirred at room temperature for 10 minutes. Sodium nitrate (12020.0 
mg, 174.21 mmol, 69 eq) was slowly added in small portions into the suspension, 
allowing for the evolution of nitrogen gas to stop before each addition, and the reaction 
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mixture was stirred for a further 4 h. The reaction mixture was filtered, washed with 
water, dried and purified using silica gel column chromatography (EtOAC: Hexane 2:3 
to 3:2). 
As an off-white powder (1,230 mg, 30 %); m.p. 132-134 °C; Rf (EtOAc: 
Hexane, 3:2) 0.4; δH (300 MHz, CDCl3) 9.20 (1H, d, J = 2. 8 Hz, H1), 
8.32 (1H, dd, J = 8.7, 2.8 Hz, H2), 7.71 (1H, d, J = 8.7 Hz, H3). 
 
General procedure for the synthesis of benzoxazole-2-thiol compounds 
Potassium ethyl xanthate (1872.4 mg, 11.7 mmol, 2 eq) was added to a solution of 2-
amino-4-nitrophenol or 2-amino-4-chloronitrophenol (5.8 mmol, 1 eq) in 25 ml of 
absolute ethanol. The reaction was heated at reflux for 4 h. The reaction mixture was 
then cooled to room temperature and concentrated to dryness under vacuum. The 
residue was dissolved in water and acidified to pH 5 using acetic acid. The resulting 
precipitate was filtered, washed with water and dried for 48 h to give the products which 
were used without further purification. 
5-Nitrobenzoxazole-2-thiol, 2.8 
As a yellow powder (1,091 mg, 95 %); m.p. 239-240 °C; Rf 
(EtOAc: Hexane, 2:3) 0.63; δH (300 MHz, DMSO-d6) 8.16 (1H, 
dd, J = 8.9, 2.4 Hz, H2), 7.92 (1H, d, J = 2.4 Hz, H1), 7.69 (1H, d, J = 8.9 Hz, H3). 
 
5-Chlorobenzoxazole-2-thiol, 2.11 (DS59) 
As a pale pink powder (970 mg, 89 %); m.p. 247-250 °C; Rf 
(EtOAc: Hexane, 2:3) 0.63; δH (400 MHz, DMSO-d6) 8.16 (1H, d, J 
= 9.0 Hz, H3), 7.30 (1H, dd, J = 9.0, 2.4 Hz, H2), 7.29 (1H, s, H1). 
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General procedure for synthesis of 2-(methylthio)-benzoxazole analogues 
Iodomethane (1.2 eq) and anhydrous potassium carbonate (1 eq) were added to a 
solution of 5-nitrobenzoxazole-2-thiol or 5-chlorobenzoxazole-2-thiol (1 eq) in 
acetonitrile (15 ml). The reaction mixture was stirred at room temperature for 4h. The 
reaction was quenched with a drop of water and the solvent removed under vacuum. 
The residue was suspended in water and extracted three times with ethyl acetate. The 
combined organic fractions were washed with brine (1x10ml) and dried over MgSO4. 
Solvent evaporation under vacuum yielded the products which were used without 
further purification. 
2-(Methylthio)-5-nitrobenzoxazole, 2.9 
As a pale pink powder (483 mg, 90 %); m.p. 147-148 °C; Rf 
(EtOAc: Hexane, 2:3) 0.83; δH  (400 MHz, CDCl3) 8.49 (1H. d, J = 
2.5 Hz, H1), 8.24 (1H, dd, J = 8.9, 2.3 Hz, H2), 7.54 (1H, d, J = 8.9 
Hz, H3), 2.82 (3H, s, H4). 
 
5-Chloro-2-(methylthio)benzoxazole, 2.12 (DS60) 
As a yellowish pink solid (2,920 mg, 91 %); m.p. 89-90 °C; Rf 
(Hexane: EtOAc, 3:7) 0.70; δH (CDCl3, 400 MHz) 7.60 (1H, d, J = 
2.1 Hz, H1), 7.24 (1H, dd, J = 8.6, 2.1 Hz, H2), 7.37 (1H, d, J = 8.6 Hz, H3), 2.79 (3H, s, 
H4) 
 
2-Bromo-5-nitro-1H-benzimidazole, 2.6  
2-mercapto-5-nitrobenzimidazole (546.6 mg, 2.8 mmol, 1 eq)) was added to a cooled 
solution of acetic acid (4 ml) and 48% aqueous HBr (0.42 ml, 3.7 mmol, 1.3 eq). 
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Bromine (0.52 ml, 10.1 mmol, 3.6 eq) was slowly added dropwise to this slurry. The 
reaction mixture solidified after addition of a few drops and was manually agitated to 
break up the solids. When all the bromine was added, acetic acid (8 ml) was added and 
the mixture was stirred at room temperature. After 4.5 h, the mixture was diluted with 
water and cooled to 0 °C. The pH of the mixture was adjusted to pH 4 using solid 
NaOH. The solid that precipitated out of solution was filtered under suction, washed with 
water, dried for 48 h and used without further purification. 
As a grey powder (0.543 g, 80 %); m.p. 229-230 °C; Rf (EtOAc: 
Hexane, 3:2) 0.6; δH (400 MHz, DMSO) 8.32 (1H, d, J = 2.3 Hz, 
H1), 8.03 (1H, dd, J = 8.9, 2.3 Hz, H2), 7.60 (1H, d, J = 8.9 Hz, 
H3). 
 
General procedure for the synthesis of alkylamine substituted 
nitrobenzothiazoles 
2-bromo-5-nitrobenzothiazole (1 eq) was dissolved in THF with warming. Ethylamine 
solution (70 % in water) or tert-butylamine (3 eq) and anhydrous potassium carbonate 
(1.5 eq) were added to the solution and the reaction mixture was stirred at 40-50 °C for 
15 hours. The solvent was removed under vacuum. The residue was suspended in 
water, extracted with EtOAC (3 x 20 ml) and washed with brine (1 x 20 ml). The 
combined organic extracts were dried over anhydrous MgSO4 and purified by silica gel 
column chromatography eluting with EtOAC: Hexane (10% to 70%).  
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N-Tert-butyl-5-nitrobenzothiazol-2-amine, 2.2a (DS1B) 
As a yellow solid (254 mg, 78 %); m.p. 64-65 °C; Rf (EtOAc: 
Hexane, 1:7) 0.40; δH (400 MHz, CDCl3) 8.43 (1H, s, H1), 8.12 
(1H, d, J = 8.2 Hz, H2), 7.46 (1H, d, J = 8.2 Hz, H3) 1.50 (9H, 
s, H4); δC (101 MHz, CDCl3)  168.22, 157.93, 142.04, 131.01, 122.27, 118.25, 116.93, 
54.41, 28.92; LRMS (EI) m/z, 251.05 (M+ C11H13N3O2S requires 251.07). 
N-Ethyl-5-nitrobenzothiazol-2-amine, 2.2b (DS1C) 
As a yellow powder (224 mg, 93 %); m.p. 208-209 °C; Rf 
(EtOAc: Hexane, 7:3) 0.60; δH (300 MHz, DMSO-d6) 8.65 (1H, 
d, J = 2.5 Hz, H1), 8.09 (1H, dd, J = 8.9, 2.5 Hz, H2), 7.45 (1H, 
d, J = 8.9 Hz, H3), 3.44 (2H, q, J = 7.2 Hz, H4), 1.23 (3H, t, J = 7.2 Hz, H5); δC (101 
MHz, CDCl3)  170.87, 157.84, 142.25, 133.68, 122.39, 118.15, 117.23, 40.56, 14.63;  
 
N-Ethyl-5-nitrobenzoxazol-2-amine, 2.9a (DS4C) 
Ethylamine solution (70 % in water) (3 eq) was added to a solution of 2-(methylthio)-5-
nitrobenzoxazole (1 eq) in 20 ml of DMF. The reaction mixture was heated at 80 °C for 
15 hours after which the solvent was removed under vacuum. The residue was purified 
by silica gel column chromatography eluting with 50 % EtOAC:Hexane. 
As a yellow powder (191 mg, 87 %); m.p. 130-131 °C; Rf 
(EtOAc: Hexane, 3:2) 0.30; δH (300 MHz, CDCl3) 8.17 (1H, d, J 
= 2.3 Hz, H1), 8.00 (1H, dd, J = 8.8, 2.3 Hz, H2), 7.29 (1H, d, J = 8.8 Hz, H3), 3.57 (2H, 
q, J = 7.2 Hz, H4), 1.35 (3H, t, J = 7.2 Hz, H5); δC (101 MHz, CDCl3) 163.66, 152.52, 
145.20, 144.08, 117.36, 111.85, 108.33, 38.22, 15.01; LRMS (EI) m/z, 207.05 (M+ 
C9H9N3O3requires 207.06). 
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General procedure for amination reactions 
A mixture of 2-bromo-5-nitrobenzothiazole, 2-bromo-5-nitro-1H-benzimidazole, 2-
bromo-5-nitropyridine, 2-(methylthio)-5-nitrobenzoxazole, 5-chloro-2-(methylthio)-
benzoxazole,  (1 eq) and the appropriate amine (3 eq) in acetonitrile was heated in a 
microwave reactor at 120 °C for 20-30 min. The solvent was removed under vacuum 
and the residue dissolved in EtOAc, washed with water (2x10 ml), a solution of 
saturated NaHCO3 (only employed when bromo-substituted reactants were used to 
neutralize HBr), brine (10 ml) and dried over MgSO4. The solvent was removed under 
vacuum to obtain the products in crude mixture. Column chromatography using a 
MeOH: EtOAc (0-20%) (for tertiary amine products) or a hexane: EtOAc gradient 
afforded the pure products. 
 
5-Nitro-N-(2-(pyrrolidin-1-yl)ethyl)benzothiazol-2-amine, 2.2c (DS11) 
As a yellow powder (230 mg, 87 %), m.p. 133-135 °C; Rf 
(MeOH: DCM: NH4OH, 10:88:2) 0.50; δH (400 MHz, 
CDCl3) 8.48 (1H, d, J = 2.4 Hz, H1), 8.18 (1H, dd, J = 8.9, 
2.34 Hz, H2), 7.50 (1H, d, J = 8.9 Hz, H3), 6.57, 3.57 (2H, 
t, J = 5.9 Hz, H4), 2.80 (2H, t, J = 5.9 Hz, H5), 2.59 (4H, m,  H6), 1.81 (4H, m, H7); δC 
(101 MHz, CDCl3) 170.75, 164.01, 157.99, 122.45, 117.95, 117.24, 53.81, 53.69, 43.51 
(x2), 23.56 (x2); LRMS (EI) m/z, 292.09 (M+ C13H16N4O2S requires 292.10). 
 
5-Nitro-N-(2-(piperidin-1-yl)ethyl)benzothiazol-2-amine, 2.2d (DS12) 
As a yellow powder (258 mg, 90 %), m.p. 130-131 °C; Rf (MeOH: DCM: NH4OH, 
10:88:2) 0.50; δH (400 MHz, CD3OD) 8.49 (1H, d, J = 2.4 Hz, H1), 8.11 (1H, dd, J = 8.9 
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Hz, 2.4 Hz, H2), 7.42 (1H, d, J = 8.9 Hz, H3), 3.62 (2H, t, 
J = 6.7 Hz, H4), 2.66 (2H, t, J = 6.7 Hz, H5), 2.53 (4H, 
m,  H6), 1.61 (4H, m, H7), 1.46 (2H, m, H8); δC (101 
MHz, CD3OD) 171.36, 157.61, 141.78, 130.83, 121.77, 
116.93, 116.90, 57.06, 54.13, 41.31 (x2), 25.10 (x2), 23.63; LRMS (EI) m/z, 306.12 (M+ 
C14H18N4O2S requires 306.12). 
 
N-(2-Morpholinoethyl)-5-nitrobenzothiazol-2-amine, 2.2e (DS13) 
As a yellow powder (228 mg, 81 %), m.p. 128-130 °C; Rf 
(MeOH: DCM: NH4OH, 10:88:2) 0.60; δH (400 MHz, 
CD3OD) 8.34 (1H, d, J = 2.4 Hz, H1), 8.00 (1H, dd, J = 
8.9, 2.4 Hz, H2), 7.30 (1H, d, J = 8.9 Hz, H3), 3.65 (4H, 
m, H7), 3.55 (2H, t, J = 6.5 Hz, H4), 2.60 (2H, t, J = 6.5 Hz, H5), 2.48 (4H, m,  H6); δC 
(101 MHz, CD3OD) 171.20, 157.48, 141.60, 130.68, 121.64, 116.753, 110.89, 66.28 
(x2), 56.67, 53.18 (x2), 41.07; LRMS (EI) m/z, 308.10 (M+ C13H16N4O3S requires 
308.09). 
 
N1,N1-Diethyl-N2-(5-nitrobenzothiazol-2-yl)ethane-1,2-diamine, 2.2f (DS18) 
As a yellow powder (218 mg, 76 %), m.p. 94-96 °C; Rf 
(MeOH: DCM: NH4OH, 10:88:2) 0.40; δH (400 MHz, 
CDCl3) 8.42 (1H, d, J = 2. 4 Hz, H1), 8.07 (1H, dd, J = 
8.9, 2.4 Hz, H2), 7.37 (1H, d, J = 8.9 Hz, H3), 3.57 (2H, 
t, J = 6.9 Hz, H4), 2.78 (2H, t, J = 6.9 Hz, H5), 2.65 (4H, q, J = 7.2 Hz, H6), 1.07 (6H, t, 
J = 7.2 Hz, H7). δC (101 MHz, CD3OD) 171.19, 157.50, 141.56, 130.68, 121.62, 116.79, 
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116.72, 50.86, 46.70, 41.74 (x2), 10.12 (x2); LRMS (EI) m/z, 294.13 (M+ C13H18N4O2S 
requires 294.12). 
 
N-Ethyl-5-nitro-1H-benzimidazol-2-amine, 2.6a (DS5C) 
As a yellow powder (188 mg, 92 %); m.p. 204-205 °C; Rf 
(EtOAc: Hexane, 3:2 ) 0.24; δH  (300 MHz, DMSO-d6) 7.94 (1H, 
d, J = 2.6 Hz, H1), 7.86 (1H, dd, J = 8.7, 2.6 Hz, H2), 7.20 (1H, 
d, J = 8.7 Hz, H3), 2.83 (2H, q, J = 7.6 Hz, H4), 1.19 (3H, t, J = 7.6 Hz, H5); LRMS (EI) 
m/z, 206.06 (M+ C9H10N4O2 requires 206.08). 
 
5-Nitro-N-(2-(piperidin-1-yl)ethyl)-1H-benzimidazol-2-amine, 2.6b (DS21) 
As a yellow powder (202 mg, 86 %), m.p. 155-158 °C; Rf 
(MeOH: DCM: NH4OH, 10:86:4) 0.50; δH (400 MHz, 
CDCl3) 8.01 (1H, d, J = 2.2 Hz, H1), 7.93 (1H, dd, J = 
8.7, 2.2 Hz, H2), 7.16 (1H, d, J = 8.7 Hz, H3), 3.59 (2H, 
t, J = 5.0 Hz, H4), 2.87 (2H, t, J = 5.0 Hz, H5), 2.79 (4H, m,  H6), 1.77 (4H, m, H7), 1.59 
(2H, m, H8); δC (101 MHz, CDCl3) 159.84, 145.32, 141.38, 136.69, 117.60, 111.76, 
107.34, 59.62, 54.39, 39.90 (x2), 25.18 (x2), 23.21; LRMS (EI) m/z, 289.17 (M+ 
C14H19N5O2 requires 289.15).  
 
N-(2-Morpholinoethyl)-5-nitro-1H-benzimidazol-2-amine, 2.6c (DS22) 
As a yellow powder (215 mg, 84 %), m.p. 186-187 °C; Rf 
(MeOH: DCM: NH4OH, 10:86:4) 0.60; δH (300 MHz, 
CDCl3) 7.82 (1H, d, J = 2.2 Hz, H1), 7.68 (1H, dd, J = 
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8.7, 2.2 Hz, H2), 6.99 (1H, d, J = 8.7 Hz, H3), 3.43 (4H, m, H7), 3.36 (2H, t, J = 5.9 Hz, 
H4), 2.42 (2H, t, J = 5.9 Hz, H5), 2.27 (4H, m,  H6); δC (101 MHz, CDCl3) 158.33, 
145.05, 140.30, 136.15, 116.72, 110.96, 106.38, 66.10 (x2), 56.90, 52.71 (x2), 38.94; 
LRMS (EI) m/z, 291.13, (M+ C13H17N5O3 requires 291.13). 
 
N1,N1-Diethyl-N2-(5-nitro-1H-benzimidazol-2-yl)ethane-1,2-diamine, 2.6d (DS24) 
As a yellow powder (241 mg, 83 %), m.p. 93-94 °C; Rf 
(MeOH: DCM: NH4OH, 10:86:4) 0.50; δH (400 MHz, 
CDCl3) 8.07 (1H, d, J = 2. 2 Hz, H1), 8.02 (1H, dd, J = 
8.7, 2.2 Hz, H2), 7.22 (1H, d, J = 8.7 Hz, H3), 3.53 (2H, t, 
J = 4.5 Hz, H4), 2.86 (2H, t, J = 4.5 Hz, H5), 2.80 (4H, q, J = 7.2 Hz, H6), 1.20 (6H, t, J 
= 7.2 Hz, H7); δC (101 MHz, CD3OD) 171.63, 162.09, 158.33, 142.01, 117.20, 111.73, 
107.19, 60.24, 53.44, 38.11 (x2), 8.03 (x2); LRMS (EI) m/z, 277.16 (M+ C13H19N5O2 
requires 277.15). 
 
5-Nitro-N-(2-(pyrrolidin-1-yl)ethyl)pyridin-2-amine, 2.4a (DS26) 
As a yellow powder (238 mg, 65 %), m.p. 195-196 °C; Rf (MeOH: 
DCM: NH4OH, 10:88:2) 0.50; δH (300 MHz, CD3OD) 8.97 (1H, d, J = 
2.7 Hz, H1), 8.17 (1H, dd, J = 9.3, 2.7 Hz, H2), 6.69 (1H, d, J = 9.3 
Hz, H3), 3.86 (2H, t, J = 6.0 Hz, H4), 3.46 (2H, t, J = 6.0 Hz, H5), 
3.43 (4H, m,  H6), 2.09 (4H, m, H7); δC (101 MHz, CD3OD) 161.58, 145.95, 136.19, 
132.15, 108.83, 54.52, 54.35, 37.65 (x2), 22.73 (x2); LRMS (EI) m/z, 236.07 (M+ 
C11H16N4O2 requires 236.13). 
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N-(2-Morpholinoethyl)-5-nitropyridin-2-amine, 2.4b (DS27) 
As a yellow powder (202 mg, 77 %), m.p. 56-58 °C; Rf (MeOH: 
DCM: NH4OH, 10:88:2) 0.60; δH (400 MHz, CDCl3) 8.91 (1H, d, J = 
2.7 Hz, H1), 8.07 (1H, d, J = 9.0 Hz, H2), 6.34 (1H, d, J = 9.0 Hz, 
H3), 3.66 (4H, m, H7), 3.44 (2H, t, J = 6.4 Hz, H4), 2.59 (2H, t, J = 
6.4 Hz, H5), 2.44 (4H, m,  H6); δC (101 MHz, CDCl3) 161.00, 147.00 (x2), 135.85, 
132.79, 66.87 (x2), 56.54, 53.28 (x2), 38.04; LRMS (EI) m/z, 252.09 (M+ C11H16N4O3 
requires 252.12). 
 
5-Nitro-N-(2-(pyrrolidin-1-yl)ethyl)benzoxazol-2-amine, 2.9b (DS23) 
As a yellow powder (222 mg, 80 %), m.p. 89-90 °C; Rf 
(MeOH: DCM: NH4OH, 10:86:4) 0.70; δH (400 MHz, 
CDCl3) 7.86 (1H, d, J = 2.3 Hz, H1), 7.59 (1H, dd, J = 8.7, 
2.3 Hz, H2), 6.82 (1H, d, J = 8.7 Hz, H3), 3.52 (2H, t, J = 
5.6 Hz, H4), 2.81 (2H, t, J = 5.6 Hz, H5), 2.60 (4H, m,  H6), 1.74 (4H, m, H7); δC (101 
MHz, CDCl3) 163.84, 152.48, 144.98, 144.08, 117.02, 111.51, 108.02, 54.31, 53.78, 
41.29 (x2), 23.46 (x2); LRMS (EI) m/z, 276.15 (M+ C13H16N4O3 requires 276.12). 
 
5-Nitro-N-(2-(piperidin-1-yl)ethyl)benzoxazol-2-amine, 2.9c (DS46) 
As a yellow solid (213 mg, 62 %); m.p. 82-84 °C; Rf 
(MeOH: EtOAc, 20:80) 0.30; δH (CDCl3, 300 MHz) 8.08 
(1H, d, J=2.0 Hz, H1), 7.91 (1H, dd, J=8.7, 2.0 Hz, H2), 
7.18 (1H, d, J=8.7 Hz, H3), 3.52 (2H, t, J=5.8 Hz, H4), 
2.60 (2H, t, J=5.8 Hz, H5), 2.51 – 2.35 (4H, m, H6), 1.70 – 1.50 (4H, m, H7), 1.46 – 1.31 
(2H, m, H8); δC (101 MHz, CDCl3) 163.76, 152.50, 145.01, 143.98, 117.17, 111.53, 
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108.17, 56.86, 54.27, 39.23 (x2), 25.57 (x2), 24.04; LRMS (EI) m/z, 290.14 (M+ 
C14H18N4O3 requires 290.14). 
 
N-(2-Morpholinoethyl)-5-nitrobenzoxazol-2-amine, 2.9d (DS31) 
As yellow crystals (250 mg, 62 %); m.p. 151-153 °C; Rf 
(MeOH: EtOAc, 20:80) 0.57; δH
 (CDCl3, 400 MHz) 8.08 
(1H, d, J=2.3 Hz, H1), 7.92 (1H, dd, J=8.8, 2.3 Hz, H2), 
7.20 (1H, d, J=8.8 Hz, H3), 3.66 (4H, t, J=4.6 Hz, H7), 
3.52 (2H, t, J=5.7 Hz, H4), 2.60 (2H, t, J=5.7 Hz, H5), 2.45 (4H, t, J=4.6 Hz, H6); δC (101 
MHz, CDCl3) 163.66, 152.59, 145.34, 144.17, 117.33, 111.98, 108.22, 66.85 (x2), 
56.69, 53.35 (x2), 39.26; LRMS (EI) m/z, 292.00 (M+ C13H16N4O4 requires 292.12). 
 
N1,N1-Diethyl-N2-(5-nitrobenzoxazol-2-yl)ethane-1,2-diamine, 2.9e (DS33)  
 As a yellow solid (182 mg, 65%); m.p. 58-60 °C; Rf 
(MeOH: EtOAc, 20:80) 0.31; δH (CDCl3, 400 MHz) 8.01 
(1H, d, J=2.3 Hz, H1), 7.84 (1H, dd, J=8.7, 2.3 Hz, H2), 
7.13 (1H, d, J=8.7 Hz, H3), 3.43 (2H, t, J=5.9 Hz, H4), 
2.65 (2H, t, J=5.9 Hz, H5), 2.51 (4H, q, J=7.1 Hz, H6), 0.94 (6H, t, J=7.1 Hz, H7); δC 
(101 MHz, CDCl3)163.84, 152.60, 145.02, 144.17, 117.15, 111.59, 108.19, 51.17, 
46.61, 40.26 (x2), 11.46 (x2); LRMS (EI) m/z, 278.14 (M+ C13H18N4O3 requires 278.14). 
 
N1,N1-Dimethyl-N2-(5-nitrobenzoxazol-2-yl)ethane-1,2-diamine, 2.9f (DS50) 
 As an orange solid (161 mg, 52 %); m.p. 123-126 °C; Rf 
(MeOH: EtOAc, 20:80) 0.60; δH (CDCl3, 400 MHz) 8.14 
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(1H, d, J=2.3 Hz, H1), 7.93 (1H, dd, J=8.7, 2.3 Hz, H2), 7.19 (1H, d, J=8.7 Hz, H3), 3.56 
(2H, t, J=5.8 Hz, H4), 2.61 (2H, t, J=5.8 Hz, H5), 2.30 (6H, s, H6); δC (101 MHz, 
CD3OD) 164.56, 152.45, 145.07, 143.69, 116.91, 114.25, 112.74, 110.22, 109.01, 
108.21, 57.56, 44.04, 39.96 (x2); LRMS (EI) m/z, 250.10 (M+ C11H14N4O3 requires 
250.11). 
 
1-(3-(5-Nitrobenzoxazol-2-ylamino)propyl)pyrrolidin-2-one, 2.9g (DS34) 
 As a brown solid (125 mg, 41%); m.p. 116-118 °C; Rf 
(EtOAc) 0.61; δH (CDCl3, 400 MHz) 8.05 (1H, d, J=2.3 
Hz, H1), 7.89 (1H, dd, J=8.7, 2.3 Hz, H2), 7.18 (1H, d, 
J=8.7 Hz, H3), 3.42 – 3.29 (6H, m, H4, H6, H7), 2.37 
(2H, t, J=8.1 Hz, H9), 1.95 – 2.04 (2H, m, H8), 1.85 – 1.73 (2H, m, H5); δC (101 MHz, 
CDCl3) δ 176.38, 163.87, 152.65, 145.06, 144.14, 117.24, 111.55, 108.24, 47.57, 39.46, 
39.42, 30.84, 26.21, 17.97; LRMS (EI) m/z, 304.13 (M+ C14H16N4O4 requires 304.12). 
 
N1,N1-Diethyl-N3-(5-nitrobenzoxazol-2-yl)propane-1,3-diamine, 2.9h (DS36) 
 As a yellow resin (201 mg, 68 %); Rf (MeOH: EtOAc, 
20:80) 0.32; δH (CDCl3, 400 MHz) 8.03 (1H, d, J=2.3 
Hz, H1), 7.87 (1H, dd, J=8.6, 2.3 Hz, H2), 7.16 (1H, d, 
J=8.6 Hz, H3), 3.53 (2H, t, J=5.9 Hz, H4), 2.63 (2H, t, J=5.9 Hz, H6), 2.55 (4H, q, J=7.2 
Hz, H7), 1.80 – 1.74 (2H, m, H5), 1.03 (6H, t, J=7.2 Hz, H8); δC (101 MHz, CDCl3) 
163.88, 152.65, 145.14, 144.49, 116.91, 111.45, 107.96, 52.67, 46.93, 43.70 (x2), 
24.83, 11.31 (x2); LRMS (EI) m/z, 292.22 (M+ C14H20N4O3 requires 292.15). 
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N1,N1-Dimethyl-N3-(5-nitrobenzoxazol-2-yl)propane-1,3-diamine, 2.9i (DS37) 
 As a yellow solid (192 mg, 61 %); m.p. 67-69 °C;  Rf 
(MeOH: EtOAc, 20:80) 0.31; δH (CDCl3, 400 MHz) 7.93 
(1H, d, J=2.2 Hz, H1), 7.76 (1H, dd, J=8.8, 2.2 Hz, H2), 
7.07 (1H, d, J=8.8 Hz, H3), 3.42 (2H, t, J=6.3 Hz, H4), 
2.34 (2H, t, J=6.3 Hz, H6), 2.11 (6H, s, H7), 1.72 – 1.65 (2H, m, H5); δC (101 MHz, 
CDCl3) 163.99, 152.50, 144.85, 144.25, 116.83, 111.13, 108.00, 58.35, 45.21, 43.10, 
25.61 (x2); LRMS (EI) m/z, 264.11 (M+ C12H16N4O3 requires 264.12). 
 
5-Nitro-N-(3-(piperidin-1-yl)propyl)benzoxazol-2-amine, 2.9j (DS48) 
As a yellow solid (207 mg, 69 %); m.p. 95-97 °C;  Rf 
(MeOH: EtOAc, 20:80) 0.31; δH (CDCl3, 400 MHz) 
8.01 (1H, d, J=2.3 Hz, H1), 7.86 (1H, dd, J=8.7, 2.3 
Hz, H2), 7.17 (1H, d, J=8.7 Hz, H3), 3.53 (2H, t, J=6.0 Hz, H4), 2.56 (2H, t, J=6.1 Hz, 
H6), 2.53 – 2.39 (4H, m, H7), 1.82 (1H, p, J=6.1 Hz, H5), 1.67 – 1.56 (4H, m, H8), 1.48 
– 1.38 (2H, m, H9); δC (101 MHz, CDCl3) 163.97, 152.61, 144.99, 144.42, 116.83, 
111.25, 107.96, 57.71, 54.33, 43.28 (x2), 25.53, 24.20 (x2), 23.88; LRMS (EI) m/z, 
304.13 (M+ C15H20N4O3 requires 304.15). 
 
5-Nitro-N-(3-(piperidin-1-yl)propyl)benzo[d]oxazol-2-amine, 2.9k (DS56) 
 As a yellow solid (162 mg, 53 %); m.p. 94-96 °C; Rf 
(MeOH: EtOAc, 20:80) 0.65; δH (CDCl3, 400 MHz) 
8.11 (1H, d, J=2.3 Hz, H1), 7.97 (1H, dd, J=8.7, 2.3 
Hz, H2), 7.26 (1H, d, J=8.7 Hz, H3), 3.80 – 3.70 (4H, m, H8), 3.61 (2H, t, J=6.0 Hz, H4), 
2.59 (2H, t, J=6.0 Hz, H6), 2.55 – 2.49 (4H, m, H7), 1.93 – 1.78 (2H, m, H5); δC (101 
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MHz, CDCl3) 163.73, 152.58, 145.10, 144.31, 117.20, 111.67, 108.13, 67.03 (x2), 
58.20, 53.72 (x2), 43.82, 24.02; LRMS (EI) m/z, 306.12 (M+ C14H18N4O4 requires 
306.13). 
 
N-(4-Methylpiperazin-1-yl)-5-nitrobenzoxazol-2-amine, 2.9l (DS41) 
 As a yellow solid (210 mg, 76 %); m.p. 129-131 °C;  Rf 
(MeOH: EtOAc, 20:80) 0.60; δH (CDCl3, 400 MHz) 8.10 (1H, 
d, J=2.2 Hz, H1), 7.94 (1H, dd, J=8.7, 2.2 Hz, H2), 7.26 (1H, 
d, J=8.7 Hz, H3), 3.74 (4H, t, J=5.1 Hz, H4), 2.53 (4H, t, 
J=5.1 Hz, H5), 2.34 (3H, s, H6); δC (101 MHz, CDCl3) 163.58, 152.66, 145.33, 144.16, 
117.01, 111.67, 108.23, 54.05 (x2), 46.00, 45.51 (x2); LRMS (EI) m/z, 262.08 (M-15) 
(M+ C12H15N5O3 requires 277.12). 
 
N-(3-Chlorobenzyl)-5-nitrobenzoxazol-2-amine, 2.9m (DS42) 
 As yellow crystals (180 mg, 59 %); m.p. 140-142 °C; Rf 
(EtOAc: Hexane, 30:70) 0.14; δH (DMSO, 400 MHz) 8.01 
(1H, d, J=2.4 Hz, H1), 7.94 (1H, dd, J=8.7, 2.4 Hz, H2), 
7.58 (1H, d, J=8.7 Hz, H3), 7.43 (1H, s, H8), 7.28 – 7.38 (3H, m, H5, H6, H7), 4.56 (2H, 
s, H4); δC (101 MHz, DMSO) 164.70, 152.96, 144.98, 144.50, 141.45, 133.59, 130.82, 
127.66, 127.54, 126.38, 117.49, 110.91, 109.38, 45.69; LRMS (EI) m/z, 303.01 (M+ 
C14H10ClN3O3 requires 303.04). 
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5-Nitro-N-(3-(trifluoromethyl)benzyl)benzoxazol-2-amine, 2.9n (DS54) 
As a brown solid (221 mg, 84 %); m.p. 156-158 °C; Rf 
(Hexane: EtOAc, 30:70) 0.20; δH (DMSO, 400 MHz) 
8.02 (1H, d, J=2.4 Hz, H1), 7.95 (1H, dd, J=9.2, 2.4 Hz, 
H2), 7.75 – 7.67 (2H, m, H3, H7), 7.65 – 7.55 (3H, m, H5, H6, H8), 4.66 (2H, s, H4); δC 
(101 MHz, DMSO) 164.72, 152.97, 144.99, 144.47, 140.38, 131.88, 130.04, 124.49, 
124.45, 124.32, 124.27, 117.53, 110.93, 109.41, 45.79; LRMS (EI) m/z, 337.08 (M+ 
C15H10F3N3O3 requires 337.07). 
 
5-Nitro-N-(pyridin-2-ylmethyl)benzoxazol-2-amine, 2.9o (DS32) 
As a yellow solid (140 mg, 52 %); m.p. 142-144 °C; Rf 
(EtOAc) 0.70; δH (DMSO, 400 MHz) 8.52 (1H, d, J=4.8 
Hz, H8), 8.00 (1H, d, J=2.4 Hz, H1), 7.94 (1H, dd, J=8.7, 
2.4 Hz, H2), 7.76 (1H, td, J=7.8 (x2), 1.8 Hz, H6), 7.58 (1H, d, J=8.7 Hz, H3), 7.41 (1H, 
d, J=7.8 Hz, H5), 7.28 (1H, dd, J=7.3, 5.1 Hz, H7), 4.65 (2H, s); δC (101 MHz, DMSO) 
164.94, 158.00, 152.99, 149.55, 144.98, 144.58, 137.38, 122.95, 121.59, 117.44, 
110.87, 109.36, 47.99; LRMS (EI) m/z, 270.06 (M+ C13H10N4O3 requires 270.08). 
 
5-Nitro-N-(pyridin-3-ylmethyl)benzoxazol-2-amine, 2.9p (DS35) 
As brown crystals (218 mg, 81%); m.p. 189-191 °C; Rf 
(EtOAc ) 0.70; δH (CD3OD, 400 MHz) 8.61 (1H, d, J=2.2 
Hz, H8), 8.47 (1H, dd, J=4.9, 1.6 Hz, H7), 8.07 (1H, d, 
J=2.3 Hz, H1), 8.01 (1H, dd, J=8.8, 2.3 Hz, H2), 7.95 – 7.87 (1H, m, H6), 7.44 (1H, d, 
J=8.8 Hz, H3), 7.45 – 7.41 (m, 1H, H5), 4.67 (4H, s, H4); δC (101 MHz, DMSO) 164.65, 
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152.97, 149.31, 149.03, 144.97, 144.48, 135.66, 134.30, 124.03, 117.50, 110.93, 
109.36, 43.98; LRMS (EI) m/z, 270.11 (M+ C13H10N4O3 requires 270.08). 
 
5-Nitro-N-(pyridin-4-ylmethyl)benzoxazol-2-amine, 2.9q (DS47) 
As an orange solid (127 mg, 38 %); m.p. 206-208 °C; Rf 
(EtOAc) 0.70; δH (CDCl3, 400 MHz) 8.61 (2H, d, J=6.1 
Hz, H6), 8.21 (1H, d, J=2.3 Hz, H1), 8.05 (1H, dd, J=8.8, 
2.3 Hz, H2), 7.34 (1H, d, J=8.8 Hz, H3), 7.32 (2H, d, J=6.1 Hz, H5), 4.74 (2H, s, H4); δC 
(101 MHz, DMSO) 164.74, 152.99, 150.16 (x2), 147.83, 144.99, 144.42, 122.49 (x2), 
117.56, 111.00, 109.43, 45.20; LRMS (EI) m/z, 270.04 (M+ C13H10N4O3 requires 
270.08). 
 
5-Nitro-N-(2-(pyridin-2-yl)ethyl)benzoxazol-2-amine, 2.9r (DS49) 
As an orange solid (254 mg, 60 %); m.p. 179-180 °C; Rf 
(EtOAc) 0.80; δH (DMSO, 400 MHz) 8.49 (1H, ddd, 
J=4.8, 1.8, 1.0 Hz, H9), 8.00 (1H, d, J=2.4 Hz, H1), 7.92 
(1H, dd, J=8.7, 2.4 Hz, H2), 7.68 (1H, td, J=7.6, 1.9 Hz, 
H7), 7.53 (1H, d, J=8.7 Hz, H3), 7.28 (1H, m, H6), 7.20 (1H, ddd, J=7.6, 4.9, 1.0 Hz, 
H8), 3.71 (2H, t, J=7.2 Hz, H4), 3.07 (2H, t, J=7.2 Hz, H5); δC (101 MHz, DMSO) 
164.59, 159.01, 152.85, 149.58, 144.92, 144.79, 136.95, 123.77, 122.08, 117.22, 
110.63, 109.15, 42.54, 37.33; LRMS (EI) m/z, 284.10 (M+ C14H12N4O3 requires 284.09). 
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N,N-Diethyl-5-nitrobenzoxazol-2-amine, 2.9s (DS39) 
 As a brown solid (132 mg, 56 %); m.p. 79-80°C; Rf (EtOAc: 
Hexane, 20:80) 0.31; δH (CDCl3, 400 MHz) 8.02 (1H, d, J=2.3 
Hz, H1), 7.84 (1H, dd, J=8.7, 2.3 Hz, H2), 7.17 (1H, d, J=8.7 
Hz, H3), 3.52 (4H, q, J=7.2 Hz, H4), 1.21 (6H, t, J=7.2 Hz, H5); δC (101 MHz, CDCl3) 
163.72, 152.84, 145.16, 144.63, 116.56, 111.25, 108.02, 43.27 (x2), 13.35 (x2); LRMS 
(EI) m/z, 235.03 (M+ C11H13N3O3 requires 235.10). 
 
2-(4-Methylpiperazin-1-yl)-5-nitrobenzoxazole, 2.9t (DS51) 
 As a yellow solid (191 mg, 70 %); m.p. 135-136 °C; Rf 
(EtOAc) 0.60; δH (CDCl3, 300 MHz) 8.03 (1H, d, J=2.3 Hz, 
H1), 7.88 (1H, dd, J=8.7, 2.3 Hz, H2), 7.20 (1H, d, J=8.7 
Hz, H3), 3.68 (4H, t, J=5.1 Hz, H4), 2.46 (4H, t, J=5.1 Hz, H5), 2.28 (3H, s, H6); δC (101 
MHz, CDCl3) 163.58, 152.70, 145.27, 144.21, 117.13, 111.77, 108.28, 54.13 (x2), 
46.18, 45.57 (x2); LRMS (EI) m/z, 262.10 (M+ C12H14N4O3 requires 262.11). 
 
5-Nitro-2-(4-phenylpiperazin-1-yl)benzoxazole, 2.9u (DS52) 
As a yellow solid (234 mg, 77 %); m.p. 178-180 °C; 
Rf (Hexane: EtOAc, 40:60) 0.50; δH (CDCl3, 300 
MHz) 8.13 (1H, d, J=2.4 Hz, H1), 7.95 (1H, dd, 
J=9.0, 2.4 Hz, H2), 7.38 – 7.14 (3H, m, H3, H7), 7.03 – 6.76 (3H, m, H6, H8), 3.98 – 
3.71 (4H, m, H5), 3.41 – 3.15 (4H, m, H4); δC (101 MHz, CDCl3) 163.50, 152.72, 
150.88, 145.33, 144.12, 129.34 (x2), 121.02, 117.28, 117.06 (x2), 111.91, 108.40, 
49.21 (x2), 45.64 (x2); LRMS (EI) m/z, 324.14 (M+ C17H16N4O3 requires 324.12). 
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2-(4-(3-Chlorophenyl)piperazin-1-yl)-5-nitrobenzoxazole, 2.9v (DS53) 
As a yellow solid (202 mg, 72 %); m.p. 155-157 °C; 
Rf (Hexane: EtOAc, 40:60) 0.60; δH (CDCl3, 400 
MHz) 8.19 (1H, d, J=2.2 Hz, H1), 8.02 (1H, dd, 
J=8.8, 2.2 Hz, H2), 7.33 (2H, d, J=8.8 Hz, H3), 7.21 (1H, t, J=8.1 Hz, H7), 6.97 – 6.77 
(3H, m, H6, H8, H9), 3.89 (4H, t, J=5.2 Hz, H5), 3.33 (4H, t, J=5.2 Hz, H4); δC (101 
MHz, CDCl3) 163.41, 152.70, 151.89, 145.36, 144.03, 135.18, 130.27, 120.69, 117.39, 
116.86, 114.85, 112.03, 108.46, 48.72 (x2), 45.44 (x2); LRMS (EI) m/z, 358.11 (M+ 
C17H15ClN4O3 requires 358.08). 
 
N1-(5-Chlorobenzoxazol-2-yl)-N2,N2-diethylethane-1,2-diamine, 2.12a (DS61) 
As an off-white solid (121 mg, 33 %) m.p. 54-56 °C; Rf 
(MeOH: EtOAc, 20:80) 0.36; δH (CD3OD, 400 MHz) 7.19 
(1H, d, J=2.0 Hz, H1) 7.17 (1H, d, J=8.4 Hz, H3) 6.96 (1H, 
dd, J=8.4, 2.0 Hz, H2) 3.44 - 3.50 (2H, m, H4) 2.68 - 2.74 (2H, m, H5) 2.60 (4H, q, 
J=7.1 Hz, H6) 1.04 (6H, t, J=7.1 Hz, H7); δC (CD3OD, 75 MHz) 163.80, 147.10, 144.15, 
129.08, 120.36, 115.19, 109.21, 51.67, 47.05, 40.31 (x2), 10.70 (x2); LRMS (EI) m/z, 
267.08 (M+ C13H18ClN3O requires 267.11). 
 
5-Chloro-2-(4-phenylpiperazin-1-yl)benzoxazole, 2.12b (DS62) 
As a pink solid (127 mg, 46 %); m.p. 145-146 °C; Rf 
(Hexane: EtOAc, 30:70) 0.70; δH (CDCl3, 400 MHz) 
7.33 (1H, d, J=1.9 Hz), 7.32 – 7.24 (2H, m, H7), 7.16 
(1H, d, J=8.4 Hz), 7.00 (1H, dd, J=8.1, 1.9 Hz), 6.98 – 6.90 (3H, m, H6, H8), 3.86 (4H, t, 
J=5.2 Hz, H5), 3.30 (4H, t, J=5.2 Hz, H6); δC (101 MHz, CDCl3) 162.83, 151.01, 147.44, 
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144.49, 129.30 (x2), 120.85, 120.65, 116.99 (x2), 116.53, 109.28, 49.19 (x2), 45.58 
(x2); LRMS (EI) m/z, 313.07 (M+ C17H16ClN3O requires 313.10). 
 
General procedure for the coupling of aromatic amines with 4,7-dichloroquinoline 
The aromatic nitro-compound (1 mmol) was dissolved in ethanol (8 ml) with warming in 
a hydrogenator bottle. 10% Pd/C (0.3 times the weight of the compound being reduced) 
was added to this solution. The reaction bottle was sealed, filled with H2 and evacuated 
twice.  It was then shaken on a Parr shaker for 12 h at 60 psi of H2 until completion of 
the reaction (monitored by TLC). The reaction mixture was filtered through Celite and 
the solvent removed under vacuum to obtain the aromatic amine. The aromatic amine 
(1 mmol, 1 eq) was mixed with 4,7-dichloroquinoline (1.1 eq) in acetonitrile (25 ml). The 
mixture was acidified with 3-5 drops of HCl and stirred at reflux for 24 h. The solvent 
was removed under vacuum after which the residue was dissolved in EtOAc (or 20% 
methanol in dichloromethane for tertiary amine compounds) and washed with saturated 
NaHCO3 (3x20 ml) and brine (1x10ml). The combined organic fractions were dried over 
anhydrous MgSO4, adsorbed onto silica gel (5g) and subjected to silica gel column 
chromatography to afford the target compounds.  
 
N5-(7-Chloroquinolin-4-yl)-N2-ethylbenzothiazole-2,5-diamine, 3.2a (DS1F) 
As a yellow powder (41 mg, 21 %); m.p. 209-210 °C; Rf 
(MeOH:DCM, 10:90 ) 0.58; δH (400 MHz, CDCl3) 8.51 
(1H, d, J = 5.3 Hz, H1), 8.04 (1H, d, J = 2.1 Hz, H5), 
7.88 (1H, d, J = 8.9 Hz, H3), 7.58 (1H, d, J = 8.5 Hz, 
H8), 7.50 (1H, d, J = 2.2 Hz, H6), 7.43 (1H, dd, J = 8.9, 2.1 Hz, H4), 7.19 (1H, dd, J = 
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8.5, 2.2 Hz, H7), 6.74 (1H, d, J = 5.3 Hz, H2), 1.54 (9H, s, H9); δC (101 MHz, CDCl3) 
164.59, 151.91, 150.92, 149.73, 148.94, 135.20, 133.12, 132.09, 129.03, 125.84, 
122.86, 121.05, 119.82, 117.75, 116.57, 102.01, 53.61, 29.10 (3C); HRMS (ESI) m/z, 
383.1097 ([M+H]+ C20H20N4SCl requires 383.1097); HPLC Purity (Method A): >99 %, tR 
= 13.70 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-ethylbenzo[d]thiazole-2,5-diamine, 3.2b (DS1G) 
As a yellow powder (52 mg, 42 %); m.p. 281-282 °C; Rf 
(MeOH: DCM) 0.59; δH (400 MHz, DMSO) 8.43 (1H, d, 
J = 9.1 Hz, H3), 8.40 (1H, d, J = 5.4 Hz, H1), 7.86 (1H, 
d, J = 2..2 Hz, H5), 7.65 (1H, d, J = 2.2 Hz, H6), 7.52 
(1H, dd, J = 9.1, 2.2 Hz, H4), 7.43 (1H, d, J = 8.5 Hz, H8), 7.20 (1H, dd, J = 8.5, 2.2 Hz, 
H7), 6.68 (1H, d, J = 5.4 Hz, H2), 3.41 (2H, q, J = 7.2 Hz, H9), 1.22 (3H, t, J = 7.2 Hz, 
H10); δC (101 MHz, DMSO) 166.47, 152.40, 150.76, 149.96, 149.68, 134.24, 133.41, 
131.62, 128.06, 125.13, 124.77, 122.99, 118.77, 118.36, 117.42, 101.45, 29.43, 14.92; 
LRMS (EI) m/z, 354.05 (M+ C18H15ClN4S requires 354.07); HPLC Purity (Method A): 
>99 %, tR = 12.70 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-(pyrrolidin-1-yl)ethyl)benzo[d]thiazole-2,5-
diamine, 3.2c (DS11B) 
As a yellow powder (96 mg, 47 %); m.p. 126-128 
°C; Rf (MeOH: DCM: NH4OH, 10:88:2) 0.47; m.p. 
δH (400 MHz, CD3OD) 8.32 (1H, d, J = 5.6 Hz, 
H1), 8.26 (1H, d, J = 9.0 Hz, H3), 7.84 (1H, d, J = 
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2.2 Hz, H5), 7.60 (1H, d, J = 2.1 Hz, H6), 7.50 (1H, d, J = 8.5 Hz, H8), 7.47 (1H, dd, J = 
9.0, 2.2 Hz, H4), 7.26 (1H, dd, J = 8.5, 2.2 Hz, H7), 6.73 (1H, d, J = 5.6 Hz, H2),  3.66 
(2H, t, J = 6.6 Hz, H9), 2.93 (2H, t, J = 6.6 Hz, 10), 2.79 (4H, m,  H11), 1.88 (4H, m, 
H12); δC (101 MHz, CD3OD) 169.61, 157.30, 152.81, 144.15, 141.15, 140.58, 133.48, 
131.99, 128.97, 126.51, 124.84, 120.47, 119.59, 117.20, 101.52, 55.54, 55.39, 41.58 
(x2), 24.04 (x2); HRMS (ESI) m/z, 424.1361 ([M+1]+ C22H23N5SCl requires  424.1363); 
HPLC Purity (Method D): >99 %, tR = 9.46 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-(piperidin-1-yl)ethyl)benzo[d]thiazole-2,5-diamine, 
3.2d (DS12B) 
As a yellow powder (106 mg, 53 %); m.p. 170-
174 °C; Rf (MeOH: DCM: NH4OH, 10:88:2) 0.40; 
δH (400 MHz, CD3OD) 8.33 (1H, d, J = 5.8 Hz, 
H1), 8.29 (1H, d, J = 8.6 Hz, H3), 7.85 (1H, d, J 
= 2.1 Hz, H5), 7.64 (1H, d, J = 2.1 Hz, H6), 7.52 
(1H, d, J = 8.5 Hz, H8), 7.49 (1H, dd, J = 8.6, 2.2 Hz, H4), 7.23 (1H, dd, J = 8.5, 2.2 Hz, 
H7), 6.75 (1H, d, J = 5.8 Hz, H2),  3.74 (2H, t, J = 6.03 Hz, H13), 3.04 (2H, t, J = 6.03 
Hz, H14), 2.96 (4H, m,  H15), 1.79 (4H, m, H16), 1.62 (2H, m, H17); δC (101 MHz, 
CDCl3) 167.19, 151.58, 150.75, 149.25, 149.11, 135.34, 132.33, 131.86, 128.57, 
125.90, 123.01, 121.43, 119.41, 117.61, 116.95, 101.73, 56.78, 54.23, 41.22 (x2), 25.56 
(x2), 24.05; HRMS (ESI) m/z, 438.1516 ([M+H]+ C23H25N5SCl requires 438.1519); HPLC 
Purity (Method D): >99 %, tR = 9.76 min. 
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N5-(7-Chloroquinolin-4-yl)-N2-(2-morpholinoethyl)benzo[d]thiazole-2,5-diamine, 
3.2e (DS13B) 
As a yellow powder (91 mg, 45 %); m.p. 162-
166 °C; Rf (MeOH: DCM: NH4OH, 10:88:2) 0.54; 
δH (400 MHz, CD3OD) 8.27 (1H, d, J = 5.6 Hz, 
H1), 8.20 (1H, d, J = 9.0 Hz, H3), 7.81 (1H, d, J 
= 2.2 Hz, H5), 7.53 (1H, d, J = 2.2 Hz, H6), 7.45 
(1H, d, J = 8.5 Hz, H8), 7.41 (1H, dd, J = 9.0, 2.2 Hz, H4), 7.21 (1H, dd, J = 8.5, 2.2 Hz, 
H7), 6.69 (1H, d, J = 5.6 Hz, H2),  3.68 (4H, m, H12), 3.56 (2H, t, J = 6.5 Hz, H9), 2.62 
(2H, t, J = 6.5 Hz, H10), 2.50 (4H, m,  H11); δC (101 MHz, CD3OD) 169.23, 152.60, 
151.53, 151.35, 149.01, 137.06, 134.42, 132.49, 126.91, 126.67, 124.54, 124.24, 
119.59, 118.95, 118.38, 102.16, 67.79 (x2), 58.40, 54.74, 42.58 (x2); HRMS (ESI) m/z, 
440.1300 ([M+H]+ C22H23N5OSCl requires 440.1312); HPLC Purity (Method D): >99 %, 
tR = 4.96 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-(diethylamino)ethyl)benzo[d]thiazole-2,5-diamine, 
3.2f (DS18B) 
As a yellow powder (66 mg, 49 %); m.p. 136-
137 °C; Rf (MeOH: DCM: NH4OH, 10:88:2) 0.40; 
δH (400 MHz, CD3OD) 8.32 (1H, d, J = 5.6 Hz, 
H1), 8.26 (1H, d, J = 9.0 Hz, H3), 7.84 (1H, d, J 
= 2.2 Hz, H5), 7.59 (1H, d, J = 2.2 Hz, H6), 7.48 
(1H, d, J = 8.5 Hz, H8), 7.47 (1H, dd, J = 9.0, 2.2 Hz, H4), 7.26 (1H, dd, J = 8.5, 2.2 Hz, 
H7), 6.73 (1H, d, J = 5.6 Hz, H2),  3.56 (2H, t, J = 6.9 Hz, H9), 2.78 (2H, t, J = 6.9 Hz, 
H10), 2.65 (4H, q, J = 7.2 Hz, H11), 1.09 (6H, t, J = 7.2 Hz, H12); δC (101 MHz, CDCl3) 
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167.38, 151.81, 150.83, 149.66, 149.18, 135.15, 133.15, 128.3, 125.69, 122.99, 121.53, 
119.42, 117.85, 116.85, 101.92, 51.44, 46.78, 42.74 (x2), 11.75 (x2); HRMS (ESI) m/z, 
426.1518, ([M+H]+ C22H25N5SCl requires 426.1519); HPLC Purity (Method A): >99 %, tR 
= 13.04 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-ethyl-1H-benzimidazole-2,5-diamine, 3.6a (DS5G) 
As an orange powder (350 mg, 26 %); m.p. 189-190 
°C; Rf (MeOH:DCM, 10:90 ) 0.61; δH (300 MHz, 
CD3OD)  8.38 (1H, d, J = 9.1 Hz, H3), 8.25 (1H, d, J = 
6.3 Hz, H1), 7.82 (1H, d, J = 2.1 Hz, H5), 7.53 (1H, dd, 
J = 9.1, 2.1 Hz, H4), 7.29 (1H, d, J = 8.3 Hz, H8), 7.24 (1H, d, J = 2.0 Hz, H6), 7.03 (1H, 
dd, J = 8.3, 2.0 Hz, H7), 6.72 (1H, d, J = 6.3 Hz, H2), 3.43 (2H, q, J = 7.3 Hz, H9), 1.30 
(3H, t, J = 7.3 Hz, H10); δC (101 MHz, CD3OD) δ 155.43, 153.25, 147.24, 144.74, 
137.14, 134.74, 131.51, 126.07, 123.99, 123.11, 117.47, 111.63, 111.37, 108.62, 
100.40, 97.84, 37.36, 13.84; HRMS (ESI) m/z, 338.1164 ([M+H]+ C18H17N5Cl requires 
338.1172); HPLC Purity (Method D): >99 %, tR = 4.90 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazole-2,5-
diamine, 3.6b (DS21B) 
As a yellow powder (80 mg, 63 %); m.p. 153-
156 °C; Rf (MeOH: DCM: NH4OH, 10:88:2) 
0.42; δH (400 MHz, CD3OD) 8.27 (1H, d, J = 9.0 
Hz, H3), 8.26 (1H, d, J = 5.6 Hz, H1), 7.82 (1H, 
d, J = 2.1 Hz, H5), 7.44 (1H, dd, J = 9.0, 2.2 Hz, 
H4), 7.25 (1H, d, J = 8.3 Hz, H8), 7.20 (1H, d, J = 2.0 Hz, H6), 6.98 (1H, dd, J = 8.3, 2.0 
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Hz, H7), 6.66 (1H, d, J = 5.6 Hz, H2),  3.54 (2H, t, J = 6.2 Hz, H9), 2.70 (2H, t, J = 6.2 
Hz, H10), 2.60 (4H, m,  H11), 1.67 (4H, m, H12), 1.53 (2H, m, H13); δC (101 MHz, 
CD3OD) 156.52, 151.51, 150.62, 148.44, 135.32, 132.33, 126.05, 125.95, 125.02, 
123.25, 117.73, 117.65, 111.75, 108.96, 100.48, 58.28, 53.92, 39.01 (x2), 24.80 (x2), 
23.12; HRMS (ESI) m/z, 421.1900 ([M+H]+ C23H26N6Cl requires 421.1907); HPLC Purity 
(Method D): >99 %, tR = 9.04 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-morpholinoethyl)-1H-benzo[d]imidazole-2,5-
diamine, 3.6c (DS22B) 
As a yellow powder (124 mg, 71 %); m.p. 149-
150 °C; Rf (MeOH: DCM: NH4OH, 10:88:2) 
0.63; δH (400 MHz, CD3OD) 8.20 (1H, d, J = 9.2 
Hz, H3), 8.19 (1H, d, J = 5.6 Hz, H1), 7.77 (1H, 
d, J = 2.2 Hz, H5), 7.16 (1H, d, J = 2.1 Hz, H6), 
7.20 (1H, d, J = 8.4 Hz, H8), 7.36 (1H, dd, J = 9.1, 2.2 Hz, H4), 6.92 (1H, dd, J = 8.4, 
2.1 Hz, H7), 6.61 (1H, d, J = 5.6 Hz, H2),  3.65 (4H, m, H12), 3.47 (2H, t, J = 6.28 Hz, 
H9), 2.58 (2H, t, J = 6.28 Hz, H10), 2.46 (4H, m,  H11); δC (101 MHz, CD3OD) 157.79, 
152.76, 152.24, 150.05, 136.54, 133.56, 127.62, 126.30, 124.58, 119.07, 118.92, 
113.03, 110.33, 101.85, 67.84 (x2), 58.86, 54.70, 40.50 (x2); HRMS (ESI) m/z, 
423.1699 ([M+H]+ C22H24N6OCl requires 423.1700); HPLC Purity (Method D): 99 %, tR = 
5.26 min. 
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N5-(7-Chloroquinolin-4-yl)-N2-(2-(diethylamino)ethyl)-1H-benzo[d]imidazole-2,5-
diamine, 3.6d (DS24B) 
As an orange resin (98 mg, 65 %); m.p. 79-80 
°C; Rf (MeOH: DCM: NH4OH, 10:88:2) 0.37; δH 
(400 MHz, CD3OD) 8.24 (1H, d, J = 9.0 Hz, H3), 
8.23 (1H, d, J = 5.6 Hz, H1), 7.80 (1H, d, J = 2.2 
Hz, H5), 7.39 (1H, dd, J = 9.0, 2.2 Hz, H4), 7.23 
(1H, d, J = 8.3 Hz, H8), 7.18 (1H, d, J = 1.9 Hz, H6), 6.95 (1H, dd, J = 8.3, 1.9 Hz, H7), 
6.64 (1H, d, J = 5.6 Hz, H2),  3.46 (2H, t, J = 6.4 Hz, H9), 2.71 (2H, t, J = 6.4 Hz, H10), 
2.60 (4H, q, J = 7.2 Hz, H11), 1.05 (6H, t, J = 7.2 Hz, H12); δC (101 MHz, CD3OD) 
172.91, 157.90, 152.68, 152.25, 150.07, 136.48, 133.52, 127.64, 126.24, 124.55, 
119.05, 118.85, 112.98, 110.30, 101.83, 53.44, 48.06, 41.46 (x2), 11.72 (x2); HRMS 
(ESI) m/z, 409.1897 ([M+H]+, C22H26N6Cl requires 409.1907); HPLC Purity (Method D): 
>99 %, tR = 10.19 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-(pyrrolidin-1-yl)ethyl)pyridine-2,5-diamine, 3.4a 
(DS26B) 
As a yellow powder (54 mg, 58 %); m.p. 143-145 °C; 
Rf (MeOH: DCM: NH4OH, 10:88:2) 0.48; δH (400 
MHz, CD3OD) 8.29 (1H, d, J = 5.6 Hz, H1), 8.24 (1H, 
d, J = 9.0 Hz, H3), 7.98 (1H, d, J = 2.7 Hz, H6), 7.81 
(1H, d, J = 2.2 Hz, H5), 7.46 (1H, dd, J = 8.8, 2.7 Hz, H7),  7.45 (1H, dd, J = 9.0, 2.2 Hz, 
H4), 6.67 (1H, d, J = 8.8 Hz, H8), 6.49 (1H, d, J = 5.6 Hz, H2),  3.56 (2H, t, J = 6.46 Hz, 
H9), 2.95 (2H, t, J = 6.48 Hz, H10), 2.86 (4H, m, H11), 1.90 (4H, m, H12); δC (101 MHz, 
CD3OD) 157.26, 151.43, 150.96, 148.64, 144.44, 136.00, 135.33, 126.36, 125.59, 
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125.17, 123.16, 123.09, 117.60, 109.24, 100.28, 55.19, 53.79, 39.57 (x2), 22.79 (x2); 
HRMS (ESI) m/z, 368.1642 ([M+H]+ C20H23N5Cl requires 368.1642); HPLC Purity 
(Method D): 91%, tR = 6.48 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-morpholinoethyl)pyridine-2,5-diamine, 3.4b 
(DS27B) 
As a yellow powder (73 mg, 61 %); m.p. 92-94 °C; 
Rf (MeOH: DCM: NH4OH, 10:88:2) 0.64; δH (400 
MHz, CD3OD) 8.30 (1H, d, J = 5.7 Hz, H1), 8.26 
(1H, d, J = 9.0 Hz, H3), 7.97 (1H, d, J = 2.6 Hz, H6), 
7.83 (1H, d, J = 2.1 Hz, H5), 7.48 (1H, dd, J = 9.0, 2.1 Hz, H4), 7.46 (1H, dd, J = 8.9, 
2.6 Hz, H7),  6.66 (1H, d, J = 8.9 Hz, H8), 6.51 (1H, d, J = 5.7 Hz, H2),  3.72 (4H, m, 
H12), 3.48 (2H, t, J = 6.47 Hz, H9), 2.66 (2H, t, J = 6.49 Hz, H10), 2.57 (4H, m, H11); δC 
(101 MHz, CD3OD) 158.83, 153.31, 151.58, 145.84, 137.34, 137.13, 127.07, 126.77, 
126.43, 124.64, 110.29, 101.63, 67.67 (x2), 58.74, 54.69, 39.39 (x2); 384.1584; HRMS 
(ESI) m/z, 384.1584 ([M+H]+ C20H23N5Cl requires 384.1591); HPLC Purity (Method D): 
>99 %, tR = 4.40 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-ethylbenzoxazole-2,5-diamine, 3.9a (DS4F) 
As a light pink powder (33 mg, 24 %); m.p. 227-228 °C; 
Rf (MeOH:DCM, 10:90% ) 0.55; δH (400 MHz, CD3OD) 
8.34 (1H, d, J = 5.6 Hz, H1), 8.27 (1H, d, J = 9.0 Hz, 
H3), 7.88 (1H, d, J = 2.2 Hz, H5), 7.48 (1H, dd, J = 9.0, 
2.2 Hz, H4), 7.32 (1H, d, J = 8.4 Hz, H8), 7.25 (1H, d, J = 2.1 Hz, H6), 7.03 (1H, dd, J = 
8.4, 2.1 Hz, H7), 6.75 (1H, d, J = 5.6 Hz, H2), 3.47 (2H, q, J = 7.2 Hz, H9), 1.31 (3H, t, J 
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= 7.2 Hz, H10); δC (101 MHz, CD3OD) 151.04, 149.70, 148.89, 135.99, 134.99, 126.79, 
125.51, 122.81, 117.97, 117.72, 111.62, 108.57, 100.74, 37.26, 13.70; HRMS (ESI) 
m/z, 339.1002 ([M+H]+ C18H16N4OCl requires 339.1013); HPLC Purity (Method A): >99 
%, tR = 11.98 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-(pyrrolidin-1-yl)ethyl)-benzoxazole-2,5-diamine, 
3.9b (DS23B) 
As a yellow powder (102 mg, 61 %); m.p. 98-102 
°C; Rf (MeOH: DCM: NH4OH, 10:88:2) 0.60; δH 
(400 MHz, CD3OD) 8.26 (1H, d, J = 5.6 Hz, H1), 
8.21 (1H, d, J = 9.0 Hz, H3), 7.79 (1H, d, J = 2.2 
Hz, H5), 7.40 (1H, dd, J = 9.0, 2.2 Hz, H4), 7.24 
(1H, d, J = 8.4 Hz, H8), 7.20 (1H, d, J = 2.1 Hz, H6), 6.96 (1H, dd, J = 8.4, 2.1 Hz, H7), 
6.70 (1H, d, J = 5.6 Hz, H2),  3.52 (2H, t, J = 6.7 Hz, H9), 2.74 (2H, t, J = 6.7 Hz, H10), 
2.58 (4H, m,  H11), 1.77 (4H, m, H12); δC (101 MHz, CD3OD) 163.56, 150.98, 150.62, 
148.76, 146.07, 143.68, 135.85, 135.24, 126.40, 125.12, 123.18, 117.87, 117.19, 
111.62, 108.76, 100.79, 54.72, 53.66, 41.21 (x2), 22.88 (x2); HRMS (ESI) m/z, 
408.1577 ([M+H]+ C22H23N5OCl requires 408.1591); HPLC Purity (Method D): 97 %, tR = 
8.64 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-(piperidin-1-yl)ethyl)benzoxazole-2,5-diamine, 
3.9c (DS46B) 
As a dark yellow-brown powder (123 mg, 69 %); m.p. 89-91 °C; Rf (MeOH: EtOAc, 
20:80) 0.35; δH (CD3OD, 400 MHz) δ 8.28 (1H, d, J=5.6 Hz, H1), 8.24 (1H, d, J=9.0 Hz, 
H3), 7.81 (1H, d, J=2.2 Hz, H5), 7.43 (1H, dd, J=9.0, 2.2 Hz, H4), 7.27 (1H, d, J=8.4 Hz, 
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H8), 7.22 (1H, d, J=2.1 Hz, H6), 6.99 (1H, dd, 
J=8.4, 2.2 Hz, H7), 6.73 (1H, d, J=5.6 Hz, H2), 
3.54 (2H, t, J=6.7 Hz, H9), 2.63 (2H, t, J=6.7 Hz, 
H10), 2.56 – 2.42 (4H, m, H11), 1.66 – 1.53 (4H, 
m, H12), 1.49 – 1.40 (4H, m, H13); δC (101 
MHz, CD3OD) 163.59, 150.92, 150.68, 148.69, 146.09, 143.65, 135.85, 135.29, 126.35, 
125.16, 123.21, 117.87, 117.24, 111.64, 108.80, 100.79, 57.46, 54.16, 39.34, 25.14, 
23.68; LRMS (EI) m/z, 421.12 (M+ C22H16ClN5O requires 421.17); HPLC Purity (Method 
A): >99 %, tR = 8.79 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-morpholinoethyl)benzoxazole-2,5-diamine, 3.9d 
(DS31B) 
As a yellow solid (107 mg, 57 %); m.p. 107-109 
°C; Rf (MeOH: EtOAc, 20:80) 0.36; δH (CDCl3, 
300 MHz) δ 8.27 (1H, d, J=5.8 Hz, H1), 8.07 
(1H, d, J=9.2 Hz, H3), 7.96 (1H, d, J=2.0 Hz, 
H5), 7.36 (1H, dd, J=9.2, 2.0 Hz, H4), 7.20 (1H, 
d, J=2.2 Hz, H6), 7.16 (1H, d, J=8.4 Hz, H8), 6.92 (1H, dd, J=8.4, 2.2 Hz, H7), 6.65 (1H, 
d, J=5.8 Hz, H2), 3.57 – 3.74 (4H, m, H12), 3.49 (2H, t, J=5.8 Hz, H9), 2.61 (2H, t, J=5.8 
Hz, H10), 2.43 – 2.50 (4H, m, H11); δC (101 MHz, CDCl3) 163.00, 150.75, 149.81, 
148.45, 146.48, 144.35, 135.59, 135.27, 127.59, 125.87, 122.10, 117.60, 117.28, 
112.47, 109.23, 101.53, 66.84 (x2), 56.86, 53.30, 39.14 (x2); LRMS (EI) m/z, 422.99 
(M+ C22H22ClN5O2 requires 423.15); HPLC Purity (Method C): >99 %, tR = 2.82 min. 
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N5-(7-Chloroquinolin-4-yl)-N2-(2-(diethylamino)ethyl)benzoxazole-2,5-diamine, 3.9e 
(DS33B) 
As a yellow solid (89 mg, 61 %); m.p. 91-93 °C; 
Rf (MeOH: EtOAc, 20:80) 0.30; δH  (CD3OD, 300 
MHz) 8.27 (1H, d, J=5.6 Hz, H1), 8.23 (1H, d, 
J=9.0 Hz, H3), 7.80 (1H, d, J=2.2 Hz, H5), 7.42 
(1H, dd, J=9.0, 2.2 Hz, H4), 7.27 (1H, d, J=8.4 
Hz, H8), 7.21 (1H, d, J=2.1 Hz, H6), 6.98 (1H, dd, J=8.4, 2.1 Hz, H7), 6.72 (1H, d, J=5.6 
Hz, H2), 3.49 (2H, t, J=6.9 Hz, H9), 2.73 (2H, t, J=6.9 Hz, H10), 2.61 (4H, q, J=7.2 Hz, 
H11), 1.05 (6H, t, J=7.2 Hz, H12); δC (101 MHz, CD3OD) 163.62, 150.97, 150.67, 
148.75, 146.10, 143.71, 135.87, 135.26, 126.39, 125.14, 123.20, 117.89, 117.23, 
111.66, 108.78, 100.80, 51.44, 46.78, 39.97, 10.29; LRMS (EI) m/z, 409.16 (M+ 
C22H24ClN5O requires 409.17); HPLC Purity (Method A): >99 %, tR = 11.34 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-(dimethylamino)ethyl)benzoxazole-2,5-diamine, 
3.9f (DS50B) 
As a dark brown resin (51 mg, 44 %); Rf (MeOH: 
EtOAc, 20:80) 0.32; δH (CD3OD, 300 MHz) 8.30 
(1H, d, J=5.6 Hz, H1), 8.26 (1H, d, J=9.0 Hz, H3), 
7.83 (1H, d, J=2.2 Hz, H5), 7.46 (1H, dd, J=9.0, 2.2 
Hz, H4), 7.31 (1H, d, J=8.4 Hz, H8), 7.23 (1H, d, 
J=2.2 Hz, H6), 7.01 (1H, dd, J=8.4, 2.2 Hz, H7), 6.74 (1H, d, J=5.6 Hz, H2), 3.54 (2H, t, 
J=6.6 Hz, H9), 2.65 (2H, t, J=6.6 Hz, H10), 2.33 (8H, s, H11); δC (101 MHz, CD3OD) 
163.61, 150.90, 150.80, 148.67, 146.16, 143.68, 135.86, 135.33, 126.31, 125.18, 
123.23, 117.87, 117.35, 111.73, 108.82, 100.80, 57.72, 44.11, 39.96; LRMS (EI) m/z, 
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381.13 (M+ C20H20ClN5O requires 381.14); HPLC Purity (Method B): 99 %, tR = 8.56 
min. 
 
1-(3-(5-(7-Chloroquinolin-4-ylamino)benzoxazol-2-ylamino)propyl)pyrrolidin-2-
one, 3.9g (DS34B) 
As a yellow solid (102 mg, 65 %); m.p. 95-97 
°C; Rf (EtOAc) 0.57; δH (CDCl3, 400 MHz) 
8.39 (1H, d, J=5.5 Hz, H1), 8.02 (1H, d, J=9.0 
Hz, H3), 7.98 (1H, d, J=2.1 Hz, H5), 7.40 
(1H, dd, J=9.0, 2.1 Hz, H4), 7.24 (1H, d, 
J=2.0 Hz, H6), 7.19 (1H, d, J=8.4 Hz, H8), 6.92 (1H, dd, J=8.4, 2.0 Hz, H7), 6.72 (1H, d, 
J=5.5 Hz, H2), 3.34 - 3.45 (6H, m, H9, H11, H12), 2.42 (2H, t, J=8.1 Hz, H14), 2.14 – 
1.99 (2H, m, H13), 1.93 – 1.80 (2H, m, H10); δC (101 MHz, CDCl3) 176.16, 163.15, 
150.70, 149.82, 148.38, 146.55, 144.51, 135.64, 135.04, 127.68, 125.94, 122.00, 
117.54, 117.15, 112.39, 109.20, 101.52, 47.50, 39.57, 39.53, 30.89, 26.44, 17.95; 
HPLC Purity: 96 %, tR = 9.95 min; LRMS (EI) m/z, 435.10 (M+ C23H22ClN5O2 requires 
435.15); HPLC Purity (Method B): 97 %, tR = 9.95 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(3-(diethylamino)propyl)benzoxazole-2,5-diamine, 
3.9h (DS36B) 
As a yellow solid (125 mg, 46 %); m.p. 79-80 
°C; Rf (MeOH: EtOAc, 20:80) 0.33; δH  
(CD3OD, 400 MHz) 8.25 (1H, d, J=5.6 Hz, H1), 
8.21 (1H, d, J=9.0 Hz, H3), 7.78 (1H, d, J=2.2 
Hz, H5), 7.37 (1H, dd, J=9.0, 2.2 Hz, H4), 7.23 
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(1H, d, J=8.4 Hz, H8), 7.20 (1H, d, J=2.2 Hz, H6), 6.95 (1H, dd, J=8.4, 2.2 Hz, H7), 6.70 
(1H, d, J=5.6 Hz, H2), 3.40 (2H, t, J=6.8 Hz, H9), 2.68 – 2.45 (6H, m, H11, H12), 1.92 – 
1.71 (2H, m, H10), 1.02 (6H, t, J=7.2 Hz); δC (101 MHz, CD3OD) 163.58, 150.95, 
150.53, 148.73, 145.96, 143.65, 135.83, 135.21, 126.42, 125.11, 123.20, 117.87, 
117.08, 111.49, 108.74, 100.78, 49.96, 46.46, 41.03, 25.60, 9.98; LRMS (EI) m/z, 
423.16 (M+ C23H26ClN5O requires 423.18); HPLC Purity (Method A): >99 %, tR = 9.02 
min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(3-(dimethylamino)propyl)benzoxazole-2,5-diamine, 
3.9i (DS37B)  
As a yellow solid (113 mg, 52 %); m.p. 55-56 °C; 
Rf (MeOH: EtOAc, 20:80) 0.27; δH (CD3OD, 400 
MHz) 8.28 (1H, d, J=5.6 Hz, H1), 8.24 (1H, d, 
J=9.0 Hz, H3), 7.81 (1H, d, J=2.2 Hz, H5), 7.43 
(1H, dd, J=9.0, 2.2 Hz, H4), 7.28 (1H, d, J=8.4 
Hz, H8), 7.22 (1H, d, J=2.0 Hz, H6), 6.99 (1H, dd, J=8.4, 2.1 Hz, H7), 6.72 (H, d, J=5.6 
Hz, H2), 3.43 (2H, t, J=6.9 Hz, H9), 2.53 (2H, t, J=7.7 Hz, H11), 2.33 (6H, s, H12), 1.92 
– 1.85 (2H, m, H10); δC (101 MHz, CD3OD) 163.64, 150.90, 150.71, 148.67, 146.06, 
143.65, 135.84, 135.29, 126.32, 125.16, 123.23, 117.86, 117.25, 111.61, 108.79, 
100.79, 56.42, 43.81 (x2), 40.55, 26.43; LRMS (EI) m/z, 395.12 (M+ C21H22ClN5O 
requires 395.15); HPLC Purity (Method C): 95 %, tR = 2.65 min. 
 
 
 
CHAPTER 6: EXPERIMENTAL 
212 
 
N5-(7-Chloroquinolin-4-yl)-N2-(3-(piperidin-1-yl)propyl)benzoxazole-2,5-diamine, 
3.9j (DS48B) 
As a yellow-brown solid (96 mg, 58 %); m.p. 
87-89 °C; Rf (MeOH: EtOAc, 20:80) 0.30; δH 
(CD3OD, 300 MHz) 8.26 (1H, d, J=5.6 Hz, 
H1), 8.21 (1H, d, J=9.0 Hz, H3), 7.79 (1H, d, 
J=2.2 Hz, H5), 7.39 (1H, dd, J=9.0, 2.2 Hz, 
H4), 7.24 (1H, d, J=8.4 Hz, H8), 7.20 (1H, d, J=2.1 Hz, H6), 6.96 (1H, dd, J=8.4, 2.1 Hz, 
H7), 6.71 (1H, d, J=5.6 Hz, H2), 3.39 (2H, t, J=6.8 Hz, H9), 2.45 – 2.32 (6H, m, H11, 
H12), 1.93 – 1.75 (1H, m, H10), 1.63 – 1.49 (4H, m, H13), 1.48 – 1.34 (2H, m, H14); δC 
NMR (101 MHz, CD3OD) 163.66, 151.02, 150.77, 148.80, 146.08, 143.70, 135.89, 
135.28, 126.40, 125.16, 123.22, 117.90, 117.28, 111.62, 108.77, 100.81, 56.38, 54.12, 
41.03, 25.76, 25.18, 23.79; LRMS (EI) m/z, 435.13 (M+ C24H26ClN5O requires 435.18); 
HPLC Purity (Method A): >99 %, tR = 9.11 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(3-morpholinopropyl)benzoxazole-2,5-diamine, 3.9k 
(DS56B) 
As a yellow solid (88 mg, 53 %); m.p. 182-
183 °C; Rf (MeOH: EtOAc, 20:80) 0.52; δH 
(CD3OD, 300 MHz) 8.28 (1H, d, J=5.6 Hz, 
H1), 8.23 (1H, d, J=9.0 Hz, H3), 7.81 (1H, d, 
J=2.2 Hz, H5), 7.42 (1H, dd, J=9.0, 2.2 Hz, 
H4), 7.26 (1H, d, J=8.4 Hz, H8), 7.21 (1H, d, J=2.1 Hz, H6), 6.98 (1H, dd, J=8.4, 2.1 Hz, 
H7), 6.72 (1H, d, J=5.6 Hz, H2), 3.74 – 3.62 (4H, m, H13), 3.53 (2H, t, J=6.6 Hz, H9), 
3.43 (2H, t, J=6.6 Hz, H11), 2.51 – 2.37 (4H, m, H12), 1.91 – 1.78 (2H, m, H10); δC (101 
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MHz, CD3OD) 163.63, 150.96, 150.64, 148.73, 146.01, 143.70, 135.85, 135.25, 126.39, 
125.14, 123.19, 117.88, 117.15, 111.55, 108.74, 100.80, 66.35, 56.04, 53.38, 40.88, 
25.58; LRMS (EI) m/z, 437.13 (M+ C23H24ClN5O2 requires 437.16); HPLC Purity 
(Method A): >99 %, tR = 11.52 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(4-methylpiperazin-1-yl)benzoxazole-2,5-diamine, 
3.9l (DS41B)  
As a yellow solid (106 mg, 49 %); m.p. 80-81 °C; Rf 
(MeOH: EtOAc, 20:80) 0.56; δH (CD3OD, 400 MHz) 
8.29 (1H, d, J=5.6 Hz, H2), 8.25 (1H, d, J=9.0 Hz, 
H3), 7.82 (1H, d, J=2.1 Hz, H5), 7.44 (1H, dd, J=9.0, 
2.1 Hz, H4), 7.34 (1H, d, J=8.5 Hz, H8), 7.25 (1H, d, 
J=2.1 Hz, H6), 7.03 (1H, dd, J=8.5, 2.1 Hz, H7), 6.74 (1H, d, J=5.6 Hz, H2), 3.75 – 3.64 
(4H, m, H9), 2.60 – 2.51 (4H, m, H10), 2.33 (3H, s, H11); δC (101 MHz, CDCl3) 163.15, 
151.79, 149.49, 149.08, 146.81, 145.15, 135.31, 135.17, 128.76, 127.75, 125.76, 
121.39, 116.30, 112.03, 109.01, 101.85, 43.05 (x2), 13.46 (x2); LRMS (EI) m/z, 408.13 
(M+ C21H21ClN6O requires 408.15); HPLC Purity (Method A): >99 %, tR = 8.87 min. 
 
 
N2-(3-Chlorobenzyl)-N5-(7-chloroquinolin-4-yl)benzoxazole-2,5-diamine, 3.9m 
(DS42B) 
As a yellow solid (71 mg, 39 %); m.p. 98-99 °C; 
Rf (Hexane: EtOAc, 20:80) 0.61; δH (CDCl3, 400 
MHz) 8.50 (1H, d, J=5.4 Hz, H1), 8.04 (1H, d, 
J=2.1 Hz, H5), 7.91 (1H, d, J=9.0 Hz, H3), 7.46 
(1H, dd, J=9.0, 2.1 Hz, H4), 7.41 (1H, s, H11), 
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7.34 – 7.23 (5H, m, H6, H8, H12), 7.00 (2H, dd, J=8.4, 2.1 Hz, H7), 6.79 (1H, d, J=5.4 
Hz), 4.70 (2H, s, H10); δC (101 MHz, CDCl3) 162.75, 151.79, 149.63, 148.84, 146.65, 
144.40, 139.63, 135.77, 135.28, 130.07, 128.98, 128.10, 127.75, 127.65, 125.92, 
125.58, 121.06, 117.49, 112.87, 109.42, 102.10, 46.63; LRMS (EI) m/z, 434.04 (M+ 
C23H16Cl2N4O requires 434.07); HPLC Purity (Method A): >99 %, tR = 13.93 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(3-(trifluoromethyl)benzyl)benzoxazole-2,5-diamine, 
3.9n (DS54B) 
As a yellow solid (73 mg, 43 %); m.p. 108-110 
°C; Rf (Hexane: EtOAc, 20:80) 0.64; δH 
(CD3OD, 400 MHz) 8.31 (1H, d, J=5.6 Hz, H1), 
8.26 (1H, d, J=9.0 Hz, H3), 7.84 (1H, d, J=2.2 
Hz, H5), 7.73 – 7.70 (1H, m, H11), 7.69 – 7.65 
(1H, m, H12), 7.60 – 7.51 (2H, m, H13, H14), 7.46 (1H, dd, J=9.0, 2.2 Hz, H4), 7.34 
(1H, d, J=8.4 Hz, H8), 7.24 (1H, d, J=2.1 Hz, H6), 7.04 (1H, dd, J=8.4, 2.1 Hz, H7), 6.75 
(1H, d, J=5.6 Hz, H2), 4.67 (2H, s, H10); δC NMR (101 MHz, CD3OD) 163.62, 150.99, 
150.75, 148.75, 146.22, 143.50, 139.81, 136.00, 135.30, 130.69, 129.06, 126.35, 
125.17, 123.89, 123.85, 123.81, 123.63, 123.59, 123.21, 117.89, 117.59, 111.90, 
108.95, 100.84, 45.41; LRMS (EI) m/z, 468.10 (M+ C24H16ClF3N4O requires 468.10);  
HPLC Purity (Method A): >99 %, tR = 14.84 min. 
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N5-(7-Chloroquinolin-4-yl)-N2-(pyridin-2-ylmethyl)benzoxazole-2,5-diamine, 3.9o 
(DS32B) 
As a yellow solid (80 mg, 61 %); m.p. 118-120 
°C; Rf (MeOH: EtOAc, 5:95) 0.59; δH (CDCl3, 
400 MHz) 8.57 (1H, d, J=4.7 Hz, H13), 8.41 
(1H, d, J=5.5 Hz, H1), 7.99 (1H, d, J=2.0 Hz, 
H5), 7.97 (1H, d, J=9.0 Hz, H3), 7.69 (1H, td, 
J=7.8 (x2), 1.8 Hz, H11), 7.40 (1H, dd, J=9.0, 2.0 Hz, H4), 7.33 (1H, d, J=7.8 Hz, H10), 
7.29 (1H, d, J=2.0 Hz, H6), 7.20 – 7.26 (2H, m, H8, H12), 6.95 (1H, dd, J=8.4, 2.0 Hz, 
H7), 6.74 (1H, d, J=5.5 Hz, H2), 4.78 (2H, s, H9); δC (101 MHz, CDCl3) 162.96, 155.51, 
151.22, 149.33, 149.14, 149.01, 146.84, 144.63, 136.79, 135.50, 135.38, 128.40, 
125.96, 122.62, 121.76, 121.40, 117.66, 117.37, 112.80, 109.34, 101.89, 47.47; LRMS 
(EI) m/z, 400.93 (M+ C24H26ClN5O requires 401.10); HPLC Purity (Method A): >99 %, tR 
= 11.29 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(pyridin-3-ylmethyl)benzo[d]oxazole-2,5-diamine, 
3.9p (DS35B) 
As a yellow solid (86 mg, 58 %); m.p. 108-109 °C; Rf (MeOH: EtOAc, 5:95) 0.78; δH 
(CDCl3, 400 MHz) 8.66 (1H, d, J=2.2 Hz, H13), 8.54 (1H, dd, J=4.8, 1.6 Hz, H12), 8.46 
(1H, d, J=5.4 Hz, H1), 8.00 (1H, d, J=2.1 Hz, 
H5), 7.90 (1H, d, J=9.0 Hz, H3), 7.78 – 7.71 
(1H, m, H11), 7.42 (1H, dd, J=9.0, 2.2 Hz, H4), 
7.30 – 7.25 (2H, m, H8, H10), 7.24 (1H, d, J=2.2 
Hz, H6), 6.96 (1H, dd, J=8.4, 2.2 Hz, H7), 6.76 
(1H, d, J=5.4 Hz, H2), 4.70 (2H, s, H9); δC (101 MHz, CDCl3) 162.66, 151.84, 149.66, 
149.40, 149.19, 148.79, 146.63, 144.29, 135.79, 135.26, 133.17, 129.01, 125.92, 
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123.58, 121.07, 117.79, 117.58, 112.90, 109.47, 102.08, 77.25, 76.93, 76.61, 44.76; 
LRMS (EI) m/z, 401.10 (M+ C24H26ClN5O requires 401.10); HPLC Purity (Method A): 
>99 %, tR = 10.87 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(pyridin-4-ylmethyl)benzoxazole-2,5-diamine, 3.9q 
(DS47B) 
As a yellow solid (26 mg, 23 %); m.p. 202-204 
°C; Rf (MeOH: EtOAc, 5:95) 0.68; δH (CD3OD, 
300 MHz) 8.52 – 8.43 (2H, m, H11), 8.31 (1H, d, 
J=5.6 Hz, H1), 8.27 (1H, d, J=9.0 Hz, H3), 7.84 
(1H, d, J=2.1 Hz, H5), 7.51 – 7.42 (3H, m, H4, H10), 7.36 (1H, d, J=8.4 Hz, H8), 7.23 
(1H, d, J=2.1 Hz, H6), 7.05 (1H, dd, J=8.4, 2.1 Hz, H7), 6.75 (1H, d, J=5.6 Hz, H2), 4.67 
(2H, s, H9); δC (101 MHz, CD3OD) 163.58, 150.96, 150.78, 149.12, 148.86, 148.72, 
146.29, 143.44, 136.05, 135.34, 126.33, 125.20, 123.22, 122.26, 117.89, 117.72, 
111.99, 109.03, 100.83, 44.73; LRMS (EI) m/z, 401.07 (M+ C24H26ClN5O requires 
401.10); HPLC Purity (Method B): 96 %, tR = 10.06 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2-(2-(pyridin-2-yl)ethyl)benzoxazole-2,5-diamine, 3.9r 
(DS49B) 
As a yellow solid (131 mg, 67 %); m.p. 89-91 °C; 
Rf (MeOH: EtOAc, 5:95) 0.70; δH  (DMSO, 400 
MHz) 9.01 (1H, s, H15), 8.52 – 8.47 (1H, m, 
H14), 8.42 (1H, d, J=9.0 Hz, H3), 8.38 (1H, d, 
J=5.4 Hz, H1), 8.06 (1H, t, J=5.7 Hz, H16), 7.85 
(1H, d, J=2.2 Hz, H5), 7.69 (1H, td, J=7.8 (x2), 1.9 Hz, H12), 7.52 (1H, dd, J=9.0, 2.2 
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Hz, H4), 7.36 (1H, d, J=8.4 Hz, H8), 7.29 (1H, d, J=7.8 Hz, H11), 7.24 – 7.17 (2H, m, 
H6, H13), 6.93 (1H, dd, J=8.4, 2.1 Hz, H7), 6.70 (1H, d, J=5.4 Hz, H2), 3.74 – 3.63 (2H, 
m, H9), 3.07 (2H, t, J=7.2 Hz, H10); δC (101 MHz, DMSO) 163.51, 159.25, 152.31, 
149.90, 149.81, 149.57, 145.97, 144.88, 136.94, 136.21, 134.28, 128.01, 125.15, 
124.85, 123.76, 122.04, 118.41, 116.89, 112.08, 109.31, 101.54, 42.53, 37.56; LRMS 
(EI) m/z, 415.09 (M+ C23H18ClN5O requires 415.12); HPLC Purity (Method A): >99 %, tR 
= 13.20 min. 
 
N5-(7-Chloroquinolin-4-yl)-N2,N2-diethylbenzoxazole-2,5-diamine, 3.9s (DS39B) 
As a yellow solid (76 mg, 58%); m.p. 189-190 °C; Rf 
(Hexane: EtOAc, 20:80) 0.60; δH (CDCl3, 400 MHz) 
8.45 (1H, d, J=5.4 Hz, H1), 7.99 (1H, d, J=2.2 Hz, H5), 
7.90 (1H, d, J=8.9 Hz, H3), 7.39 (1H, dd, J=8.9, 2.2 
Hz, H4), 7.23 – 7.25 (2H, m, H6, H8), 6.88 (1H, dd, J=8.3, 2.2 Hz, H7), 6.76 (1H, d, 
J=5.4 Hz, H2), 3.59 (3H, q, J=7.2 Hz, H9), 1.29 (4H, t, J=7.2 Hz, H10) δC (101 MHz, 
CDCl3) 163.15, 151.79, 151.67, 149.49, 149.08, 146.81, 145.15, 135.31, 135.17, 
128.76, 125.76, 121.39, 116.30, 112.03, 109.01, 101.85, 43.05 (x2), 13.46 (x2); LRMS 
(EI) m/z, 366.11 (M+ C20H19ClN4O requires 366.12); HPLC Purity (Method A): >99 %, tR 
= 12.97 min. 
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N-(7-Chloroquinolin-4-yl)-2-(4-methylpiperazin-1-yl)benzoxazol-5-amine, 3.9t 
(DS51B) 
As a yellow solid (77 mg, 47 %); m.p. 113-115 °C; 
Rf (MeOH: EtOAc, 20:80) 0.55; δH (DMSO, 400 
MHz) 9.02 (1H, s, quinolinyl NH), 8.41 (1H, d, 
J=9.0 Hz, H3), 8.38 (1H, d, J=5.4 Hz, H2), 7.85 
(1H, d, J=2.2 Hz, H5), 7.52 (1H, dd, J=9.0, 2.2 Hz, H4), 7.43 (1H, d, J=8.2 Hz, H8), 7.23 
(1H, d, J=2.0 Hz, H6), 6.98 (1H, dd, J=8.2, 2.0 Hz, H7), 6.70 (1H, d, J=5.4 Hz, H2), 3.60 
(4H, t, J=5.0 Hz, H9), 2.42 (4H, t, J=5.0 Hz, H10), 2.22 (3H, s, H11); δC (101 MHz, 
DMSO) 163.04, 152.38, 150.03, 149.68, 146.20, 144.55, 136.64, 134.27, 128.10, 
125.15, 124.82, 118.49, 117.21, 112.20, 109.72, 101.64, 54.18, 46.21, 45.66; LRMS 
(EI) m/z, 393.12 (M+ C21H20ClN5O requires 393.14); HPLC Purity (Method A): >99 %, tR 
= 11.50 min. 
 
N-(7-Chloroquinolin-4-yl)-2-(4-phenylpiperazin-1-yl)benzoxazol-5-amine, 3.9u 
(DS52B) 
As a yellow solid (222 mg, 74 %); m.p. 96-
98 °C; Rf (EtOAc) 0.49; δH (DMSO, 400 
MHz) 9.03 (1H, s, quinolinyl NH), 8.42 (1H, 
d, J=9.0 Hz, H3), 8.39 (1H, d, J=5.3 Hz, 
H1), 7.86 (1H, d, J=2.2 Hz, H5), 7.52 (1H, dd, J=9.0, 2.2 Hz, H4), 7.45 (1H, d, J=8.4 Hz, 
H8), 7.29 – 7.16 (3H, m, H6, H12), 7.05 – 6.94 (3H, m, H7, H11), 6.82 (1H, t, J=7.2 Hz, 
H13), 6.72 (1H, d, J=5.3 Hz, H2), 3.75 (4H, t, J=5.0 Hz, H, H10), 3.27 (4H, t, J=5.0 Hz, 
H9);  δC (101 MHz, DMSO) 163.07, 152.34, 151.29, 150.17, 149.80, 146.38, 144.64, 
136.96, 134.29, 129.46, 128.17, 125.08, 124.80, 119.98, 118.68, 117.29, 116.60, 
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112.33, 109.69, 101.94, 48.52, 45.73; LRMS (EI) m/z, 455.12 (M+ C26H22ClN5O requires 
455.15); HPLC Purity (Method A): >99 %, tR = 15.41 min. 
 
2-(4-(3-Chlorophenyl)piperazin-1-yl)-N-(7-chloroquinolin-4-yl)benzoxazol-5-amine, 
3.9v (DS53B) 
As a yellow solid (39 mg, 40 %); m.p. 90-92 
°C; Rf (EtOAc) 0.52; δH (CDCl3, 400 MHz) 
8.46 (1H, d, J=5.3 Hz, H1), 8.00 (1H, d, 
J=2.1 Hz, H5), 7.89 (1H, d, J=9.0 Hz, H3), 
7.40 (1H, dd, J=9.0, 2.1 Hz, H4), 7.31 – 7.25 (2H, m, H6, H7), 7.24 – 7.15 (1H, m, H11), 
6.95 (1H, dd, J=8.4, 2.1 Hz, H7), 6.92 (1H, t, J=2.2 Hz, H14), 6.89 – 6.86 (1H, m, H12), 
6.84 – 6.80 (1H, m, H13),  6.77 (1H, d, J=5.4 Hz, H2), 3.92 – 3.80 (4H, m, H10), 3.38 – 
3.22 (4H, m, H9); δC (101 MHz, CDCl3) 162.89, 152.03, 151.82, 149.68, 148.89, 146.77, 
144.54, 135.89, 135.21, 130.16, 128.93, 125.82, 121.22, 120.45, 117.86, 117.19, 
116.73, 114.69, 112.61, 109.36, 102.07, 48.67, 45.47; LRMS (EI) m/z, 489.10 (M+ 
C26H21Cl2N5O requires 489.11); HPLC Purity (Method A): >99 %, tR = 15.94 min. 
 
N-(7-Chloroquinolin-4-yl)-2-((dimethylamino)methyl)benzoxazol-5-amine, 3.9w 
(DS30B) 
As an off white powder, (63 mg, 49 %); m.p. 156-158 
°C; Rf (MeOH: EtOAc, 20:80) 0.27; δH (300 MHz, 
CDCl3) δ 8.37 (1H, d, J = 5.4 Hz, H1), 7.88 – 7.94 
(2H, m, H3, H5), 7.54 (1H, d, J = 2.1 Hz, H6), 7.46 (d, 
J = 8.6 Hz, H8), 7.30 (1H, dd, J = 9.0, 2.2 Hz, H4), 7.21 (1H, dd, J = 8.6, 2.1 Hz, H7), 
6.68 (1H, d, J = 5.4 Hz, H2), 3.73 (2H, s, H9), 2.34 (6H, s, H10); δC (101 MHz, CD3OD) 
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164.75, 151.11, 150.36, 148.82, 148.48, 141.53, 136.86, 135.39, 126.47, 125.36, 
123.21, 122.28, 118.03, 115.03, 111.18, 100.96, 55.09, 44.04; LRMS (EI) m/z, 352.01 
(M+ C19H17ClN4O requires 352.11); HPLC Purity (Method C): 98 %, tR = 2.78 min. 
 
N-(7-Chloroquinolin-4-yl)-2-(2-methoxyethyl)benzoxazol-5-amine, 3.9x (DS58B) 
As a light pink solid (106 mg, 65 %); m.p. 165-166 
°C; Rf (MeOH: EtOAc, 20:80) 0.62; δH (CD3OD, 300 
MHz) 8.33 (1H, d, J=5.5 Hz, H1), 8.27 (1H, d, J=9.0 
Hz, H3), 7.84 (1H, d, J=2.1 Hz, H5), 7.63 – 7.59 
(2H, m, H6, H8), 7.47 (1H, dd, J=9.0, 2.2 Hz, H4), 7.35 (1H, dd, J=8.6, 2.2 Hz, H7), 6.77 
(1H, d, J=5.5 Hz, H2), 3.89 (2H, t, J=6.2 Hz), 3.37 (2H, s), 3.21 (2H, t, J=6.2 Hz); δC 
(101 MHz, CD3OD) 167.58, 156.58, 150.21, 142.90, 142.26, 140.17, 139.21, 133.37, 
127.89, 124.91, 122.88, 119.14, 116.70, 115.91, 111.71, 100.24, 68.50, 57.54, 28.89; 
LRMS (EI) m/z, 353.08 (M+ C19H16ClN3O2 requires 353.09); HPLC Purity (Method A): 
>99 %, tR = 12.83 min. 
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6.5 ANTIPLASMODIAL ACTIVITY ASSAYS 
6.5.1 In vitro antiplasmodial assay against K1 and NF54 strains of P. 
falciparum1,2 (Swiss Tropical and Public Health Institute) 
In vitro activity against the erythrocytic stages of the K1 (chloroquine and pyrimethamine 
resistant, originated in Thailand) and NF54 P. falciparum strains was determined using 
a 3H-hypoxanthine incorporation assay. Compounds were dissolved in DMSO at 10 
mg/ml and added to parasite cultures incubated in RPMI 1640 medium without 
hypoxanthine, supplemented with HEPES (5.94 g/l), NaHCO3 (2.1 g/l), neomycin (100 
U/mL), AlbumaxR (5 g/l) and washed A+ human red cells at 2.5 % hematocrit (0.3% 
parasitemia). Serial drug dilutions of eleven three-fold dilution steps covering a range 
from 100 to 0.002 μg/ml were prepared. The 96-well plates were incubated in a 
humidified atmosphere at 37 °C; 4 % CO2, 3 % O2 and 93 % N2. After 48 h, 50 μl of 3H-
hypoxanthine (=0.5 μCi) was added to each well of the plate. The plates were incubated 
for a further 24 h under the same conditions. The plates were then harvested with a 
Betaplate™ cell harvester (Wallac, Zurich, Switzerland), and the red blood cells 
transferred onto a glass fiber filter then washed with distilled water. The dried filters 
were inserted into a plastic foil with 10 ml of scintillation fluid, and counted in a 
Betaplate™ liquid scintillation counter (Wallac, Zurich, Switzerland). IC50 values were 
calculated from sigmoidal inhibition curves by linear regression using Microsoft Excel. 
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6.5.2 In vitro antiplasmodial assay against the W2 strain 3,4  
(Department of Medicine, San Francisco General Hospital, University of San Francisco) 
The protocol described by Rosenthal et al. was used in this assay 3. The chloroquine-
resistant W2 strain of P. falciparum (1 % parasitemia, 2 % hematocrit) was cultured in 
0.5 ml of medium in 48-well culture dishes. Stock solutions of inhibitors (10 mM) in 
DMSO were added to cultured parasites to a final concentration of 20 μM. From the 48-
well plates, 125 μM of culture was transferred to two 96-well plates. Serial dilutions of 
inhibitors were made to final concentrations of 10 μM, 2 μM, 0.4 μM, 80 nM, 16 nM, and 
3.2 nM. Cultures were maintained at 37 °C for 2 days after which the parasites were 
washed and fixed with 1 % formaldehyde in PBS. After 2 days parasitemia was 
measured by flow cytometry using the DNA stain YOYO-1 as a marker of cell survival. 
 
6.6 IN VIVO ANTIMALARIAL EFFICACY STUDIES 5,6  
(Swiss Tropical and Public Health Institute) 
All efficacy studies were approved by the institutional animal experimentation ethics 
committee. In vivo antimalarial activity was usually assessed for groups of three 
(treatment group) or five (untreated control group) female NMRI mice (20–22 g) 
intravenously infected on day 0 with a GFP-transfected P. berghei ANKA strain 
(donated by A. P. Waters and C. J. Janse, Leiden University, The Netherlands) (2 x 107 
parasitized erythrocytes per ml) (Roche). Compounds formulated in SSV (70/30 Tween 
80/ethanol and diluted 10 x with water) were administered orally in a volume of 10 ml/kg 
as four consecutive daily doses (24, 48, 72 and 96 h after infection). Blood smears were 
collected and stained on day 4 after infection. The degree of infection (parasitemia 
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expressed as per cent infected erythrocytes) was determined using microscopy. Activity 
was calculated as the difference between the mean per cent parasitemia for the control 
and treated groups expressed as a per cent relative to the control group. The survival 
time in days was also recorded up to 30 days after infection. A compound was 
considered curative if the animal survived to day 30 after infection with no detectable 
parasites. 
 
6.7 CYTOTOXICITY ASSAYS 
6.7.1 In vitro cytotoxicity against L6 cells 7,8  
(Swiss Tropical and Public Health Institute) 
Assays were performed in 96-well microtiter plates, each well containing 100 μl of RPMI 
1640 medium supplemented with 1 % L-glutamine (200 mM) and 10 % fetal bovine 
serum, and 40,000 L6 cells (a primary cell line derived from rat skeletal myoblasts). 
Serial drug dilutions of eleven three-fold dilution steps covering a range from 100 to 
0.002 μg/mL were prepared. After 72 hours of incubation the plates were inspected 
under an inverted microscope to assure growth of the controls and sterile conditions. 10 
μl of Alamar Blue was then added to each well and the plates incubated for another 2 
hours. The plates were then read with a Spectramax Gemini XS microplate fluorometer 
(Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wavelength 
of 536 nm and an emission wavelength of 588 nm. The IC50 values were calculated by 
linear regression from the sigmoidal dose inhibition curves using SoftmaxPro software 
(Molecular Devices Cooperation, Sunnyvale, CA, USA). 
 
CHAPTER 6: EXPERIMENTAL 
224 
 
6.7.2 In vitro cytotoxicity against CHO cells 
 (Division of Pharmacology, University of Cape Town) 
Test samples were screened for in vitro cytotoxicity against a mammalian cell-line, 
Chinese Hamster Ovarian (CHO) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT)-assay. The MTT-assay is used as a colorimetric 
assay for cellular growth and survival, and compares well with other available assays 
9,10. The tetrazolium salt MTT was used to measure all growth and chemosensitivity. 
Test samples were tested in triplicate on one occasion. The test samples were prepared 
to a 20 mg/ml stock solution in 100 % DMSO. Stock solutions were stored at -20ºC. 
Further dilutions were prepared in complete medium on the day of the experiment. 
Samples were tested as a suspension if not completely dissolved. Emetine was used as 
the reference drug in all experiments. The initial concentration of emetine was 100 
μg/ml, which was serially diluted in complete medium with 10-fold dilutions to give 6 
concentrations, the lowest being 0.001 μg/ml. The same dilution technique was applied 
to the all test samples. The highest concentration of solvent to which the cells were 
exposed to had no measurable effect on the cell viability (data not shown). The 50% 
inhibitory concentration (IC50) values were obtained from full dose-response curves, 
using a non-linear dose-response curve fitting analysis via GraphPad Prism v.4 
software. 
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6.8 DETERGENT MEDIATED Β-HEMATIN FORMATION INHIBITION ASSAY  
(Department of Chemistry, University of Cape Town) 
The β-hematin formation inhibition assay method described by Carter et al. was 
modified for manual liquid delivery 11,12. Two stock solutions of the samples were 
prepared by dissolving the pre-weighed compound in DMSO with sonication to give 20 
mM and 2 mM solutions of each sample. These were delivered to a 96-well plate in 
duplicate to give concentrations ranging from 0–1000 μM (final well concentration) with 
a total DMSO volume of 10 μL in each well, after which deionised H2O (70 μL) and NP-
40 (20 μL; 30.55 μM) were added. Plates containing coloured compounds were pre-
read on a on a SpectraMax plate reader for blanking purposes. A 25 mM haematin 
stock solution was prepared by sonicating hemin in DMSO for one minute and then 
suspending 178 μL of this in 1M acetate buffer (pH 4.8). The homogenous suspension 
(100 μL) was then added to the wells to give final buffer and hematin concentrations of 
0.5 M and 100 μM respectively. The plate was covered and incubated at 37°C for 5–6 
hrs. Free heme was detected using the pyridine-ferrichrome method developed by 
Ncokazi and Egan 13. A solution of 50 % (v/v) pyridine, 30 % (v/v) H2O, 20 % (v/v) 
acetone and 0.2 M HEPES buffer (pH 7.4) was prepared and 32 μL added to each well 
to give a final pyridine concentration of ~5 % (v/v). Acetone (60 μL) was then added to 
assist with haematin dispersion. The UV-vis absorbance of the plate wells was read on 
a SpectraMax® 340 PC384 Absorbance Microplate Reader (Molecular Devices, 
Sunnyvale, CA, USA). Sigmoidal dose-response curves were fitted to the absorbance 
data using GraphPad Prism v3.02 to obtain a 50 % inhibitory concentration (IC50) for 
each compound. 
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6.9 TURBIDIMETRIC SOLUBILITY ASSAY14 
Stock solutions of samples and control compounds were prepared in DMSO at a 
concentration of 10 mM. The assay was carried out using flat-bottomed transparent 96-
well microtiter plates. A predilution plate was prepared by adding 20 μl of DMSO into 
row G and 50 μl of DMSO into rows B to F. Using a micropipette 80 μl of the stock 
solution was transferred into row G and mixed with the DMSO already in the well. 
Subsequently, the solution in row G was serially diluted by taking 50 μl from one row to 
the next all the way to row B. This was done in triplicate to give concentrations of 0.25, 
0.50, 1.00, 2.00, 4.00 and 8.00 mM. 
The actual dilution for the solubility assay was carried out in triplicate separately in 
DMSO and PBS. The dilution plate was preloaded with the DMSO (200 μl in row A wells 
and 196 μl in the rest of the wells) and 196 μl of PBS. Aliquots of 4 μl were then 
transferred from the corresponding wells in the predilution plate to the dilution plate. 
DMSO (4 μl) was added to the row A PBS wells while 4 μl of the stock solution were 
added in triplicate to the row H DMSO and PBS wells. The final concentrations in the 
wells were 0, 5, 10, 20, 40, 80, 160 and 200 μM, in rows A through H, rescpetively. The 
plate was covered and incubated at room temperature for two hours after which 
absorbance was read at 620 nm on a SpectraMax® 340 PC384 Absorbance Microplate 
Reader (Molecular Devices, Sunnyvale, CA, USA). The means of the DMSO and PBS 
readings for the different concentrations were separately calculated using Microsoft 
Excel. The figures for rows B to H were each subtracted from the mean for row A. The 
results for the DMSO and PBS solutions were plotted against concentration and the 
point of deflection from the origin was taken as the upper bound of solubility. 
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6.10 CYP INHIBITION ASSAY 
Recombinant enzymes were obtained from Cypex Limited, Dundee, Scotland, UK. 
Inhibitors and NADPH were purchased from Sigma Aldrich, St. Louis, MO, USA. The 
marker substrates were from BD Gentest Corporation, Woburn, MA, USA. Absorbance 
readings were taken on a Wallac Victor2™ Multilabel Counter (Wallac AB, Oxfordhuset, 
Upplands Vasby, Sweden). 
Incubations were carried out in black 96 well microtiter plates. A master mix was 
prepared by mixing ice cold water, buffer, substrate and enzyme, in that order. The 
master mix was added to all the 96 wells. Inhibitor was added to the appropriate wells 
and solvent to the wells without inhibitor and the blanks. Test compounds were added to 
the rest of the wells. The plate was pre-incubated for 10 min at 37 °C. NADPH was 
added to all wells except the blanks. The plate was incubated for 15 min at 37 °C. 
Reaction was stopped by adding 75 μl of 1 mM Tris solution in 80% ACN. NADPH was 
added to the blanks. Fluorescence was measured appropriate excitation and emission 
wavelengths. The setups for the various enzymes are given in Tables 6.2-6.6. 
 
Table 6.2: CYP1A2 incubation setup 
Component [Stock] Vol/well (μl) Conc/well 
Master mix (μl)  
(105 wells) 
CYP1A2 13.3 pmol/μl 0.04 0.5 pmol 3.9 
CEC in 40% ACN 120 μM 5 3 μM 525 
α-naphthaoflavone 
(or test compound) 
100 μM 
(150, 1000 μM) 4 
0.001, 0.01 μM 
(3, 20 μM)  
KPO4 buffer 1 M 20 0.1 M 2100 
NADPH 20 mM 10 1 mM  
Water  160.96  16901 
Exc/Emission λ (nm) 405/460   
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Table 6.3: CYP3A4 incubation setup 
Component [Stock] Vol/well (μl) Conc/well 
Master mix (μl) 
(105 wells) 
CYP3A4 3.9 pmol/μl 0.51 2  pmol 53.8 
BFC in 40% ACN 400 μM 5 10 μM 525 
Ketoconazole 
(or test compound) 
150, 1000 μM 4 
0.01, 0.1 μM 
(3, 20 μM) 
 
KPO4 buffer 1 M 20 0.1 M 2100 
NADPH 20 mM 10 1 mM  
Water  160.49  16901 
Exc/Emission λ (nm) 405/535   
 
Table 6.4: CYP2C9 incubation setup 
Component [Stock] Vol/well (μl) Conc/well 
Master mix (μl)  
(105 wells) 
CYP2C9 2.1 pmol/μl 2.38 5 pmol 250 
MFC in 40% ACN 3.4 mM 5 85 μM 525 
Sulfaphenazole 
(or test compound) 
150, 1000 μM 4 
0.1, 1 μM 
(3, 20 μM) 
 
KPO4 buffer 1 M 20 0.1 M 2100 
NADPH 20 mM 10 1 mM  
Water  158.62  16655.2 
Exc/Emission λ (nm) 405/535   
 
Table 6.5: CYP2C19 incubation setup 
Component [Stock] Vol/well (μl) Conc/well 
Master mix (μl)  
(105 wells) 
CYP2C19 4.9 pmol/μl 0.41 2 pmol 42.86 
MFC in 40% ACN 1400 μM 5 35 μM 525 
Ticlopidine 
(or test compound) 
150, 1000 μM 4 
1, 10 μM 
(3, 20 μM) 
 
KPO4 buffer 1 M 20 0.1 M 2100 
NADPH 20 mM 10 1 mM  
Water  160.59  16861.95 
Exc/Emission λ (nm) 405/535   
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Table 6.6: CYP2D6 incubation setup 
Component [Stock] Vol/well (μl) Conc/well 
Master mix (μl) 
(105 wells) 
CYP2D6 3.8 pmol/μl 1.31 5 pmol 138.16 
MAMC in 40% ACN 600 μM 5 10 μM 525 
Thioridazine 
(or test compound) 
150, 1000 μM 4 
0.1, 1 μM 
(3, 20 μM) 
 
KPO4 buffer 1 M 20 0.1 M 2100 
NADPH 8 mM 10 0.4 mM  
Water  159.69  16767.45 
Exc/Emission λ (nm) 390/460   
 
6.11 TIME DEPENDENT CYP3A4 INHIBITION ASSAY 
6.11.1 Incubation 1 (Inactivation assay) 
A two-step incubation scheme consisting of an inactivation assay and an activity assay 
was used according to the method by Thelingwani et al. 15. In the inactivation assay, the 
master mix comprising buffer, water and enzyme was added to all wells. A 5 µl aliquot 
of test compound or control was added to columns 1-4, 7-10 and solvent to columns 5, 
6, 11 and 12 of the 96-well plate according to the format shown in Table 6.7. The plate 
was pre-warmed for 5 min at 37 °C. Water (10 µl) was added to columns 1-6 and 
NADPH (10 µl) to columns 7-12. The plate was incubated for 15 min at 37 °C. 
Table 6.7: Inactivation assay setup 
 
Stock conc. Vol / well(µl) Final conc. 
Master mix (315 
wells) 
Enzyme 3.9 pmol/µl 1.28 5 pmol/well 404 µl 
inhibitor 40, 200 µM 5 2, 10 µM 
 NADPH 10 mM 10 1 mM 
 KPO4 0.4 M 50 0.2 M 15750 µl 
Water 
 
33.7 
 
10621 µl 
Final volume  100   
Volume of master mix/well 85 µl 
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6.11.2 Incubation 2 (Activity assay) 
The master mix, prepared as indicated in Table 6.8, was added to all wells. The plate was pre-
warmed for 5 min at 37 °C. A 20 µl aliquot was transferred from plate 1 into the corresponding 
wells in plate 2. NADPH was added to all wells except columns 6 and 12 (blanks). The plate 
was incubated for 15 min at 37 °C. Reaction was stopped by adding 75 μl of 1 mM Tris solution 
in 80% ACN. NADPH was added to the blanks. Fluorescence was measured appropriate 
excitation and emission wavelengths. Results were analyzed as previously described 15. 
 
Table 6.8: Activity assay setup 
 
Stock conc. Vol / well(µl) Final conc. 
Master mix (315 
wells) 
BFC 520 µM 5 13 µM 1575 µl 
incubate 1  20 
 NADPH 20 mM 10 1 mM 
 KPO4 0.4 M 100 0.2 M 31500 µl 
Water   65.0 
 
20475 µl 
Final volume 200   
Volume of master mix/well 170 µl 
 
6.12 EC-ESI/MS TRAPPING EXPERIMENTS 
The EC/ESI-MS system setup was based on the method previously reported 16,17 
Samples were infused through an ESA Coulochem 5011 analytical cell (ESA Inc., 
Bedford, MA, USA). The electrochemical cell was controlled by an ESA Coulochem II 
potentiostat (ESA Inc.). Samples were infused through the electrochemical cell by a 
syringe pump at a flow rate of 5 ml/min. A make-up flow of 50 ml/min was added before 
the electrochemical cell by a HP1050 high-performance liquid chromatography (HPLC) 
system (Hewlett Packard, Palo Alto, CA, USA). The sample was collected in glass vials 
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containing glutathione, methoxylamine or potassium cyanide as the trapping agents for 
subsequent analysis by LC/MS 17. 
 
6.13 METABOLIC STABILITY ASSAY 18 
This assay was conducted in 96-well plate format. Test compounds and controls were 
prepared from 10 mM DMSO stock solutions. 0.40 mg protein/ml microsomes (pooled 
Human mixed gender, male Mouse BALB/c) from XenoTech were incubated with 1 mM 
test compound at 37 °C. Metabolic reactions were initiated by the addition of the co-
factor NADPH and the plates were incubated for 30 minutes. The reactions were 
quenched with triple the volume of acetonitrile containing carbamazepine as internal 
standard. The centrifuged and filtered samples were analysed by HPLC-MS/MS to 
determine the remaining concentrations of the test compounds. Control standards 
(midazolam and propranolol) were included in the assay to provide quality control and 
an indication of the metabolic capacity of the microsomes used. 
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APPENDIX 1 
 
ANTIPLASMODIAL ACTIVITY (WITH STANDARD DEVIATION)AGAINST THE NF54 
(CHLOROQUINE SENSITIVE), K1 AND W2 (DRUG RESISTANT) PLASMODIUM FALCIPARUM 
STRAINS 
K1 AND NF54 STRAINS 
Code Structure 
Antiplasmodial IC50   
(nM) 
K1 sd* NF54 sd* 
3.9a 
(DS4F) 
N
HN
Cl
N
O
NH
 
1003 29.2202 466 29.2202 
3.9b 
(DS23B) 
N
HN
Cl
N
O
NH
N
 
56.4 13.9403 15.4 2.0560 
3.9w 
(DS30B) 
N
HN
Cl
N
O N
 
411 16.0333 213 8.5029 
3.9d 
(DS31B) 
N
HN
Cl
N
O
NH
N
O
 
198 3.3362 108 17.8624 
3.9o 
(DS32B) 
N
HN
Cl
N
O
NH
N
 
883 14.0770 406 1.7596 
3.9e 
(DS33B) 
N
HN
Cl
N
O
NH
N
 
41.5 2.4396 10.7 0.0000 
3.9g 
(DS34B) 
N
HN
Cl
N
O
NH
N
O
 
773 82.7291 1876 206.0117 
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Code Structure 
Antiplasmodial IC50   
(nM) 
K1 sd* NF54 sd* 
3.9p 
(DS35B) 
N
HN
Cl
N
O
NH
N
 
704 42.2311 309 22.8752 
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N
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N
O
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N
 
84.9 15.1651 14.2 2.6583 
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N
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N
O
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N
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3.9s 
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N
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N
O
N
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3.9l 
(DS41B) 
N
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O H
N N N
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N
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3.9c 
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N
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Cl
N
O
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N
 
23.7 7.3218 9.7 0.2370 
3.9q 
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N
HN
Cl
N
O
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N
 
1553 12.3174 630 0.2649 
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Code Structure 
Antiplasmodial IC50   
(nM) 
K1 sd* NF54 sd* 
3.9j 
(DS48B) 
N
HN
Cl
N
O
NH
N
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N
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O
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N
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N
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O
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N
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N
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Code Structure 
Antiplasmodial IC50   
(nM) 
K1 sd* NF54 sd* 
3.9x 
(DS58B) 
N
HN
Cl
N
O O
 
2111 45.9679 1094 9.9930 
ADQ 
N
HN
Cl
OH
N
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(DS23) 
O2N
N
O
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N
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(DS32) 
O2N
N
O
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N
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O2N
N
O
NH
N
 
10992 2659.5434 >37839 - 
2.9s 
(DS39) 
O2N
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O
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(DS49) 
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N
O
N
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O
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N
 
30752 97.0105 >35178 - 
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Code Structure 
Antiplasmodial IC50   
(nM) 
K1 sd* NF54 sd* 
2.9u 
(DS52) 
O2N
N
O
N N
 
>38130 - >38130 - 
2.12b 
(DS62) 
O2N
N
O
N N
 
>30838 - >30838 - 
2.9b 
(DS23) 
Cl N
O
N N
 
>31869 - >31869 - 
CQ 
 
275 37.7101 9.7 1.6483 
ARTS 
 
2.3 0.9461 3.4 1.2709 
*sd=standard deviation; ADQ=Amodiaquine; CQ=Chloroquine; ARTS = Sodium artesunate 
W2 STRAIN 
Code Structure 
Antiplasmodial IC50   
(nM) 
W2 sd* 
3.2a 
(DS1F) 
N
NH
Cl
N
S
HN
 
1158 125.86501 
3.9a 
(DS4F) 
N
NH
Cl
N
O
HN
 
490.85 92.84312 
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3.6a 
(DS5G) 
N
NH
Cl
N
HN
HN
 
500.78 580.28011 
3.2c 
(DS11B) 
N
NH
Cl
N
S
HN
N
 
12.185 0.2899138 
3.2d 
(DS12B) 
N
NH
Cl
N
S
HN
N
 
12.955 0.2474874 
3.2e 
(DS13B) 
N
NH
Cl
N
S
HN
N O
 
39.625 1.9445436 
3.2f 
(DS18B) 
N
NH
Cl
N
S
HN
N
 
10.565 0.1909188 
3.6b 
(DS21B) 
N
NH
Cl
N
HN
HN
N
 
4579.65 6305.059 
3.6c 
(DS22B) 
N
NH
Cl
N
HN
HN
N O
 
188.6 4.5254834 
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3.9b 
(DS23B) 
N
NH
Cl
N
O
HN
N
 
8.3145 1.4163349 
3.6d 
(DS24B) 
N
NH
Cl
N
HN
HN
N
 
199.65 5.4447222 
3.4a 
(DS26B) 
N
NH
N
Cl
HN N
 
20.68 2.2344574 
3.4b 
(DS27B) 
N
NH
N
Cl
HN N
O
 
40.79 4.7376154 
ADQ 
 
4.903 0.205061 
CQ 
 
49.49 1.2727922 
ARTS 
 
11.71 0.8768124 
*sd=standard deviation; ADQ=Amodiaquine; CQ=Chloroquine; ARTS = Sodium artesunate 
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